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Abstract
Despite the experience gained over several decades in various types of light-based
medical treatments, the optimization of the corresponding therapeutic protocols
and accurate forecasting of their outcome have not yet been achieved in many cases.
The difficulty often arises from the heterogeneity of living tissues, their variable
optical properties, and from the heterogeneous distribution of the photoactive or
photosensitive substances - whether naturally present in the tissue or artificially
adde.
Our work focuses on the individualization and control of irradiation parameters, in
order for the physician to be able to elicit a predictable clinical response in the
irradiated tissues. In this thesis, we present three separate studies in which we
tried to evaluate the possibility of individualizing and optimizing the corresponding
clinical outcomes by measuring or monitoring certain, particular parameters.
In a first clinical study, performed at the medical practice of Dr Vezzola, MD, in
Saló, Italy, the human eye’s retinal reflectance was measured and mapped, in the
framework of subthreshold thermal laser therapy, using an excitation wavelength
identical to that of the treatment laser, i.e. at 810nm. The specific goal of this
study was to correlate the occurrence of retinal burns with the measured infrared
retinal reflectance. This study was performed using a modified fundus camera to
record infrared reflectance images of the retina, and by recording the slit-lamp
based laser therapy parameters (irradiation parameters and spot location) in such
a way so as to overlay the map of the laser treatment spots on the corresponding
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reflectance fundus image. The clinical study demonstrated the expected existence
of spatial variations in light reflectance at 810 nm (probably due to changes of the
tissue absorption), which we then tried to relate to the occurrences of retinal burns
observed during the laser treatment. The analysis of the results obtained with
the applied conditions, did not however show a clear correlation between the local
retina reflectance, the laser beam parameters, and the occurrence of retinal burns.
Therefore we postulate that either the absorbing structures of the retina cannot
be seen with the imaging device we used, possibly due to its limited resolution, or
other important elements play a role in the laser-tissue interactions during this type
of lasers-light interaction with the local retinal tissue.
The second study was pre-clinical, performed at EPFL, and aimed at monitoring in
real-time the tissular oxygen concentration during photodynamic therapy (PDT). It
was performed in vivo on the chicken embryo’s chorio-allantoic membrane (CAM)
model, which was submitted to aminolevulinic acid (ALA)-based PDT. The molec-
ular oxygen, which is thought to be an essential actor in the cascade of reactions
leading to the tissular PDT effect, is actually the main molecule responsible for
the photosensitizer’s (PS) triplet state quenching. Therefore, the delayed fluores-
cence lifetime of the photosensitizer, protoporphyrin IX (PpIX), was measured with
a specially designed and assembled, optical fiber-based, time-resolved spectrofluo-
rometer, and used as a proxy for tissular pO2. Simultaneously, vascular damages
caused by PDT were characterized and quantified, to check for correlation be-
tween the two parameters. Using the PS’s delayed fluorescence lifetime to evaluate
tissular pO2 proved to be a quite reasonable strategy, due to the fact that it is
possible to measure the pO2 at the location of the PS molecule. The study’s results
demonstrate a robust, linear correlation between tissular pO2 reduction and vascu-
lar damage extent. They also suggest that the amount of oxygen consumed during
PDT could be a useful, measurable parameter for assessing and/or controlling the
PDT’s therapeutic effect.
The third, clinical, study aimed at measuring the fluorescence photobleaching of
the PpIX photosensitizer due to PDT. This study was performed at the “Hôpi-
taux Universitaires de Genève - HUG”, in Geneva, Switzerland, in collaboration
with Dr Denis Salomon, MD, and Dr Behrooz Kasraee, MD, in the framework of
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a series of standard clinical PDT treatments of aktinic keratoses (AK), which is a
pre-cancerous skin lesion. The lesions’ fluorescence intensity was quantified with a
specially adapted quantitative imaging device, using a homogeneous and constant
intensity fluorescence excitation light. The specific goal was to check for a relation
between the extent of photobleaching of the PS (in this case PpIX, which was in-
duced by the administration of Metvix®) and the clinical outcome (disappearance
of AK) evaluated several months after the treatment. The study’s results show that
the amount of photobleached PS is strongly and linearly correlated to the fluores-
cence measured before the treatment. Likewise, the preliminary assessment of the
clinical outcomes confirms the existence of a correlation of these outcomes with the
PS’s fluorescence bleaching, thus making it possible, in principle, to select and op-
timize the PDT’s irradiation parameters before starting the treatment. The results
of this study demonstrate the relevance of measuring the PS’s photo-bleaching for
optimizing PDT and forecasting of its outcome.
Keywords: Optic nerve head, Retina, Infrared fundus reflectance, Monitoring, Ther-
mal laser, 810 nm, Tissular, Oxygen, In vivo, Lifetime, PpIX, Luminescence, De-
layed fluorescence, Subthreshold, PDT, CAM, ALA, Tissular Oxygen, Vascular
effect, AK, Photobleaching
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Sommario
Precise previsioni degli effetti terapeutici indotti in seguito all’interazione con una
radiazione luminosa restano tuttora difficili. Nonostante la grande esperienza accu-
mulata nell’utilizzo della luce in diverse applicazioni cliniche, l’ottimizzazione dei
corrispondenti protocolli terapeutici non é ancora stata raggiunta. La difficoltà na-
sce dalla conformazione eterogenea dei tessuti, dalle diverse caratteristiche ottiche
e dalle diverse e particolari concentrazioni delle sostanze responsabili dell’assorbi-
mento della radiazione. L’oggetto e l’obiettivo alla base dei progetti qui sviluppati
consiste nell’individualizzazione dei parametri d’irradiazione permettendo così di
ottenere, in modo sistematico, sempre la stessa risposta dai tessuti irradiati. In
questa tesi sono state studiate tre situazioni, rispettivamente, tre parametri dif-
ferenti per verificare se attraverso la loro misura e il loro controllo si potessero
omogeneizzare e ottimizzare i risultati clinici.
Il primo progetto, portato a termine presso lo studio medico del Dr Vezzola, con-
siste in uno studio clinico nel quadro di un trattamento laser termico della retina.
L’assorbimento del fondo retinico, valutato tramite la misura della quantità di lu-
ce riflessa in seguito a un’eccitazione a medesimo spettro del laser di trattamento
(810nm), é stato caratterizzato e mappato. L’obiettivo specifico era di valutare
l’occorrenza delle bruciature retiniche durante il trattamento laser in funzione della
quantità di luce riflessa dallo stesso fondo retinico. Un fluorangiografo standard é
stato dunque modificato in modo tale da poter registrare la riflessione del fondo
retinico anche nello spettro infrarosso. Parallelamente, durante la terapia laser,
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somministrata attraverso una lampada a fessura, i parametri d’irradiazione laser
e la localizione dello spot laser sono stati registrati. In questo modo il coefficente
di riflessione retinico, corrispondente alla zona irradiata da ogni singlo spot laser,
ha potuto essere studiato precisamente. I risultati hanno dimostrato l’esistenza di
significative variazioni spaziali del coefficiente di riflessione dovute probabilmente
ad un assorbimento eterogeneo della radiazione luminosa. Tuttavia lo studio ha
dimostrato che non esiste una chiara correlazione tra: il coefficiente di riflessione
retinico, i parametri d’irradiazione e l’occorrenza di bruciature retiniche. Detto ciò
si presume che, in questo tipo di trattamento, esistano altri elementi che giocano un
ruolo chiave nell’interazione tra tessuto e radiazione laser; alternativamente si può
pensare che le strutture responsabili dell’assorbimento non siano visibili attraverso
le nostre misure, data la limitata risoluzione delle immagini infrarosso.
Il secondo studio, eseguito presso l’EPFL, su un modello animale in vivo trattato
con ALA (“Chick Chorio-Allantoic Model”, CAM), aveva come obiettivo, il control-
lo, in tempo reale e durante la terapia fotodinamica (PDT), della concentrazione
dell’ossigeno molecolare (pO2) contenuto nei tessuti. Infatti, l’ossigeno molecolare,
oltre ad essere l’attore principale nelle reazioni a catena che portano all’effetto PDT,
é il principale responsabile della riduzione del tempo di vita dello stato elettronico
di tripletto del fotosensibilizzatore (PS), la protoporfirina IX (PpIX). Di conseguen-
za, uno speciale spettrofluorimetro risolto nel tempo, basato su una singola fibra
ottica, é stato costruito per poter misurare il tempo di vita della fluorescenza ri-
tardata del PS e così valutare la pO2 nei tessuti. Contemporaneamente, l’effetto
vascolare indotto dalla PDT é stato caratterizzato e quantificato, permettendo di
verificare la correlazione esistente tra questi due parametri. La strategia adottata si
é rivelata essere particolarmente interessante, grazie all’insita possibilità di ottenere
misure della pO2 all’esatta corrispondenza spaziale del PS. I risultati dello studio
mostrano una correlazione consolidata tra la riduzione della pO2 e l’importanza dei
danni vascolari indotti. La quantità di ossigeno consumata durante la PDT po-
trebbe essere dunque un parametro utile (e misurabile) per verificare, monitorare,
e asservire l’irradiazione PDT e così ottimizzare gli effetti terapeutici.
Il terzo studio clinico, aveva come obiettivo la misura del fotodecadimento del foto-
sensibilizzatore (PS) durante la PDT. Lo studio é stato eseguito in collaborazione
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con “les Hôpitaux Universitaires de Genève - HUG” nell’ambito di una serie di
trattamenti clinici standard per il trattamento di lesioni cutanee pre-cancerogene
(aktinic keratosis). L’intensità della fluorescenza del PS, accumulato nelle lesioni, é
stata misurata tramite un’apparecchiatura costruita appositamente e caratterizza-
ta da un’illuminazione della zona analizzata rigorosamente costante ed omogenea.
L’obiettivo specifico era di studiare la correlazione esistente tra il fotodecadimento
del PS (PpIX; indotto, in questo caso, attraverso la somministrazione di Metvix®)
ed i risultati clinici valutati a diversi mesi dal trattamento. I risultati mostrano un
robusta correlazione tra il fotodecadimento del PS e la fluorescenza misurata prima
dell’illuminazione PDT. Allo stesso modo, i risultati clinici preliminari confermano
l’esistenza di una tendenza verso una robusta correlazione tra il fotodecadimento e
gli effetti terapeutici indotti. Con ció, diviene possibile selezionare e ottimizzare i
parametri d’illuminazione della terapia PDT prima o durante il trattamento. Nel
caso specifico del trattamento di lesioni di aktinic keratosis, il risultato di questo
studio fornisce una chiara indicazione della pertinenza nell’utilizzo del fotodecadi-
mento del PS per l’ottimizzazione dei protocolli PDT e per prevederne gli effetti
terapeutici.
Parole chiave: Nervo ottico, Retina, Riflessione infrarossa, Monitoraggio, Laser
termico, Sotto soglia, 810 nm, In vivo, Tempo di vita, PpIX, Luminescenza, Fluo-
rescenza ritardata, PDT, CAM, ALA, Ossigeno tissulare, Effetto vascolare, AK,
Fotodecadimento
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1General Objectives of the Thesis
The Biomedical Photonics Group at EPFL (Previously known as the EPFL Photomedicine
Group.) is active in the field of clinical photodetection of cancers and light based therapies.
Specific research interests and goals in this field focus mostly in the context of clinical applica-
tions, on optimizing the irradiation parameters, improving the selectivity of photosensitizers,
the reliability of light based diagnosis, and generally ameliorating the efficacy of light based
therapies.
The Group’s research efforts aim at clinical, pre-clinical, and fundamental studies. In
particular, we seek to get a better understanding of the mechanisms involved, to optimize the
influence of specific parameters for successful photodiagnostics or for light based therapies.
This strategy is due to the fact that, currently, intra- and inter- patient fluctuations, false
positive or false negative detections, and lesion recurrences, still characterize the outcome of
many light-based clinical applications.
The present thesis aimed at studying the possibility of individualizing and optimizing the
irradiation parameters used in certain phototherapies, by measuring or monitoring, during the
treatment, certain particular tissular properties. In this work, we considered three different
applications and, respectively, three different tissular parameters.
The first, clinical, study aimed to analyze the influence of the near infra-red optical ab-
sorbance of the eye fundus, on the appearance of retinal burns during a subthereshold laser
therapy. This was done in the hope to prevent side effects, by adapting the irradiance of the
thermal laser to the local fundus reflectance.
The second, pre-clinical, study aimed to monitor the tissular molecular oxygen depletion
during photodynamic therapy (PDT), a parameter known to play an important role in the
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PDT effect induced in the tissue.
The third, clinical, study seeked to measure the photosensitizer (PS) photobleaching during
PDT, also a parameter related to the induced PDT effect. In these two studies, measuring the
considered parameter was done in the hope that its knowledge could help to reduce intra-, and
inter-patient fluctuations in PDT outcome, and possibly also help optimizing and individual-
izing the PDT protocol itself.
4
2Selected Concepts of Photomedicine
Photobiology is the study of how light - usually natural sunlight - interacts with living organisms
or tissues and of physiological processes stemming from such interactions, e.g. photosynthesis
and animal vision. Photomedicine may be considered as a sub-discipline of medicine, taking
advantage of appropriate, available photobiological knowledge to study and develop the use of
light - usually from an artificial source such as a lamp or a laser - for diagnosing or treating
certain pathological conditions in human organs or tissues.
In this chapter, we present certain aspects of the aforementioned disciplines needed to
understand the work and results reported in this thesis: an overview on optical properties of
biological tissues (§2.1), an overview on light-tissue interactions (§2.2), and an overview on the
physical basis of luminescence (§2.3). To conclude this introduction, we present a somewhat
more detailed overview on Protoporphyrin IX, a photosensitizer used in this work (§2.4).
2.1 Tissue Optics
To study how light interacts with matter, particularly with biological tissues, we need knowl-
edge of the studied (bio-)material’s optical properties. We introduce, hereunder, the standard
parameters used to characterize how illuminated biological tissues influence the propagation
of the light irradiating them. Four principal interactions can be identified: reflection, refrac-
tion, absorption, and scattering. Four fundamental microscopic parameters, corresponding to
these 4 light-matter interaction types characterize the optical properties of biological tissues:
the absorption coefficient µa, the scattering coefficient µs, the refraction index n, and the
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phase function φ (see Table 2.1). Mathematical modeling of the above-mentioned light-tissue
interactions relies on these four (tissular) microscopic optical parameters.
The absorption and scattering coefficients µa and µs are defined to be the probability of
absorption, respectively scattering, per unit path-length. Their inverse is actually the mean
free path before occurrence of an absorption, respectively a scattering, event. The refraction
index n, defined as the ratio of light speed in a vacuum relative to that speed in the tissue,
is the main parameter responsible for light refraction and reflection. The last fundamental
microscopic parameter, the phase function φ (s, s′), describes the probability density of a photon
to be scattered from direction s to direction s′. Therefore, this parameter characterizes the
geometric dispersion of the scattered light. By definition an isotropic scattering matter is
characterized by φ (s, s′) = 14pi (See Equation 2.1)∫
4pi
φ (s, s′)dω = 1 (2.1)
Using these four fundamental microscopic parameters, we can derive other, dependent quan-
tities, often used in practice, such as the total extinction coefficient: µt = µa + µs, and its
inverse: Lt = 1/µt , which is the mean free optical path of incident photons in a turbid media.
Another useful parameter is the scattering distribution in a turbid media, described by the
anisotropy factor g, obtained by computing the mean cosine of the scattering angle. The value
of g, in a scale from −1 to 1, characterizes the direction of the scattering: a value of: g = 1
denotes purely forward scattering, while: g = −1 corresponds to purely backward scattering
and: g = 0 denotes isotropic scattering. For example, in most biological tissue, the value of
g ranges from 0.7 to 0.99 [16], indicating that photons are preferably scattered in the forward
direction. Using g, we can compute a reduced scattering coefficient : µ′s = (1 − g)µs, which
takes into account the anisotropy of scattering in the studied media.
Nevertheless, in usual, real situations, where samples of bulk tissue are analyzed, the mi-
croscopic parameters are difficult to evaluate, as these situations are characterized by the
occurrence of multiple scattering/absorption events. As a consequence, to characterize the
optical properties of thick or massive samples, three macroscopic parameters are defined, :
the effective attenuation coefficient µeff , is equal to the inverse of the tissue depth at which
the incident spatial irradiance is attenuated by a factor 1/e (36%); the diffuse reflectance R
is computed as the proportion of the light backscattered by the tissue; similarly, the diffuse
transmission T is computed as the ratio of the light transmitted by the tissue relative to the
light transmitted by an 100% transmission sample. It then becomes possible to evaluate the
6
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Fundamental microscopic parameters
µa Absorption coefficient [cm−1]
µs Scattering coefficient [cm−1]
n Refraction index
φ (s, s′) Phase function
Dependent microscopic parameters
µt = µa + µs Total extinction coefficient [cm−1]
Lt = (µt)−1 Free optical path length [cm]
a = µs/µt Albedo
g =
∫
4pi φ (s, s′) cos(ω)dω Anisotropy factor
µ′s = (1− g)µs Reduced scattering coefficient [cm−1]
Macroscopic parameters
µeff =
√
3µa(µa + µ′s) Effective attenuation coefficient [cm−1]
d = 1/µeff Effective penetration depth [cm]
R Diffuse reflectance
T Diffuse transmittance
Table 2.1: Optical parameters used to characterize light-tissue interactions. The fundamental,
microscopic parameters are the absorption coefficient (µa), the scattering coefficient (µs), the re-
fraction index n, and the phase function (φ), from which all other parameters are deduced.
microscopic parameters from the macroscopic ones by using specific, theoretical models of light
propagation. For example, the following relation between µeff and the microscopic parameters
µa and µ′s is obtained, in the context of the diffusion approximation by [27]:
µeff =
√
3µa(µa + µ′s) (2.2)
The microscopic parameters of different tissues have been studied by numerous groups [25],
whose measurements do not always allow for the adoption of a consensus value, for some
tissue/parameter combinations.
In Table 2.2, we report these parameters for the outermost skin layer (the human epidermis),
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showing their dependence on the wavelength. The reported values also support the wavelength-
dependency of the effective penetration depth of light in massive samples.
Optical Parameter Wavelenght [nm]
[cm−1] 400 630
µa 15 2
µs 900 70
µ′s 300 20
g 0.74 0.8
Table 2.2: Typical microscopic optical parameters for the human skin epidermis [23]
Typical values for the effective penetration depth (1/µeff ) for tissues like the skin (See
Figure 2.1(a)) varies from several hundreds of µm to some mm in the red and near infrared
(600− 900nm). Blue light (≈ 400nm), by contrast, will only penetrate several tens of µm. It
is worth noting that, in the clinical field, the penetration depth is now frequently defined as the
depth where the incident light is decreased by one order of magnitude (i.e. I = 0.1× I0) rather
than the theoretically correct factor of 1/e (i.e. I = 0.36 × I0). As a consequence, “decadic”
penetration depths defined in this way are much larger: thus, in normal skin, we would have a
“decadic” penetration of : 300− 400µm at 400 nm and 6− 7mm at 600 nm [2, 26].
Different studies were conducted to find out the main parameters influencing the penetration
depth. Obeid et al. [17], for example, while studying the penetration of red light in the skin (at
630nm), observed a significant - and expected - correlation with the so-called Fitzpatrick skin
type1. In this case the penetration depth ranging form 600µm to 1500µm is probably limited
by absorption of the melanin, which is found in different concentration in the six skin “types”.
Indeed, light absorption plays an important role in photomedical applications, the major
light-absorbing molecules in mammalian tissues being: oxy- and deoxy-hemoglobin, melanin,
myoglobin and water, see Figure 2.1(b). Examination of these absorption spectra helps to
define the optical therapeutic window to find a strategy to efficiently treat the target lesions.
1The Fitzpatrick skin type scale, developed in 1975 by T.B. Fitzpatrick, classifies the response of the different
types of skin to UV light, on a 0-100 scale, divided in 6 types. It describes several lumped properties: genetic,
reaction to solar UV light and tanning habits. For example: “Type II (scores 8-16): white; fair; red or blond
hair; blue, hazel or green eyes; Usually burns, tans with difficulty”
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(a) Effective penetration depth in breast tis-
sue
(b) Principal absorbers in biological tissue
Figure 2.1: (a) Typical penetration depth of light in the skin as a function of light wavelength,
adaptated form Vo-Dinh and Masters [27]. (b) Absorption spectra of commonly found absorbing
molecules in living tissues, showing the “therapeutic optical window” between 600 and 1000 nm [3].
2.2 Light-Tissue Interactions
This discussion focuses on some of the different types of phenomenae which can be observed
when light is applied to biological tissue. For convenience a laser light source is considered to
support the following discussion, due to its monochromaticity, short pulse duration, and high
radiance. However, similar observations can be inferred for non-coherent light sources, provided
that these sources allow for the tissue irradiance and exposure times, needed to observe all the
different types of possible light-tissue interactions [4].
Tissue characteristics as well as parameters of the laser irradiation may lead to a diversity
of outcomes. The laser light delivered is characterized by its wavelength (in nm), duration or
exposure time (in s), and tissue irradiance in (W/cm2). Among these, for a given amount of
applied energy density, the exposure time appears as a crucial discriminant between different
types of interactions.
Following the invention of the laser by Maiman [13], many studies were conducted to in-
vestigate its potential effects on tissues, using all kinds of laser systems and tissue targets.
Eventually a consensus emerged and resulted in five main categories of interaction types, still
in use today: photochemical interactions, thermal interactions, photoablation, plasma induced
ablation, and photodisruption. The domains (in terms of exposure time and power density),
where these five basic interaction types are usually observed are shown in Figure 2.2.
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Figure 2.2: Map of laser tissue interactions. (The ordinate expresses the applied power density or
irradiance in W/cm2. The abscissa represents the exposure time in seconds. Two diagonals show
constant radiant energy densities at 1 J/cm2 and 1000 J/cm2, respectively) The circles give a rough
estimate of the associated laser parameters. Adapted from Boulnois [3]
These characteristic domains fall roughly between two parallel diagonal lines, corresponding
to constant radiant energy density of 1 J/cm2 and 1000 J/cm2, respectively. According to this
chart, and at these energy levels, the exposure time scale can be roughly divided into five
sections [16]:
• photochemical interactions, from several thousands seconds down to 1 s;
• thermal interactions, from several tens of seconds down to several µs;
• photoablation, from 1µs down to 1ns and
• plasma-induced ablation and photodisruption, for exposure times shorter than 1ns (in
this case we can observe an overlap, depending on optical dose).
Hereunder, we will focus specifically on thermal interactions, which are at the core of the
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work described in Part I, and on photochemical interactions, which are essential for the work
reported in Parts II and III.
2.2.1 Thermal Interactions
When discussing thermal interactions, the principal effect sought is the heating of the irradi-
ated sample. In general, photothermal processes originate via a two step precess. First the
excitation light is absorbed and the energy of photons is transfered to the electronic, and/or
vibrational, and/or rotational, excited states of the irradiated molecules. Successively, these
excited molecules de-excites (with decay lifetimes form 10−13 to 10−12 s), through non-radiative
de-excitation (thermalization), giving their energy to adjacent molecules, increasing the sys-
tem’s kinetic energy, and by definition, also the temperature of the irradiated tissues. The
two-step reaction, leading to local temperature increase, can be schematically represented as
[3]:
Absorption A+ hν → A∗
Thermal relaxation A∗ +M(Ecin)→ A+M(Ecin + ∆Ecin)
where A represent the target molecule, which is promoted, following photon absorption,
to an electronically and/or vibrationally excited state A∗. Thereafter, by collision or inelastic
scattering, the kinetic energy of an adjacent partner molecule (M) is increased through the
transfer of the excess internal energy of A∗.
Thanks to the numerous possible thermal decay pathways, a photothermal process is highly
efficient. Moreover, by comparing the typical energies of laser photons (Er:YAG laser: 0.35
eV; Nd:YAG laser: 1.2 eV; ArF laser: 6.4 eV) with the kinetic energy of a molecule at room
temperature (0.025 eV) we see that the absorption of a single photon can easily lead to a very
large and quick temperature increase.
The peak value of the temparature reached, and the period during which the increased
tissue temperature is maintained, will actually define the tissue response to light radiation. In
practice, independently form the administration mode (through continuous wave (CW) laser
radiation or pulsed laser), carefull adaptation of the exposure time may lead to four main
different outcomes: coagulation, vaporization, carbonization, and melting.
As an example, the histological appearance of coagulated tissue is illustrated in figure 2.3,
where 120 pulses from an Er:YAG laser were applied to an excised cornea. Coagulated tissue
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appears significantly darker than other tissue, when staining the tissue with hematoxylin and
eosin. During the process of coagulation, temperatures reach at least 60 ◦C, and coagulated
tissue becomes necrotic [16]
Figure 2.3: Human cornea coagulated with 120 pulses from an Er:YAG laser. Figure adapted
from [16](pulse duration: 90µs, pulse energy 5mJ , repetition rate: 1Hz, bar: 100µm)
By carefully examining Figure 2.3 we may see that the irradiated tissue is being affected
at the absorption location, but also, that the thermal effect affects deeper structures. These
irreversible structural changes, induced by the photothermal process, reflect tissue thermo-
genesis caused by thermal conduction of the absorbed incident power. In order to minimize
thermal damage to the zones adjacent to the irradiation location, and obtain a smaller necrotic
zone, it is important to adjust the irradiation exposure time. The scaling parameter for this
time-dependent thermal conduction process is called the thermal relaxation time, τT , obtained
by equating the characteristic optical penetration light depth L (L = 1α) to the characteristic,
time-dependent, thermal penetration depth, zT (zT (t) =
√
4κt). The optical penetration depth
and thermal penetration depth, are respectively the parameters that characterize the distance
at which a light irradiation and a temperature drop by a factor of 36% (1/e) is observed. Con-
sequently, τT is defined as the threshold time needed to confine the temperature increase to a
depth on the order of the optical penetration depth (see Equation 2.3).
L =
√
4κτT (2.3)
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where κ (cm2/s) is the tissue diffusivity, a lumped physical parameter characterizing the
material’s thermal response (which depends on thermal conductivity, specific heat and density).
For example, the diffusivity of liquid water is κ ≈ 1.4× 10−3 cm2/s.
Therefore, a clinical thermal laser application has to be carefully designed in order to
provoque strictly localized effects (thermal confinement). This is especially important in opthal-
mologic laser treatments of the retina, where the usual target tissue, the retinal pigmented
epithelium (RPE), is immediately adjacent to the visual photoreceptors layer, which is only a
few tens of µm away. Thus, to avoid iatrogenic blind spots in the field of view of the treated
patient, the diffusion of heat away from the absorption site has to be carefully controlled.
Along these lines, retinal subthreshold laser therapies were recently introduced: they con-
sist in application of thermal laser radiations, inducing a well localized temperature increase,
deemed useful to promote the healing effect, but simultaneously avoiding any thermal denatu-
ration of the photoreceptor layers (i.e. “retinal burns”).
2.2.2 Photochemical Interactions
A light-tissue interaction is considered as being “photochemical” when it can empirically be
observed that light has caused chemical effects and/or reactions within the tissue, its com-
partments or its macromolecules. One of the best examples was created by evolution itself,
the photosynthesis. For a photochemical interaction to exist, a specific chromophore must be
present in the tissue (the chlorophyll in the vegetal tissue, in the case of photosynthesis) which
will usually act as the catalytist of some specific chemical reaction or set of reactions (the pro-
duction of carbo-hydrates from water and carbon dioxyde, in the case of photosynthesis). As
shown in Figure 2.2 photochemical interactions are usually induced at very low power densities
(typically 1W/cm2) and long exposure times (ranging from tens of seconds to several minutes),
and photochemical processes can thus be initiated with simple, non-coherent light sources or
even by daylight (e.g. photosynthesis, sun-tanning). Hence, to obtain a desired photochemical
reaction, without undesirable, thermal side-effects, low power densities and long exposure times
are preferred.
Photochemical interactions are at the root of most mechanisms involved in photodynamic
therapy (PDT). PDT is a treatment modality which takes advantage of the effects induced
by light in the tissue, tissular oxygen, and a light sensitive drug, the photosensitizer (PS) [5].
A PS, with known spectral properties, is administered to the target tissue, where the above
mentioned photochemical reactions are triggered by applying light from a source spectrally
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matched to the PS’s absorption spectra. This results in the formation of cytotoxic products,
mainly reactive oxygen species (ROS), which may destroy, or provoque the death of target
cells, organs or tissue components.
From a photochemical perspective (see Figure 2.4) the energy of the absorbed light photon,
promotes the photosensitizer molecule to an electronically excited singlet state (1PS). From
there, three routes are available: the radiative or non-radiative relaxations of the excited singlet
molecule to its ground state (0PS), and intersystem crossing of the excited singlet to an excited
triplet state (3PS∗) which, finally, may in turn, either relax to the ground state (by non-
radiative or radiative routes), or take part in one of several sets of photochemical reactions,
with the tissular substrate and tissular oxygen (See §2.3 for details).
The radiative decays of the excited singlet and excited triplet states of the PS are called
fluorescence and phosphorescence, respectively. Typical lifetimes of fluorescence are of the
order of nanoseconds, whereas phosphorescence may last several milliseconds, up to seconds.
Thus, excited triplet PS molecules, which do not immediately relax to the ground state, may
interact with the surrounding environment and molecules during a relatively long time period:
according to Foote [7], this mainly takes place by two competing photochemical pathways,
known as Type I and Type II mechanisms (Fig. 2.4). They are characterized by either the
generation of free radicals or radical-ions (Type I), or the transfer of energy to tissular oxygen
molecules, which are excitated to their highly reactive singlet state, noted here as 1O2 for short
(Type II).
In Type I reactions, the triplet state PS interacts with any nearby molecule - other than
oxygen - producing free neutral or ionized radicals. Further reaction of these radicals with
triplet oxygen may lead to the formation of hydrogen dioxide or superoxide anions.
In Type II reactions, the triplet state PS directly reacts with molecular triplet oxygen 3O2
which is promoted to its excited singlet state 1O2. Such triplet-triplet reactions are highly
favored [10].
Both, type I and type II photochemical reactions occur in parallel, and both may produce
ROS that will interact with cells, inducing apoptosis, or leading directly to necrosis via oxidative
processes. The relative importance of the two reaction paths depends on several parameters, the
nature of the photosensitizer used and the oxygen concentration being the most important [7,
18]. Nevertheless, for most photosensitizers employed in PDT, type II photochemical reactions
represent the dominant process [9, 28]. This is the case for Protoporphyrin IX [5, 24], the
photosensitizer used in the experiments developed in Parts II and III of the present work.
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2.3 Physico-Chemical Aspects of Luminescence
In Parts II and III of this thesis, we seek to monitor two specific parameters, the PS’s delayed
fluorescence (DF) lifetime and the PS’s fluorescence photobleaching, respectively, in view of
optimizing the clinical outcome of PDT. In this section of our introduction, we offer an overview
of some aspects of luminescence, necessary to understand these two parameters.
Luminescence is the phenomenon of light emission by a system. Depending on the na-
ture of the excitation mechanism (which promoted the system from its ground to its excited
state), this light emitting phenomenon is called chemiluminescence, bioluminescence, electro-
luminescence, cathodoluminescence, or photoluminescence. In the studies presented here, we
are mainly interested in photoluminescence, as the system (the PS) is excited with visible light.
Photoluminescence, in turn, can be categorized as fluorescence or phosphorescence, depending
on the nature of the system’s excited state: Fluorescence corresponds to the decay of a short-
lived, excited singlet state, while phosphorescence is caused by the decay of a longer-lived,
excited triplet state. The various molecular processes related to luminescence are conveniently
represented in a so-called Jablonski diagram, see Figure 2.5. In this diagram, some of the elec-
tronic (thick horizontal lines) and vibrational (thin horizontal lines) energy levels, or states, of
a specific molecule are represented, as well as some of the relevant state transitions (i.e. energy
conversions).
We will focus here on only two physico-chemical process, the “quenching” of an excited
state and the “photobleaching”, both relevant for this work.
15
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Figure 2.4: Photochemical reaction pathways of an irradiated photosensitizer molecule, PS: If the
excited PS molecule does not relax through fluorescence, phosphorescence or non-radiative decay, it
may take part in a number of photochemical reactions, following either the Type I or Type II initial
mechanisms, with the substrate or tissular oxygen, in its triplet ground state O2(3Σ−g ). This results
in the production of reactive oxygen species (ROS), causing dose-dependent cellular damage. The
most important ROSs are: H2O2, hydrogen peroxide; O2(1∆g), singlet oxygen (excited state); O−•2
, superoxide anion; and OH−•, the hydroxyl radical. Other species involved: SOD, superoxide
dismutase; X+/−, anion/cation species; X•, radical species. Adapted from a figure published by
[20].
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Figure 2.5: Jablonski diagram of a luminescent molecule. The diagram indicates, with thick
horizontal lines, the ground state (S0), the first and second electronically excited singlet states
(S1 and S2), and the first (electronically) excited triplet state (T1) of the molecule, each with its
vibrational levels (thin lines). Transitions between the energy levels are depicted by vertical arrows˙:
straight arrows for radiative transitions, wavy arrows for non-radiative decays. The molecule is
promoted to an electronically excited singlet states by the absorption of light, possibly relaxing very
rapidly (< 10−12 s) to its vibrational ground state (“vibrational relaxation”). Internal conversion
(IC) is the non-radiative transition from a higher electronic state to a lower one. Fluorescence is
the radiative transition of a molecule from a higher electronic singlet state to its ground state S0.
Typically, these transitions occur within 10−9 s. Intersystem crossing (ISC) describes the transition
between an excited singlet state of the molecule and its triplet state. Such transitions are quantum
mechanically “forbidden” and therefore “long-lived” (≈ 10−3 s). The emission of light resulting
from the radiative de-excitation of the triplet called phosphorescence.
17
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2.3.1 Quenching of Excited States
For a normally luminescent molecule, total or partial replacement of its (luminescent) radiative
relaxation route by a radiationless (non-luminescent) decay, due to its interacting with an
adequate species - the quencher - through electronic energy or charge transfer, is known as
“quenching” (of the luminescence). Thus, any molecule causing a decrease in the luminescence
intensity of a PS (or, more generally, a fluorophore) is considered as a “quencher” [10, 15].
Quenching resulting from collisional encounters between the PS and quencher is called
collisional or dynamic quenching. In this case, upon contact with the quencher, the excited
fluorophore returns to its ground state, without emission of photons or structural change of the
fluorophore - the latter in contrast with certain other types of quenching mechanisms - [19]. This
quenching phenomenon has been widely studied and is still used to characterize processes in
many biochemical applications. For example, in photodynamic therapy (see §2.2.2), the triplet
state of the PS is dynamically quenched by tissular molecular O2, which leads to the production
of the useful, cytotoxic ROSs such as 1O2. A fundamental characteristic of dynamic quenching
is the existence of a relationship between quencher concentration and: (i) the intensity of the
radiative decay, (ii) the lifetime of the excited state being quenched. Dynamic quenching is
described by the well-known Stern-Volmer equation 2.4:
F0/F = τ0/τ = 1 + kqτ0[Q] (2.4)
where F0, τ0 and F , τ are the intensity and lifetime of the radiative decay in the absence,
respectively the presence of quencher. kq is the bimolecular quenching constant, and [Q] is the
concentration of quencher.
In Part II of this thesis, a specific instrument was developed to measure the lifetime of the
PS’s triplet state during PDT, in view of evaluating the tissular oxygen concentration, oxygen
being a known quencher.
2.3.2 Photobleaching
Photobleaching is defined as an irreversible photochemical destruction of a fluorophore. As a
rule, photobleaching represents a limitating factor in many optical based diagnostic methods
and therapeutic treatments. Note, however, that in certain photomedical applications, such
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as fluorescence recovery after photobleaching, the induced local destruction of a specific fluo-
rophore is used to analyze the lateral diffusion and the association and disassociation coefficients
characterizing the binding of proteins to cellular structures.
During PDT, ROSs (e.g. 1O2) generated by the photochemical reactions, are thought to be
the main responsible, not only for induced tissue effects, but also for the observed photobleach-
ing of the PS. Consequently, under certain conditions, the photobleaching may be linearly
correlated with the induced tissular effect [6, 24, 29]. One important condition to meet, in
order to observe this relation, is that molecular oxygen has to be abundantly present in the
treated tissue, to avoid being a limiting factor in the PDT effect.
In Part III of this thesis, we check if the clinical outcome of PDT, performed on a superficial
skin condition (actinic keratosis), can be predicted by measuring the amount of photobleached
PS.
2.4 Protoporphyrin IX
In view of optimizing PDT, various photosensitizing drugs have been developed. On the other
hand, two classes of photosensitizers can be distinguished: exogenous PSs and endogenously
induced fluorochromes, i.e fluorochromes that are not directly administered to the patient but
generated by the patient’s organism after application of a precursor, either topically or sys-
temically. PpIX is such an endogenous photosensitizer. The build-up of PpIX in the patient’s
body is promoted by administering a specific precursor, 5-aminolaevulinic acid (ALA), either
systemically, or topically to the target tissue. PpIX is considered as an efficient PS, thanks to
the high observed 1O2 quantum yield [21], with a high sensitizing potential. It can be used for
treating many conditions in different body locations. On the other hand, PpIX is an intermedi-
ate species in the biosynthesis of heme, the iron-containing constituent of hemoglobin. PpIX is
therefore produced and present in almost all mammalian cells. It is to be noted that a chronic,
excessive accumulation of PpIX leads to different severe condition, one among these is called
erythropoietic protoporphyria [22], causing permanent light sensitization and liver disfunction.
Luckily, a transient, selective accumulation of PpIX in a target organ does not present ad-
verse effects other than transient photosensitization of the administered zone. Moreover the
clearance of the accumulated excess of PpIX is relatively fast (less than 48h).
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Figure 2.6: Heme’s simplified biosynthesis. A first enzyme, 5-aminolevulinate synthase (ALAS),
catalyzes the reaction of glycine with succinyl CoA, giving one molecule of 5-aminolevulinic acid
(5-ALA). This is followed by the condensation of two 5-ALA molecules, catalyzed by the enzyme 5-
aminolevulinate dehydratase (ALAD), into one molecule of porphobilinogen (PBG). An enzymatic
cascade of reactions then converts four molecules of PBG, in several steps, into one molecule of
protoporphyrin IX (PpIX). Heme is produced when the enzyme ferrochelatase inserts a ferrous iron
into PpIX. To note the negative feedback exerted by the presence of Heme on the first catalysis
reaction leeding to the biosynthesis of 5-ALA. A: acetate; P: propionate. Adapted and simplified
from [8].
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2.4.1 Biosynthesis of Protoporphyrin IX
PpIX is produced during the biosynthesis cycle of heme. This cycle is depicted in the simplified
Figure 2.6.
The initial step is the condensation of glycine and succinyl coenzyme A (succinyl CoA) to
5-ALA (ALA for short) in the mitochondrion. The ALA molecule passes into the cytoplasm
where it is first dimerized to PBG, 4 molecules of which undergo various chemical reactions,
regulated by enzymes, to produce, in several steps, the phototoxic PpIX. The last step is
the chelation, enabled by the enzyme ferrochelatase, of a ferrous iron ion (Fe2+) into the
porphyrin ring, resulting in the non-fluorescent heme molecule. The heme molecule is then
further transformed to hemoglobin. On the other hand, ALA production is regulated by heme
through a negative feedback mechanism, i.e. a cellular increase of the concentration of heme
(itself derived from ALA, through the PpIX) inhibits the normal, biologic pathway of ALA
production.
ALA (Levulan®) is one of the most common, photomedically approved, precursor of PpIX.
Several derivatives of ALA are also in medical use, such as, for example, its methyl ester (MAL,
Metvix®) and its hexyl ester (HAL, Hexvix®). Exogenously administered ALA (or one of its
derivatives) appears to “fool” the negative feedback mechanism of heme production. Thus,
the external application of ALA can lead to a temporary accumulation of PpIX. The amount
of accumulated PpIX depends on the cell type or pathology. For instance certain, neoplastic
cells show a higher accumulation of PpIX after administration of exogenous ALA than healthy
ones. The resulting fluorescence intensity contrast between healthy tissues and lesions is used
in ALA-induced PpIX fluorescence, for detection of dysplasia and early neoplasia [11, 12, 14].
2.4.2 Spectral Properties of Protoporphyrin IX
Studying the PpIX’s emission and excitation spectra (see Fig. 2.7), they show that this PS may
be excited at several wavelength. In particular we observe a small but significant absorption
in the red spectrum (630 − 635nm). As described in §2.1, this portion of the spectrum is of
high interest due to the high penetration of red light (6 − 7mm) in soft tissues. Thus, PDT
might be efficiently administrated also to relatively deep seated structures in the tissues.
Simultaneously, the possibility to efficiently excite PpIX with shorter wavelengths, is of
interest if the lesions are confined to the superficial layers of the target tissue. Thus the PDT
selectivity could be further enhanced. Different studies have, for example, analyzed the induced
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pain during PDT in function of the PDT illumination wavelength. It was shown that at shorter
wavelength (405nm) the pain experienced by the patients was significantly reduced even if the
photochemotherapeutic dose is kept constant [1].
To conclude, PpIX’s many useful properties explain why it is considered as a excellent
photosensitizer, which is used in a number of clinical applications.
Figure 2.7: PpIX’s emission (Ex. at 405 nm) and excitation (Em. at ≈ 700 nm) spectra
2.5 Applications of Selected Concepts
We have briefly introduced some of the relevant aspects of photomedicine necessary to under-
stand the work developpes in this thesis. We will now present the three different developed
topics. Part I presents a clinical study aiming to improve the control over a subthreshold
thermal laser therapy. In this study the reflectance of the eye fundus was measured to verify
whether a correlation exists with the aptitude to create “retinal burns”.
Part II, present a pre-clinical in vivo study where we evaluates whether of the PpIX’s
delayed fluorescence is a valuable parameter to control and predict the PDT vascular effect in
the chick chorioallantoic membrane model.
Finally, the third project, a clinical study, analyses the PpIX’s fluorescence photobleaching
during a superficial PDT skin treatment, see Part III. The aim, of this study was to evaluate
whether the photobleaching is a valuable parameter to predict the clinical outcome of PDT
treatment for actinic keratosis.
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3Introduction
3.1 A brief Overview of Lasers in Ophthalmology
The laser has become a standard tool for the treatment and diagnostic of various conditions
affecting the eye, including the retina [16, 18, 21, 23, 24, 26, 27]. Many retinal conditions
can be more or less efficiently treated by delivering suitable laser light: age-related macular
degeneration (AMD) [1, 18], diabetic retinopathy, retinal tears [2, 3], macular edema [7] and
intraocular tumors [4, 19]. In certain cases (e.g. retinal tears), the laser is used to perform a
mechanical welding of the retinal layers. In some other pathologies (e.g. diabetic retinopathy),
the periphery of the retina is denatured, in order to increase the amount of oxygen in the treated
area and in the macular region, thereby preserving central vision. In many ophthalmologic laser
treatements, photothermal reactions is the main interaction modality, as it is the case during
pan-retinal photocoagulation (PRP) which is used to treat for instance diabetic retinopathy [8,
10, 15, 20].
Photothermal regimes and thus photocoagulation can cause undesired modifications of the
irradiated tissue (e.g. retinal burns). If such burns occur in the retinal layers (see Figure 3.1),
they can produce a transient whitish lesion, and may result in a permanent local scotoma (i.e.
area of diminished vision) in the patient’s field of view. Even though retinal burns are still
the endpoint for different laser therapies [14], it was shown that clinical efficacy is not always
related to the extent or appearance of those tissue modifications [6, 12, 13, 17].
Large variations in the optical properties of the retina in the visible and/or the near infrared
have been demonstrated by other groups [4, 5, 9, 11, 25]. In order to improve the laser treatment
safety by preventing the retinal burns, we had in mind to reduce the laser irradiation time or
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Figure 3.1: Histological layers of the human eye fundus (adapted from Polyak [22])
the laser irradiance if the local retinal area presents a strong absorbtion. We tried to validate
this strategy during the retinal treatment with a new and promising subthreshold infrared
(810nm) laser therapy, namely the hydrodynamic rebalancing laser (HRL).
3.2 Objectives of this Work
The present work aimed at investigating if the observed side effects (“retinal burns”) during
HRL therapy were correlated with the presence of highly absorbing structures in the fundus
tissue. In order to reach this goal, a standard fundus camera was modified to record the eye
fundus reflectance at the same wavelength as the treatment laser (810nm).
The presence of highly absorbing structures was evaluated by recording an infrared re-
flectance image (810nm) just before the onset of HRL treatment. During HRL treatment, the
exact retinal location and the irradiation parameters of each HRL laser spot were recorded.
Additionally, the clinician reported each laser spot that led to the formation of “retinal burns”.
Knowing the exact position of the infrared laser spots we could study the local infrared
reflectance of the fundus and so evaluate the correlation with the aptitude to create “retinal
burns”.
Thanks to the vivid collaboration between the Biomedical Photonics-EPFL laboratory and
the two medical doctors: Dr Vezzola and Dr Sickenberg we designed, a clinical study in order
to investigate whether the HRL could be optimized. In Chapter 4, we present the results of
this clinical study, performed in the private clinical practice of Dr Vezzola in Saló, Italy.
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Abstract
In the Hydrodynamic Rebalancing Laser (HRL) treatment of eye disease, the pre-
diction of the exact response of the retinal tissue to the thermal diode laser (810
nm) is not trivial. HRL is a novel ophthalmic therapy based on the administration
of focused, sub-threshold near infrared radiation to selected spots of the eye’s fun-
dus. We are interested in the parameters responsible for the heterogeneity of tissue
responses. Variation of the tissular optical absorbance at the laser’s wavelength was
hypothesized to be a main cause of the observed uneven tissue response, including
the undesired occurence of burns. We therefore studied the normalized fundus re-
flectance at 810 nm with a standard fundus camera, whose response was extended
to the near-infrared spectral region. Thus, for each laser spot, we recorded the lo-
cation (with a resulotion of about 20µm), the irradiation parameters and the tissue
response, in order to discover any measurable correlation between tissue response
and the value of the local, normalized, infrared fundus reflectance.
The results do not show any clear correlation. There may be several reasons for
this, one being that the geometrical resolution of the reflectance images, taken with
our infrared fundus camera, is not sufficient to see “small” (typically 10µm in di-
ameter) absorption centers. Moreover, due to the weak absorbance of the fundus,
and to the significant scattering of the near infrared laser light, it is not easy to
distinguish between reflected and scattered light. Although local variations of the
fundus optical absorption almost certainly play an important role in the occurrence
of burns, other tissue parameters, that influence heat diffusion, and thus the tem-
perature increases induced by the laser, also had to be discussed and analyzed in the
framework of our experimental results. We conclude that standardizing the results
of HRL therapy, or any similar infrared diode laser-based therapy, by adapting the
laser pulses to local optical properties will require more sophisticated technologies.
Including imaging the retina’s reflectance with an improved resolution.
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4.1 Introduction
The laser has become a standard tool for
the treatment and diagnostic of various
conditions affecting the eye including the
retina [58, 63, 68, 71, 72, 75, 76]. Many reti-
nal conditions such as age-related macular de-
generation (AMD) [2, 63], diabetic retinopa-
thy, retinal tears [5, 17], macular edema[34]
and intra ocular tumors [18, 64] can be more
or less efficiently treated by delivering suit-
able laser light. In certain cases (e.g. retinal
tears) the laser is just used to perform a me-
chanical welding of the retinal layers. Other
laser therapies include the treatment of sec-
ondary cataract with pulsed YAG lasers, the
treatment of glaucoma, and the correction of
vision. In some other pathologies (e.g. dia-
betic retinopathy) the periphery of the retina
is denatured as the oxygen amount delivered
to the inner retina of those treated areas in-
creases and thereby potentially helps to pre-
serve central vision. In some cases, the mech-
anisms that lead to improvement of the vision
are not yet fully understood and are the ob-
ject of much ongoing research. Despite the
observed treatment efficacy, a deeper under-
standing of the mechanism of the treatments
is still needed for further optimization.
The regimes and types of laser-tissue in-
teractions commonly used in these retinal
treatments are either photochemical or pho-
tothermal. Photochemical reactions take
place, for example, during the treatment
of exudative AMD by photodynamic ther-
apy [78, 84, 87]. Photothermal reactions
are, instead, the main interaction modality
during pan-retinal photocoagulation (PRP)
[36, 41, 57, 65] which is used to treat for
instance diabetic retinopathy. Photothermal
regimes and, more particularly, photocoagu-
lation can cause undesired modifications of
the irradiated tissue, among which retinal
burns. If such burns are induced in the neu-
ronal layers, they can produce a transient
whitish lesion, significantly increasing light
scattering, and may result in a permanent lo-
cal scotoma in the patient’s field of view.
Even though the denaturation of the neu-
ronal layers are still common in different laser
therapies [51], the clinical efficacy was shown
to be independent from the extent or appear-
ance of those tissue modifications [9, 24, 47,
48, 60]. Several new irradiation protocols in
ophthalmology, known as “subthreshold pro-
tocols” which also rely on somewhat different
laser sources have been developed. They aim
at a controlled and limited temperature in-
crease of the neuronal retinal layers and seek
to avoid retinal burns [25, 47, 57].
1The thermal relaxation time, τT , of a tissue is a time-scaling parameter of the thermal conduction process.
It is obtained by equating the characteristic optical penetration depth, L, to the time-dependent characteris-
tic thermal penetration depth, zT (t) =
√
4kt, where k is the tissue thermal diffusivity of the tissue. Thus:
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The temperature increase can be re-
stricted to the irradiated tissues if the laser
irradiation period is kept much shorter than
the tissue’s thermal relaxation time. 1 For ex-
ample, several groups [4, 15, 16] have studied
what is sometimes designated as micropulse
laser thermotherapy, whereby repetitive short
laser (Nd-YLF laser 527nm, 1.7µs) pulses
at a large irradiance (0.2-0.4 MW/cm2) are
administered to selectively treat the retinal
pigmented epithelium (RPE). Even though
the highly absorbing RPE cells are directly in
contact with the photoreceptors and the neu-
ronal layers, irradiation times of the order of
a fewµs allow to photomechanically destroy
them while while inducing light changes to
the nearby photoreceptors. Analysis of the
results obtained with these methods indicates
an amelioration of the clinical outcome and a
reduction of side effects.
Another example of such subthresh-
old therapies is transpupillary thermotherapy
(TTT). It was evaluated for the treatment
of subfoveal choroidal neovascularisation in
AMD [32, 38, 53, 62, 64, 73], as well as
non-exsudative AMD [27, 56, 63, 89]. For
this treatment, a near infrared (IR, 810nm)
diode laser was chosen because of its high tis-
sue penetration and the relatively weak ab-
sorption of melanin and macular pigments at
this wavelength. These characteristics en-
able to target deeper structures, typically
100 − 300µm below the photoreceptors and
the neuronal layers of the retina, therefore
preserving them, even during long irradiation
periods, thanks to the limited heat diffusion,
from the deep-seated absorbing centers. Long
(usually 60 s) laser pulses with small irradi-
ance (2-8W/cm2) are used to significantly in-
crease the temperature in the neighbourhood
of the sub-macular choroidal neovascularisa-
tion [23, 43, 52]. This heating induces vessel
damage and thrombosis to the pathological
neovascularisation. Morover, the weak ab-
sorption of hemoglobin at this wavelenght al-
lows for macular irradiation even in the pres-
ence of retinal and subretinal hemorrhage,
which, once again helps to preserve the neu-
ronal layers.
The treatment of the retina by “hydro-
dynamic rebalancing laser (HRL)” therapy
[67, 79] is yet another approach presenting
similarities with TTT. HRL consists of the
administration of 70 to 200 laser spots (at
810nm) in selected locations of the retina
that are not vital for sight, thus excluding
the optic nerve. Direct treatment of the mac-
ula, as is the case in TTT, would not be safe.
(see figure 4.5). Clinical observations (Dr.
E. Vezzola and Dr. M. Sickenberg, private
communications) suggest that the best clini-
cal outcome is achieved by administering laser
pulses near the upper limit of the subthresh-
old regime.
τT = L2/4k.
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There laser treatment is performed with a
conventional slit-lamp and a Goldmann con-
tact lens [55], which gives access to a large
field of view and helps to avoid excessive
movement of the patient’s eye. HRL makes
use of a CW near infrared laser (810 nm),
with power levels from 0.4 to 1.0 W, a con-
stant spot diameter of ∅ 100µm on the retina
and irradiation pulses ranging from 50 to 200
ms [67].
Historically the developments of HRL
treatment modalities is based on the clinical
observation by Walter [86], who noticed sig-
nificant modifications of the temporal border
of the optic nerve head (ONH). He observed
that in certain diseases processes and with
advancing age there is a progressive degen-
eration of the para-disc retinal pigment ep-
ithelium, followed by a vasoproliferation of
the disc vessels followed by a slow diffusion of
serous fluids between the pigment epithelium
and the inner limiting membrane of Bruch.
The process of degeneration and effusion
of the proteinaceous material in the serum
tend to pool either in micro or macroscop-
ically observable areas to produce small de-
tachments of the retinal pigment epithelium.
As this degenerative process extends over a
period of years, there is a slow but progressive
degeneration of the pigment epithelium, fol-
lowed by liberation of vasoproliferative which
responsible for the formation of pathological
neovessels.
These abnormalities were present in sev-
eral patients affected by different pathologies.
This led to the working hypothesis that nu-
merous macular diseases have a pathological
origin associated with the ONH’s disk leak-
age of extravascular fluids. Vezzola then pro-
posed a new 810nm laser treatment to restore
the hydrodynamic balance within the poste-
rior pole.
Although the mechanistic processes at the
base of HRL therapy are not well under-
stood, a reasonable hypothesis seems that the
laser acts in such a manner that it reduces
some of the typical effects induced by aging
and/or ocular hypertension [1, 31, 35, 44, 59].
This hypothesis is supported by work per-
formed by Sickenberg et al. [79], who stud-
ied the initial stages of fluorescein angiogra-
phy, performed on patients with chorioretinal
neovascularisation (wet AMD). Fluorescence
angiography with fluorescein and a scanning
laser ophthalmoscope demonstrated a small
but measurable ONH’s leakage in some of
the patients. It was not at all clear whether
these leaks had a physiological or patholog-
ical cause, but these observations suggested
that the leakage was related to a rupture of
the hemato-retinal barrier or to direct leaking
of cerebrospinal fluids into the retinal space.
Several thousands patients have now been
treated by HRL therapy, with a good safety
profile. These treatments were associated
with “unpredictable” retinal burns, in 2-3%
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of the laser spots. Albeit much more rare,
small haemorrhages were observed in 2% of
the laser spots. These side effects were cate-
gorized as “unpredictable” because their oc-
currence could not be correlated with the ef-
fective laser parameters or the average fundus
absorbance as perceived by the clinician (E.
Vezzola, personal communication). There-
fore, a reasonable hypothesis was to attribute
these side effects to a heterogeneous distri-
bution of “deep-seated optical absorbing cen-
ters” in the eye’s fundus. This assumption
was supported by the fact that firing the
HRL laser on large pigmented structures of
the choroid (choroidal nevi) frequently led
to such side effects. Also, both small deep-
seated absorbing centers of the eye’s fundus
and choroidal pigmented structures, are fre-
quently difficult to localize, even under near
infrared fundus inspection.
Large variations in the optical properties
of the retina, in the visible and/or the near
infrared, have been demonstrated by other
groups [18, 20, 39, 42, 74]. Thus the present
study aimed at investigating if the observed
side effects of HRL were correlated to the
presence of highly absorbing structures in the
fundus tissue. A logical strategy to prevent
the occurrence of the described side effects
and, consequently, to improve the safety of
the HRL treatment, would then consist of re-
ducing the laser spots irradiation time or the
laser irradiance, at locations of the retina pre-
senting a strong absorption. Direct in vivo
measurements of the eye’s fundus absorption
is not possible, which is why clinical diagno-
sis, including inspection of the retina, make
use of fundus reflectometry. Thus, measur-
ing the fundus reflectance, in particular when
executed at the wavelenght of the treatment
laser, could possibly help to evaluate spatial
variations of the fundus absorption, in an ap-
proach similar to that used by de Graaf et al.
[19], Ludwig et al. [49], Naess et al. [61]. This
strategy was applied in the present study.
4.2 Materials and Methods
4.2.1 Study Design
As mentionned previously, HRL treatement
elicits a small percentage of “unpredictable”
responses from fundus tissue, even when the
laser’s irradiation parameters are kept con-
stant. Given our working hypothesis, which
links this heterogeneity in the tissue reaction
to the pigmentation density and its distribu-
tion in the eye’s fundus, our study focused
on the frequency of induced retinal burns as
a function of the local tissue absorbance - as
“deduced” from its reflectance - measured at
the laser spot location.
For this, one near infrared (810 nm) re-
flectance (IRR) image of the fundus was taken
before the laser therapy. During the therapy,
a video camera was focused on the eye fundus.
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Whenever a laser pulse was administered by
the clinician, the corresponding video image,
showing the precise laser spot position, was
captured and recorded. Simultaneously, the
laser power and irradiation time used were
recorded, in order to draw up an accurate
cartography of the HRL treatment. The map
of the laser spot positions and irradiation pa-
rameters was then superimposed on the initial
IRR fundus image.
During the treatment, the clinician was
asked to assess whether the laser-tissue inter-
action created or not a visible retinal “burn”.
Each laser spot was thus characterized and
tagged with the clinician’s observation, thus
allowing us to establish wether a correlation
existed between the local fundus reflectance
and the laser tissue response.
The study took place in April and June
2008 and all measurements were done in Salò,
Italy. 35 patients (for a total of 46 eyes
treated by HRL) took part in the study. Of
these, 16 patients (for a total of 20 eyes
treated by HRL), with ages ranging from 22
to 78 years (µage = 50.75 ± 16.12 years), pro-
vided the data effectively used in the study
(see §4.3).
All these patients gave their informed con-
sent to be part of the study. Their enrolement
only implied to take two supplementary im-
ages and to record the laser parameters, in
addition to the usual HRL treatment. In the
“standard” procedure, 3 fundus images are
taken to planify the HRL treatment: a stan-
dard color picture, a red-free picture and a
fluorescein angiogram. In the framework of
the present study, supplementary fundus im-
ages were taken as follows: one infrared image
just before the HRL session, to measure the
fundus reflectance, and one white-light im-
age just after each administered laser spot,
to record the spot location.
4.2.2 HRL Treatment
HRL treatments are routinely performed in
several private practice since, up to June
2010, more than 5000 patients had been
treated. A typical HRL treatment session
consists of a series of 100 − 200 laser shots,
with the laser beam focused on the RPE.
According to the clinical observations, treat-
ment efficacy is maximal (data not pub-
lished) when using laser pulses at the upper
limit of the subthreshold regime. During the
treatment, shots aimed at the macula and
the optic nerve head, are carefully avoided.
The laser treatement is administered via a
solid state, CW, ophthalmologic laser source
(810nm), coupled to a standard slit lamp.
The irradiation parameters are chosen by
the clinician, depending on the apparent fun-
dus pigmentation and clarity of the ocular
media of each patient. To evaluate these irra-
diation parameters, a test laser pulse is shot
on a temporal, periferical zone of the eye fun-
dus (A similar procedure is also used during
37
4. HRL MONITORING (SUBMITTED PAPER)
Figure 4.1: Optical transmission of the standard filters (A1, B1), and of the replacement and
additional filters (A, B, C, D), used in the ophthalmoscope. A1: Original Canon® EOS-D1 CCD
filter; B1: Original redfree filter; A: X-Nite CCD filter, used for balanced color images; C: New
CCD filter, used for IRR images; B: Replacement redfree filter; D: IRR image excitation filter.
PRP, to find, in that case, laser parameters
adequate for creating mild retinal burns).
In this study, the laser spot diameter on
the retina was kept constant to ∅100µm for
all the treated patients and the laser power
was set to 1 W - except in one particular
case where the power was lowered to 0.4 W -.
This was at the clinician’s demand, in view
of keeping these laser spots at the limit of
the subthreshold regime (the specific patient
was affected by a severe myopic condition).
The maximum irradiation time was chosen
by the clinician and set between 50 and 200
ms. However, the laser firing system allowed
the clinician to terminate irradiation before
this preset, maximum time was reached, thus
making it possible to “personalize” and mod-
ulate every single laser spot. Anyway the pre-
cise duration of the laser irradaition was mea-
sured as described in §4.2.3
4.2.3 Instrumentation
Acquisition of the IR Reflectance im-
ages
The setup used to record IR reflectance im-
ages relied on standard commercial appara-
tus, with minor modifications. It consists of
a digital camera (Canon®, EOS-1D) attached
to an ophthalmoscope (Canon®, CF-60UVi).
The sets of filters in the camera and the oph-
thalmoscope were replaced as described here-
under (see figure 4.1).
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The CCD filter of the camera was changed
to improve its sensitivity in the near in-
frared. Thus the band-pass filter used for
visible wavelengths (A1), which was normally
mounted in front of the CCD, was replaced
by a clear glass window (C). The ophthal-
moscope’s filter set was modified to match
the enhanced spectral sensibility of the cam-
era. Thus the standard green band-pass fil-
ter (B1) for removing parasitic transmission
bands in the IR range, was replaced with an
interferometric filter (B) (Chroma®, HQ585-
30X) in order to enable the acquisition of
the diagnostic “redfree” images with minimal
noise. A visible-wavelengths band-pass fil-
ter (A), (LDP LCC®, X-NiteCC1), was used
to acquire white-light balanced color images.
Finally a near-infrared band-pass filter (D)
(Chroma®, HQ790/95X) was used to filter
out the flash light when acquiring the fun-
dus IRR images. Note that the band-pass
filter for the acquisition of the fluorescein
angiograms was not modified. These minor
modifications did not affect the effective res-
olution of the diagnostic system, which was
found to be about 40 µm for the standard
color pictures.
HRL treatment:
Data acquisition and processing
The setup is schematically shown in Fig. 4.2.
The clinician (1) administered the HRL treat-
ment to the patient’s eye (3) using a stan-
dard slit-lamp (2) (Takagi®, SM-70N). To fire
a laser pulse, the clinician pressed on the
laser driving pedal switch (4). Additionally,
the clinician was instructed to press a sec-
ond pedal switch (4b) whenever he perceived
an increased reflectance, i.e. a withening of
the treated spot, thus tagging the laser spot
as a retinal burn. A digital video camera
(Optronics®, CS-450) was coupled to the slit-
lamp (2) to record the position of each laser
spot. Simultaneously the effective irradiance
period (tL) and the laser power (PL), were
measured with a calibrated fast photodiode
(OSRAM®, BPX61, typical switching time 20
ns) integrated in the medical laser (5) (Op-
tikon 2000 S.p.a., Elios, λ = 810nm). The
photodiode signal was digitized and analysed
with a data aquisition board (Acquitek, CH-
3150) integrated to the PC (6).
Recording of the HRL treatment infor-
mation (laser position, irradiation parameters
and clinician’s observations) was triggered by
the fast photodiode, every time the clinician
pressed on the laser driving pedal switch (4).
Dashed-lines with arrows in figure 4.2 repre-
sent the driving signals. A self written soft-
ware drove the aquisition of the data from the
3 different sources as shown by the solid-lines
with arrows in figure 4.2.
The fast photodiode was calibrated
with a standard power sensor (Coherent®,
FieldMaster-GS LM-2) to give the effectively
delivered power (PL) and the irradiation time
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Figure 4.2: Schematic representation of the experimental HRL treatment setup, used in this
study: at the beginning of the session, the clinician (1), examines the patient’s eye (3) through
the slit-lamp (2), which incorporates also the video camera; he then adjusts the treatment laser
(5), setting the desired power and maximum irradiation time; to apply one laser pulse, he presses
on the pedal switch (4a), which (i) starts the laser, whose beam is directed on the eye fundus by
the dichroic mirror (DM) and the Goldman lens (GL), and, (ii) triggers the recording of the corre-
sponding video image and laser parameters in the PC (6); the clinician releases pedal switch (4a)
to stop the irradiation; if he observes the formation of a retinal burn, he tags the corresponding
laser spot, by pressing pedal switch (4b).
(TL) measured at full width half maximum of
each laser spot. The calibration procedure
showed that these measurements where char-
acterized by a precision of about ± 10%. The
image of the laser treatment site, acquired
with the video camera attached to the slit-
lamp, was recorded immediately at the be-
ginning of the laser irradiation. The time
needed for acquiring this image and transfer-
ing it to the PC was less than 40 ms (aver-
age file size ≈1 MB), which was shorter than
the shortest irradiation period. Recording of
all the measured HRL treatment parameters
was done in less than 400 ms. This duration
was compatible with the ≈ 2 Hz laser fir-
ing frequency typically used in the HRL laser
treatment protocol.
Data Superimposition/Registration
A semi-automatic procedure was used to
record the information and superimpose the
slit-lamp pictures with the IRR images. In
a first, automated step, the slit-lamp im-
ages, which reported the laser spot locations,
were transformed, re-oriented and scaled to
the images taken with the ophthalmoscope.
In a second, manual step, the slit-lamp im-
ages reporting the HRL treatment position,
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were registered with the corresponding IRR
image. The registration process relied on
the presence of at least a partial, charac-
teristic vascular pattern in the slit-lamp im-
ages, which had to be found and identified in
the wide field ophthalmoscopic IRR pictures.
Both patterns were then manually registered,
in a two step process: (i) with the help of
a dedicated registration software (ImageJ®,
Turboreg, [81]), assisting the manual regis-
tration, the slit-lamp images were registered
with the top of the “redfree” fundus images,
where the vessels appeared with a good con-
trast (see figure 4.3), thus providing a clear
cartography of the HRL treatment; (ii) the
HRL cartography was, again with the help of
the mentioned software, registered with the
top of the IRR image. According to this soft-
ware’s specifications, the precision of these
computer-assisted registrations is in the sub-
pixel range. In our case we estimated it to be
on the order of 50 µm on the retina.
Figure 4.3: Image registration: HRL irradi-
ation parameters and spot position (B), su-
perimposition on the “red-free” image (A).
White bar 500µm on the retina
4.2.4 Eye Fundus Infrared Re-
flectance (IRR) Image Pro-
cessing
Quantitative measurements of the fundus re-
flectance rely on the standardization and cal-
ibration of the fundus illumination. Even
though the parameters of the flash, used for
acquiring the IRR images, were kept constant
for all patients, this did not result in a sta-
ble and homogeneous illumination of the fun-
dus. The excitation heterogeneity was due,
among others, to variations in the patients’
pupil diameter, the optical properties of their
eye media and the entrance angle of the exci-
tation light, rather than to flash fluctuations.
Therefore, the IRR images were normalized
to the flash’s image pattern, using a simple
image processing method: for any specific
case, the reflectance image was filtered with
a low-pass filter (< 3 lp/mm on the retina)
to extract the flash excitation pattern. The
IRR image was then normalized by dividing
the image itself by the flash excitation pat-
tern, resulting in a normalized IRR image,
corrected for illumination heterogeneity, over
the whole image (see figure 4.4).
Such normalized images efficiently em-
phasize variations in local IR reflectance - at
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Figure 4.4: Correction of IR eye fundus images for the heterogeneity of the ophthalmoscope ex-
citation light: (A) Raw IR fundus image at 810 nm; (B) Intensity pattern of the 810 nm excitation
light flash; (C) Corrected IR fundus image obtained by dividing image (A) by image (B). White
bar 1mm on the retina
the price of the loss of information on the
absolute local reflectance. Despite the lat-
ter shortcoming, detecting these variations in
the fundus reflectance (i.e. in its absorbance)
made possible the investigation of the as-
sumed correlation between laser parameters,
tissue properties and clinical outcome.
4.3 Results
As already mentionned, 35 patient (46 eyes)
were treated by HRL in April and June 2008.
A total of 5660 laser spots were placed in 46
retinas, causing 131 retinal burns (2.3%). No
hemorrhage occurred. As retinal burns did
not occur in all the cases, and, in some other
cases, the slit-lamp images of interest did not
present any visible vascular pattern (needed
for the registration procedure) the study fo-
cused on the remaining, usable cases, i.e. on
20 treated eyes from 16 patients.
To be able to analyse and compare the
results, also in function of their pathology,
the 20 eyes were subdivided in 6 pathology-
specific groups: Glaucoma (7 eyes), Papillary
Atrophy (4 eyes), Age Related Macular De-
generation (4 eyes), Retinitis Pigmentosa (3
eyes), Myopic Retinopathy (1 eye) and Dia-
betic Retinopathy (1 eye). From the point
of view of the ergonomy and adaptability of
the measurements, the minor modifications
brought to the standard medical device (re-
quired for image acquisition and laser data
capture) did not significantly influence the
medical practice working habits (the increase
treatment time is about ≈ 10%). However,
the HRL administration rhythm had to be re-
duced, to allow for a correct acquisition of all
useful parameters. On the other hand, acqui-
sition of the extra, initial IRR image became
part of the routine diagnosis, thanks to the
useful propensity of these images to highlight
the presence of large, deep-seated absorbing
structures, such as choroidal naevi.
We performed the registration procedure
for all the laser shots tagged as “having
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caused retinal burn” (i.e. about 2 to 4 per
treated eye), plus a few “subthreshold” laser
spots around them i.e. 5 to 10 “subthreshold”
shots, located within 1 mm of each “burn-
causing” shot. Data analysis started with
the slit-lamp images reporting the retinal po-
sition of these nearby 5-to-10 subthreshold
laser spots, selected for comparison purposes,
as their proximity should reduce the influence
on the optical absorbance, of other tissular
parameters, including choroidal blood flow,
accumulated chorio-retinal fluids and chorio-
retinal thickness.
Figure 4.5: Subdivision of the retina in 2
treatment zones. The treated zones, I and
II, are delimited with dark lines. The macu-
lar and ONH zones, circled and hatched with
light lines, are to be spared.
In addition, the retina was divided in two
zones (see Fig. 4.5), in view of grouping
the fired laser spots in relatively homoge-
neous retinal zones: zone I was defined to
be an annular region around the ONH; zone
II was delineated by the inferior and supe-
rior retinal arcades. During the study, the
laser spot diameter (∅100µm) and the radi-
ant power (1W ; 125W/mm2) were kept con-
stant, except for a dozen of laser spots fired
in zone II of a single, strongly myopic, eye,
where the radiant power was lowered to 0.4W
(50W/mm2): this was done at the clinician’s
demand, in view of keeping these laser spots
at the limit of the subthreshold regime, as
detailed in §4.2.2.
The results are presented in Figure 4.6,
which shows the analyzed laser spots inde-
pendently from the patient’s eye pathology.
Occurences of retinal burns are shown by tri-
angular marks (M) while subthreshold spots
are marked with filled dots (•).
The same results are presented in Fig-
ure 4.7, taking into account the treated
eyes’ pathologies. Specific symbols are as-
signed to each pathology. Retinal burns are
distinguished from subthresholds laser spots
through the use of a filled symbol.
All results do not show a clear correla-
tion between local IR reflectance and propen-
sity to retinal burns. This can also be ob-
served by examining groups of iso-energetic
laser spots (which lie along horizontal lines in
our scatterplots). Retinal burns appear to be
randomly distributed between low reflectance
spots (i.e. high absorbance) and high re-
flectance spots (i.e. weak absorbance), sug-
gesting that the local normalized reflectance
is not an adequate parameter to predict the
occurrence of retinal burns.
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(a) Retinal zone I (b) Retinal zone II
Figure 4.6: Scatterplots showing the occurrence of retinal burns (M) as a function of the local,
normalized IR reflectance and the effective laser energy administered. Subthreshold laser spots are
shown as filled dots (•)
Furthermore, by analysing the results
according to laser shot radiant energy
(i.e. along the vertical axis in Fig. 4.6),
considerable variations (up to a factor of 5)
in the energy of retinal burn-tagged laser
spots can be noted. Similarly, in figure 4.7,
pathology-specific clustering along the verti-
cal axis is observed: patients affected by re-
tinitis pigmentosa, for example, were found
to be grouped in the lower part of the graph.
This may be related to a high absolute value
of their fundus’ absorbance, which is not mea-
surable with our setup.
4.4 Discussion
Reflectance imaging is a reference method
for analysing the eye fundus. Since the first
quantitative studies published in 1950, sev-
eral hundred investigations of the in vivo hu-
man eye fundus were done [8]. This growing
interest in quantitative measurements par-
alleled the adoption of new, laser-based di-
agnostic technologies, such as the scanning
laser ophthalmoscope and optical coherence
tomography (OCT), now considered as stan-
dard opthalmologic instruments [14, 77].
Most of these investigations aimed at as-
sessing the retinal oxygen contents or the
macular pigmentation density, in different
pathologies [7, 8, 12, 21, 88], while a small
number of studies focused on systems or
methods to optimize the irradiation parame-
ters in thermal retinal therapies. Thus, in the
framework of PRP, the treated spot’s quanti-
tative reflectance was monitored to adapt the
irradiation time: it was found that the very
changes in tissue reflectance, induced by reti-
nal burns, could be used to drive this thermal
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(a) Zone I (b) Zone II
Figure 4.7: Scatterplots of all treated eyes, according to retinal zone and eye pathology. Empty
symbols correspond to subthreshold laser spots. Filled symbols correspond to retinal burns. 9:
Myopic Retinopathy; M: Retinitis pigmentosa; : Atrophic Age Related Macular Degeneration; :
Papillary Atrophy; O: Diabetic Retinopaty; : Glaucoma.
therapy and control the extent of tissue mod-
ifications [6, 10, 11, 66].
To our knowledge, however, no study in-
vestigated the local infrared reflectance to op-
timize a thermal, IR laser therapy. The main
advantages of near IR radiation reside in (i)
their deeper tissue penetration, as compared
to shorter wavelengths, and (ii) in their im-
proved transmission through blood and reti-
nal edema [82, 83]. In general, the fraction
(20 − 30 % at 810 nm) of diode laser radia-
tion absorbed by the ocular fundus, is much
smaller than that of shorter wavelengths (≈
95% at 532 nm) [3]. This explains why much
more IR radiant energy is needed to produce
retinal burns (20 kJ/cm2 at 810 nm as com-
pared to 1 J/cm2 at 532 nm).
More precisely, the light fraction absorbed
in the RPE is about 30− 35 % at 810nm, as
compared to ≈ 70% at 532nm [3, 30, 46].
Therefore the pigmentation and the amount
of hemoglobin within the choroid, which is
linked to choroidal thickness, will probably
play a significant role in the absorption pro-
cess. Moreover, in such a situation, where
there are no evidently dominating absorb-
ing structures, modeling the thermal pro-
cess causing the retinal burns is difficult.
The most plausible hypothesis is that the
IR radiant energy is primarily absorbed by
the choroidal melanocytes and by the RPE;
the heat generated at these two main ab-
sorbing centers, then diffuses to the neu-
roretinal layers, where it causes the retinal
burns [13, 18, 40, 46, 70]. It follows that ho-
mogenizing the outcome of IR thermal ther-
apies on the basis of the tissue’s absorbance
is not trivial, as the absence of correlation
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found in our study could be the consequence
of several effects.
First of all, it is worth recalling that this
therapy relies on a protocol at the upper limit
of the “subthreshold” regime, which implies
that all the laser spots administered were
very close to the radiant energy required to
generate a retinal burn. We should also note
that (i), our absorbance measurements are
integrated over all the eye media and fun-
dus layers and (ii), the longitudinal distribu-
tion of the absorbing centers was not mea-
sured. Therefore, small changes in eye tis-
sues properties or in the administered energy
could lead to these apparently heterogeneous
results. Hereunder, other parameters that
may influence the tissue’s response to HRL
treatment are analyzed and discussed:
Small, involuntary patient’s eye move-
ments during the spot’s duration (max. 200
ms) can probably be neglected: this relatively
short irradiation time, the almost painless na-
ture of the treatment, the nearly invisible
laser beam and the Goldmann contact lens
assisted irradiation are all elements that sup-
port this assumption [28, 55, 82]. In a recent
publication Lund [50] studied the impact of
small-scale ocular motion on retinal thermal
laser therapies. The relief factor1 depended
on the irradiation time; it was calculated to
be ≈ 10% for an irradiation of 200 ms. As
these evaluations were made in the framework
of an He-Ne laser therapy (633 nm), it follows
that, for the more spatially diffuse tissue ab-
sorption during IR therapy, this relief factor
should be further reduced.
Laser spot focus changes, caused by the
clinician’s aiming errors, are probably also
not important. Even though the small nu-
merical aperture of the human eye could in-
duce a notable reduction in irradiance, by a
factor of up to 3 when a longitudinal error
of 400µm is assumed. Adjusting the laser
spot focus when using a standard slit-lamp is
easy, and intra-therapy laser spot focus varia-
tions are probably minimal. Moreover, weak
absorption and strong diffusion in RPE and
choroidal tissues further reduce the effect of
this parameter.
The choroidal blood flow is known to play
an effect in the cooling down process. How-
ever, in thermal irradiations, this tissue cool-
ing effect is only significant for long therapies
(> 10 s) [22, 37, 51, 54].
Diffusion of the infrared radiation is prob-
ably the main cause of the lack of correla-
tion found in our study. It has been shown,
[26], that reflectance at 810 nm of dark-
pigmented fundi and light-pigmented fundi,
did not strongly differ. This suggests that the
1the “relief factor” is defined as the ratio between the retinal thermal threshold damage in a moving eye and
in a theoretical stationary eye. Therefore, if during the treatment the patient’s eye movement are dampen, the
“relief factor” will decrease accordingly
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reason why such reflectance measurements
failed to provide us with useful information
on the absorbing structures in the eye fun-
dus, stems from the inability of such measure-
ments to discriminate between reflected light
and scattered light. Weak absorption and
long scattering distances are thus probably
responsible for the poor detection of absorb-
ing centers in the choroid. Although large
and highly pigmented choroidal structures are
easily seen, physiological choroidal pigmenta-
tion changes cannot be detected. This hy-
pothesis is supported by many publication
where the imaging of the choroid was found
to be difficult, even with more sophisticated
techniques [14, 26, 33, 77].
Variations in choroidal thickness and in
the spatial distribution of the melanocytes
probably play an important role in retinal
burns: if the IR radiation is indeed absorbed
by the RPE and the choroid, then the heat
deposited in these absorbing centers must dif-
fuse down to the neuronal layer to create a
retinal burn; the longitudinal location of the
melanocytes may thus exert a significant in-
fluence on the tissue reaction [80]. Also, the
resulting heating effect may notably change
in function of the chorio-retinal thickness and
the presence of exudate.
Recent setups, still at the research
stage, can produce contrasted images of the
choroidal structures [29, 69, 80, 85], with a
much better resolution than that of our fun-
dus camera. At a wavelength of 810 nm, the
latter had an estimated resolution on the or-
der of ≈ 100µm for structures at the surface
of the retina, dropping to maybe ≈ 300µm
for structures deeper into the choroidal tis-
sue. Optical coherence tomographic systems,
adapted to investigate these choroidal struc-
tures, at the longer wavelength of 1100 nm,
could also yield more valuable information.
Another interesting approach, relying on
the measurement of the longitudinal re-
flectance profile (i.e OCT A-scan) of the
laser spot during irradiation, was proposed
by Lanzetta and Dorin [45], Lanzetta et al.
[47]. It enables the detection of reflectance
variations of specific layers within the fun-
dus. This approach could allow, for example,
to monitor the reflectance of Bruch’s mem-
brane, and use this measurement to modu-
late the laser irradiation period, to prevent
the formation of visible retinal burns [33].
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5Introduction
5.1 A Brief Overview on Tissular Oxygen
Molecular oxygen is one of the most important gas in our environment since it is found as
either a reactant or a product in a vast number of chemical and biochemical reactions. Thus,
the determination of oxygen is important in various fields of chemical and clinical analysis, as
well as for environmental monitoring [8]. The amount of oxygen is one of the most important
variables in many physiological, pathological and therapeutic processes. We can express the
amount of oxygen as a concentration [O2] or partial pressure of oxygen pO2; these are related
by [O2] = pO2/kH , where kH is the Henry’s constant [atm×L/mol]. In the present document
we will use the pO2 [%].
There is an increasing recognition that it would be very useful to directly measure the pO2 in
tissues with sufficient sensitivity, accuracy and ease. This would enhance the basic understand-
ing of many types of physiological and pathophysiological phenomena at both macroscopically
and microscopically levels. Such measurements could enable clinicians to improve the diagnosis
and the treatment of many diseases, such as cancer and peripheral vascular insufficiency [29, 31].
Additionally, the response of tumors to ionizing radiation highly depends on pO2 [31].
Therefore, different approaches were developed in radio-oncology to measure the tissular oxygen
in vivo. The critical value was found to be about 5mmHg; tissues with a lower pO2 were shown
to be significantly more resistant to ionizing radiation [28, 31]. In a series of experimental and
clinical studies, different studies demonstrated that clinical measurements of the pO2 provided
useful inforamtions to predict the tumors response to radiation therapy [6, 19, 28, 32]. Despite
the limited precision and the invasiveness of the technology used for these measurements, it is
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interesting to note that their results were already significant.
Currently available techniques to measure the pO2 can be broadly classified in two cate-
gories: (i) direct methods (invasive and noninvasive) that measure the [O2] or pO2, (ii) indirect
methods that measure a parameter related to the presence of oxygen, such as the saturation
of hemoglobin [13].
The existing methods for directly measuring the pO2 in cells and tissues include the Clark
electrode [11, 25, 26], fluorescence quenching [22, 23], O2 binding to myoglobin [10], chemilu-
minescence [7], phosphorescence quenching [1, 30] and spin label oximetry [4, 12, 20]. Indirect
methods include the “comet assay” [2, 21] and drugs that selectively localize in hypoxic tis-
sues. All these techniques, however, have some significant limitations, especially regarding
their ability to make repeated measurements, their degree of invasiveness, and/or their sensi-
tivity/accuracy. Considerable efforts are still ongoing in order to solve these problems [9, 18].
Luminescence lifetime measurements of the oxygen-dependent phosphorescence quenching to
evaluate intravascular pO2 is another common approach used in vivo [3, 16, 33, 34]. Shonat
et al. [24] was the first to apply phosphorescence quenching imaging in vivo in retinal vessels
by measuring the lifetime of a palladium porphyrin. An advantage of lifetime measurements is
their independence to the concentration of the luminophore, making quantitative measurements
possible in vivo. Most of the measurements of the tissular oxygen using the phosphorescence
quenching technique have been based, up to now, on the use of porphyrin derivatives which
are not approved for clinical use yet [5, 24, 27]. This situation explains why indirect methods
are used to assess the oxygenation of tissues in humans.
The need for oxygen measurements at the cellular level, combined with the increasing
concern for the understanding of the basic mechanisms responsible for the tissue destruction
during PDT [15], strongly stress the interest of developing new approaches to assess the level
of oxygen in different compartments of biological tissues. One promising approach, realistically
applicable in the clinics, consists to determine the oxygen concentration via measurements of
the delayed fluorescence of approved photosensitizers [14, 17, 18]. This approach would be
intrinsically minimal invasive and will virtually measure the cellular pO2 in the near proximity
of the activated photosensitizer molecules within the PDT target zone. This last characteristic
is of high interest; such a measurement would enable the measure of the O2 consumption
exactly in the same place were the reactive oxygen species (ROS) are produced.
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5.2 Objectives of this Work
The first objective of this study was to demonstrate the feasibility of monitoring the tissular
pO2 in vivo by time-resolved measurements of the PpIX’s delayed fluorescence (see Part I
§2.4). To reach this goal, a new fiber based time-resolved spectrofluorometer was designed.
The delayed fluorescence signal of the PpIX was then measured on the chick chorioallontoic
membrane (CAM) in vivo model following topical administration of ALA.
As described in §5.1 the tissular pO2 is depleted during PDT due to various photochemically
initiated reactions between the PS and the oxygen. Therefore, the second objective was to
verify the existing correlation between the tissular pO2 depletion and the PDT irradiation dose
administered to the CAM. Finally, we also wanted to verify whether monitoring tissular pO2
consumption during PDT would predict the CAM’s induced vascular damages.
Therefore, in Chapter 6, we will characterize the designed time-resolved spectrofluorometer
and present the first preliminary pO2 in vivo measurements.
In Chapter 7, we will present the correlation between the tissular oxygen depletion and the
PDT light dose, as well as the correlation between the PDT induced vascular damages and the
tissular pO2 depletion.
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Abstract
A new optical-fiber-based spectrofluorometer for in vivo or in vitro detection of de-
layed fluorescence is presented and characterized. This compact setup is designed
so that it can be readily adapted for future clinical use. Optical excitation is done
with a nitrogen laser-pumped, tunable dye laser, emitting in the UV-Vis part of
the spectrum. Excitation and luminescence signals are carried to and from the bi-
ological tissues under investigation, located out of the setup enclosure, by a single
optical fiber. These measurements, as well as measurements performed without a
fiber on in vitro samples in a thermostatable quartz cell, in a controlled-atmosphere
enclosure, are possible due to the efficient collection of the laser induced lumines-
cence light which is collected and focused on the detector with a high aperture
parabolic mirror. The detection is based on a gated photomultiplier which allows
for time-resolved measurements of the delayed fluorescence intensity. Thus, relevant
luminescence lifetimes, in the microsecond-to-millisecond range can be measured,
with near total rejection of the sample’s prompt fluorescence. The instrument’s
spectral and temporal resolution, as well as its sensitivity, are characterized and
measurement examples are presented. The primary application foreseen for this
setup is the monitoring and adjustment of the light dose delivered during photody-
namic therapy.
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Photodynamic therapy (PDT) is a well es-
tablished method for the treatment of Age-
related Macular Degeneration (AMD) and
various kinds of light-accessible tumors [23,
46]. It relies on the use of light, a light-
sensitive dye molecule and molecular oxy-
gen present in the tissue [5, 10, 22, 28, 33,
41, 49, 51, 53, 66, 69, 76]. The mecha-
nisms responsible for tissue destruction by
PDT involve highly reactive singlet oxygen
[1O2(1∆g)], or oxygen radical species gener-
ated by the photoexcited dye molecule also
called the photosensitizer (PS). These oxygen
species oxidize the biological substrate thus
inducing photodamage which can lead to di-
rect cell death and/or blood vessel occlusion
[43, 51, 77]. The efficiency of this process
depends among others on the concentration
of tissular oxygen. Excitation of the PS to
the lowest excited singlet state, which can, in
some molecules, undergo intersystem cross-
ing to the PS’s triplet state, may be followed
by phosphorescence of this triplet state. This
phosphorescence may, in turn, be quenched
by the tissue oxygen, allowing for an indi-
rect measurement of the dissolved molecular
oxygen concentration using the Stern-Volmer
equation 6.1. The latter relates this tissular
oxygen concentration [O2] to the photosensi-
tizer’s triplet state phosphorescence intensity
I and its lifetime τ as follows:
I0/I = τ0/τ = 1 + kqτ0[O2] (6.1)
where I0 and I are the phosphorescence
intensities in the absence, respectively the
presence of an oxygen concentration [O2], τ0
and τ are the corresponding phosphorescence
lifetimes and kq is the bimolecular quenching
constant.
Measuring the oxygen concentration [O2],
usually expressed as its partial pressure pO2,
at the actual location where the PS is ap-
plied for PDT, can help to determine and op-
timize the therapeutic light dose, if knowl-
edge is available on several other PDT pa-
rameters [76]. Indeed, differences in the oxy-
gen consumption rate as well as differences
between the initial oxygen concentration in
normal and neoplastic tissues are likely to be
responsible for over - or under - treatment of
the targeted tissues. In any case, the oxy-
gen concentration in the tissue and its diffu-
sion towards the PDT-treated zone will influ-
ence the therapeutic efficacy. Furthermore,
it is known that certain regions of larger tu-
mors can become hypoxic, which may neg-
atively affect the efficacy of PDT or radio-
therapy [6, 11, 32, 52, 65, 75]. More gener-
ally, measurement of the pO2 can in principle
provide valuable information for the early di-
agnosis of various diseases. Among others,
this may be the case for exsudative AMD,
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as well as vascular occlusive diseases, dia-
betic retinopathy and possibly even glaucoma
[12, 54, 61]. Such diseases are very likely asso-
ciated with changes of the micro-vasculature
due to decreased cellular oxygen concentra-
tions [1, 26, 74].
Various kinds of oxygen-sensitive phos-
phorescent molecules have been proposed to
monitor the pO2 [56, 60, 73]. However only a
few among them can be exploited as PSs and
none of these oxygen sensing molecules have
been approved for use in humans. Unfortu-
nately, most PSs - including PpIX, which is
commonly used for PDT treatment of onco-
logic conditions - do not present a phospho-
rescence that is easily detectable in vivo, ei-
ther because the phosphorescence quantum
yield is too low and/or because this lumines-
cence takes place at wavelengths too long to
be easily detected [4, 56, 60]. PpIX’s triplet
state de-excitation has been measured at low
temperature (77◦K) in a solid octane ma-
trix [68], showing a phosphorescence peak at
around 792 nm, a quantum yield of 6× 10−3
and a lifetime of 11 msec, with a non-radiative
T1-S0 decay probability about twice as large
as the radiative one. More recently, phos-
phorescence lifetimes of HpD and PpIX were
measured at room temperature at 894 nm -
but in lipophilic milieux [45]. In a biological
milieu at about 37◦C, the non-radiative de-
cay pathways are even more favoured than
at low temperature in non-polar matrixes.
Thus, measuring PpIX’s phosphorescence un-
der experimental conditions compatible with
a clinical environment would be very difficult
indeed [44, 63]. This difficulty can be over-
come by measuring the delayed fluorescence
lifetime instead of the PS’s phosphorescence
lifetime [25, 38, 41]. This idea underlies the
work described in the present paper. The
“delayed fluorescence” (DF) phenomenon is
schematically represented in the Jablonski di-
agram of Figure 6.1.
The electronic ground state of the PS
is a singlet state (S0). Upon light ab-
sorption (1) the PS is excited to a short-
lived, vibrationally excited, first excited sin-
glet state which rapidly vibrationally relaxes
to its ground state S1 . The overall lifetime
of S1 in cuvette conditions is about 15ns for
PpIX in acqueous solution [34], and ≈ 7ns
in-vivo [31, 57]). The PS can return to the
S0 state by fluorescing (2) or by internal con-
version (3). Alternatively, S1 can undergo
“spin-forbidden” intersystem crossing (ISC)
to the triplet state T1, (4). This fairly long-
lived T1 state, whose lifetime is in the µs-
to-ms range for PpIX, may return directly
to the ground state by phosphorescence (5)
or through a non-radiative path (6). Some
molecules in the T1 state may, however, have
sufficient thermal energy to undergo reverse
ISC, from a vibrationnally excited level of T1
to the S1 singlet state (7), after which they
may return to the ground state, through what
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Figure 6.1: Jablonski diagram of the PpIX photosensitizer and its interaction with molecular
oxygen. See text for details.
is now delayed fluorescence (2’): i.e. the PS
returns to the ground state by emitting pho-
tons of essentially the same spectral distribu-
tion as normal “prompt” fluorescence. How-
ever, this “delayed fluorescence” (DF) gen-
erally has a much weaker intensity than the
prompt fluorescence and its lifetime is similar
to that of phosphorescence. This is why de-
layed fluorescence might sometimes be taken
for phosphorescence [48]. In the presence
of molecular oxygen, near-resonant collisional
energy transfer (8) between the T1 state of
PpIX and the T0 ground state (3Σ) of molec-
ular O2 takes place, leading to (9) the excita-
tion of O2 (3Σ) to its S1 singlet excited state
O2(1∆1) [30, 58] and simultaneously the re-
turn of PpIX to its ground S0 state.
One advantage of using this approach for
the in-vivo measurement of tissular pO2 is
that no exogenous molecular probe needs to
be administered. In the case of PpIX, an ad-
ditional benefit arises from the fact that it
becomes possible, through the PS’s quenched
phosphorescence, to measure the pO2 at the
very locations where the PS is acting (see
§6.3.2).
In this paper, we report on the de-
sign, characterization (in terms of excitation
source, spectral and temporal resolution and
sensitivity), and calibration, of a sensitive,
time-resolved, optical-fiber-based spectroflu-
orometer, which can be used for both in vitro
and in vivo detection of delayed fluorescence.
The setup must be able to detect the very
weak DF signals emitted by most PS’s, and
allow (in the case of in vivo PDT), for using
an optical fiber to probe tissues which would
be difficult to access otherwise, for instance
in the hollow organs.
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Figure 6.2: Optical design and overall geometry of the spectrofluorometer. (1) dye laser; (2)
metal-and-wood experimental enclosure, x = 430 mm, y = 230 mm, height = 250 mm; (3’) di-
aphragm; (3) lens, F = 150 mm; (4) parabolic mirror with cylindrical hole; (5) irradiation location;
(6) optical fiber; (6’) Thermostatable cell holder; (7) Gatable photomultiplier; (8) rotatable optical
filters holder; digotal storage oscilloscope and PC; (10) signal delay generator.
6.2 Design of the Spectroflu-
orometer
One specific problem of this oxygen measure-
ment approach is that prompt (normal) flu-
orescence (PF) and DF have essentially the
same spectroscopies. In addition, the system
must be usable for in vivo measurements. An
optimal and practical design of the measure-
ment setup must therefore address three main
problems: (i) The weak intensity of the DF
signal, as compared to the much stronger nor-
mal fluorescence, requires a high light gath-
ering and transmission capacity. (ii) Because
DF and PF differ only by their lifetimes, we
need a system to discriminate between these
two signals: basically, the detector must be
blinded during the emission of the strong PF
to enable the detection of the much weaker
DF. (iii) The system should allow both to
measure in vitro samples and to monitor liv-
ing tissues.
The first and third concerns are dealt
with and discussed under section 6.2.1 here-
under, while section 6.2.2 deals with the sec-
ond problem. We also discuss the mathemat-
ical processing of the acquired data in sec-
tion 6.2.3. Validation of the sensitivity of the
measurements, and their calibration, includ-
ing the setup’s spectral and temporal resolu-
tion, are dealt with in sections 6.2.4 and 6.2.5,
respectively.
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6.2.1 General design and Optics
A schematic representation of the appara-
tus is shown in Figure 6.2. The excitation
light pulses at 405 nm are provided by a dye
laser (1) ( LTB® model UDL-200), pumped
by a pulsed N2 laser (not shown, LTB® model
MSG 803-TD). The laser beam enters the
main, light-tight, blackened experimental en-
closure (2) through a small hole and then
passes through an iris diaphragm (3’) which
blocks most of the spontaneous emission of
the dye cell. The beam passes through a small
channel drilled in the parabolic mirror (4) (
Edmund Optics® NT47-103, 90°off-axis, alu-
minium coated, EFL = 50.8 mm), while be-
ing focused with a low luminescence plano-
convex lens (3) (Edmund Optics® NT47-276,
∅ 20 mm, EFL = 150 mm) onto the tip
(5) of a multimode optical fiber (6) (Laser
Components® HCG-M0550T, core diameter
= 550 µm, NA = 0.22). For in-vitro exper-
iments, a quartz cuvette (Hellma®, 174-QS)
is held inside the apparatus at the irradia-
tion location (5), using a thermostatable cu-
vette holder (6’), see figure 6.3. The plano-
convex lens (3) is mounted on a 5-degrees-
of-freedom holder, allowing for easy focus-
ing of the laser beam on a pre-defined point,
(5). The luminescence emitted from the ir-
radiated sample is collected by the far-end
of the optical fiber (6) and returned to the
enclosure, where a large fraction (probably
more than 80 %) of this light falls on the
parabolic metal mirror (4) and is reflected
and focused by it on a gatable photomultiplier
(PMT) (7) (Hamamatsu® R955). The re-
flected laser light and unwanted optical back-
ground noise are filtered out by a band-pass
filter (Chroma® HQ645/75) in the filter wheel
(8). The PpIX DF signal is recorded with a
digital storage oscilloscope (DSO) (Lecroy®
LT342), connected to a PC (9). Note that
a signal delay generator (10) (Stanford Re-
search Systems®, DG535) is used to synchro-
nize the gating of the PMT with the laser
pulses and to trigger the DSO with the DF
signals.
Figure 6.3: Thermostatable quartz cell
holder with dual, water-heated side-blocks.
Cast aluminium, x = 55mm, y = 32mm,
z = 45mm.
The present optical design, based on the
use of a parabolic mirror, presents some ad-
vantages as compared to standard configu-
rations for optical-fiber-based spectrometers.
These include: (i) the abscence of spectral
distortions due to the fact that no refraction
- but only reflections - take place in this part
of the optical setup; (ii) no autoluminescence
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is induced in this optical element which, due
to its metallic nature, does not interact with
the excitation pulse; (iii) the solid angle of
acceptance of the parabolic mirror (≈ 0.6 sr)
is larger than the entrance solid angle of the
optical fiber (≈ 0.15 sr), which leads to a
high light recovery fraction; (iv) the mirror’s
parabolic shape eliminates the need of an ad-
ditional lens to focus the luminescence emit-
ted by the fiber tip (or the quartz cuvette)
on the detector. This is because the detec-
tor’s window is conveniently located at the
imaging point of this mirror. Note: the setup
is designed for a 1:1 magnification.
The fiber-based measurement mode is
well suited for in vivo studies, where the light
must be delivered to tissue, outside of the
setup’s light-tight enclosure. When measur-
ing a sample in the thermostatable quartz cell
(6’), placed at the focal point of the laser
beam (5), again a sizable fraction of the lumi-
nescence from the liquid sample falls on the
parabolic mirror. The measurements in that
case are thus completed inside the light-tight
enclosure (2). This leads to a higher sensitiv-
ity and less noise. In addition, it is possible,
if desired, to control the temperature the hu-
midity and gas composition in the enclosure.
6.2.2 Delayed and Prompt Fluores-
cence Discrimination
As the whole setup is constructed in a
light-tight enclosure, undesired light is elim-
inated. The time-resolved detection of the
weak DF signal nevertheless requires gating
to avoid saturation of the detector by the
much stronger PF signal. To achieve this,
the photomultiplier tube can be electrically
switched on, about 3µs after the laser pulse.
During this time, the intensity of any PF de-
creases to the noise level. Because the inten-
sity of the PF is at least 2 orders of magni-
tude stronger than that of the DF, and be-
cause the photons of the PF hit the inac-
tive photocathode during the ≈ 3µs offset-
time, fast recovery of the high gain as well as
proper correction for PMT artefacts are re-
quired. For these reasons, we used an R955
Hamamatsu PMT with a broad wavelength
response (185 − 900nm), low noise and high
gain.
Figure 6.4: Chronogram of the PMT gating
and signal acquisition process.
A gated D-Type socket assembly
(Hamamatsu® C1392-57) was used together
with this PMT. The PMT is “gated” by hold-
ing the photocathode at a potential of about
+10 V with respect to the first dynode. The
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gate function is driven by an external user-
triggered TTL pulse. In this way, the PMT
is blinded during the laser excitation and
prompt fluorescence emission. The signal de-
lay generator (10, Figure 6.2) thus turns the
PMT off, about 5µs before triggering the
laser pulse, for about 8µs. The rise time for
the gating is typically 400ns (see Figure 6.4).
6.2.3 Data Acquisition and Analy-
sis
The DF signal is transformed by the PMT
into an analog electrical signal which is sup-
plied to the DSO for averaging. The analog
signal from about 30 transients is digitized1
and transferred to the PC for further analy-
sis. The parameters describing the lumines-
cence decay are obtained by fitting the time-
dependent digitized signal f(t) with a sum of
exponential functions:
f(t) =
n∑
i=1
Ai exp
(t/τi) (6.2)
The set of exponential lifetimes (τi) char-
acterizes the PS molecule and its physical en-
vironment. Each pre-exponential factors Ai is
proportional to the intensity of the ith com-
ponent to the total luminescence intensity.
The Levenberg-Marquardt (L-M) method
is used for non-linear least-squares fit of the
measured data [37, 39, 47, 55, 62]. We wrote
and used an Octave® [GNU GPL] L-M algo-
rithm implementation. The calculated math-
ematical fits were graphically checked by plot-
ting the residuals of each fit and the autocor-
relation of the residuals [7, 19], as shown, e.g.,
in Figure 6.5.
6.2.4 Setup calibration and system
sensitivity
We have validated and calibrated the setup
through luminescence measurements on well-
characterized molecules. The luminescence
lifetime of reference samples depends on
the fluorochrome’s environment, on small
changes in the molecular structure, on the
presence of quenchers and on temperature.
For these reasons, we have chosen two dif-
ferent cristalline lanthanide(III) complexes
whose properties and behaviours were known
to be stable in the chosen environments.
The first reference compound was a pow-
dered samarium complex: [SmIII -(hfa)3(4-
cypNO)]2 [18] 2. This sample was used
to verify the validity of our measurements
close to the temporal resolution limit of our
system (≈ 0.7µs, see §6.2.5). When the
luminescence of this powder was measured
with our setup, we observed a signal with a
mono-exponential lifetime of (1.27 ±0.09µs).
This compares well with the litterature value
1as a 24 bits floating point number (IEEE 745) corresponding to a decimal precision of log10(224) ≈ 7
decimal digits
2hfa− = hexafluoroacetylacetonate; 4-cpyNO = 4-cyanopyridine N-oxide
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Figure 6.5: Analysis of the fitting results: the semi-logarithmic scale used to plot the experimental
data and the fitting results help to visualize a bad fit. Random dispersions, around zero, of the
residuals and their autocorrelation, confirm the quality of the fit.
of (1.13 ± 0.05µs) [15]. The second ref-
erence compound was a 2:3 stoichiometric
solution of an europium complex [EuIII -
:H2LC2] in water/glycerol (9/1, v/v)1 whose
lifetime is expected to be in the milliseconds
range. With a fiber-to-quartz-cell distance
of 100µm, we measured a mono exponential
decay with a lifetime of (2275 ± 127)µs , as
compared to the published value of (2200 ±
100)µs [15]. The small differences of < 10%
resp. < 5% observed between our measure-
ments and those made by Chauvin et al are
compatible with the stated error limits. They
might be explained by small differences in (i)
the sample excitation wavelengths: 355 nm
vs 405 nm, and (ii) the actual physical envi-
ronments of the lanthanide complexes.
The sensitivity of the system was de-
termined by measuring the time-resolved
luminescence decay of solutions of PpIX
in dimethyl sulfoxide (DMSO) and of
Pd-meso-tetra(4-carboxyphenyl)-porphyrin
(PdTCPP) in phosphate buffered saline
(PBS). PpIX is a frequently used photosen-
sitizer and presents a delayed fluorescence
[13, 14, 40], while PdTCPP is a commonly
used oxygen sensor for in vivo measurements
[4, 56, 60, 62, 70]. Luminescence decays were
thus measured at decreasing concentrations
ranging between 10−4 and 10−7M , within
1 hour of sample preparation. The sensitiv-
ity limit was then determined for the lowest
photosensitizer concentration, still yielding
measurements with a signal to noise ratio
(SNR) allowing for the retrieval of accurate
lifetimes. The latter is defined here as the
1H2LC2: homoditopic ligand 6,6’ - for very long luminescence lifetimes
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(a) SNR of the time-resolved luminescence decay of
PpIX (MW= 606 g/mol) in DMSO solution at differ-
ent concentrations, at standard environmental oxy-
gen concentration (pO2 ≈ 150 mm Hg)
Concentration [M ] SNR
5× 10−5 64.45
1× 10−5 36.46
8.2× 10−6 32.97
1.6× 10−6 5.64
8.2× 10−7 2.89
(b) SNR of the time-resolved lumi-
nescence decay of PdTCPP (MW=895
g/mol) in PBS solution at different con-
centrations
Concentration [M ] SNR
5× 10−5 28.1
1× 10−5 26.3
5× 10−6 23.0
1× 10−6 10.2
5× 10−7 6.4
Table 6.1: Setup sensitivity assessment
standard deviation on the measured lifetime
being < 10%. The SNR was expressed as
the ratio of the signal to the RMS noise level.
Tables 6.1(a) and 6.1(b) show the calculated
SNR at the different concentrations. The
sensitivity of the system is therefore suffi-
cient to measure the weak delayed fluores-
cence of PpIX in typical in vivo conditions
where its concentration might be on the order
of 1× 10−5M .
After these preliminary validating results,
we compared the radiant DF energy of PpIX,
which is proportional to the area under the
recorded signal - and therefore to the totality
of detected DF photons - to its total lumines-
cence. The ratio of these energies yields an es-
timate of the DF’s detectability. The DF sig-
nal was recorded and measured as already de-
scribed. The signal of the total luminescence
(proportional to the sum of all molecule’s
emissive desexcitation) was measured by (i)
adding neutral density (OD 3.9) filters be-
tween the parabolic mirror and the PMT,
and (ii) recording the luminescence emitted
by the PpIX sample from the beginning of the
laser excitation pulse. The ratio of the total
PpIX’s luminescence to its DF was found to
be 145:1 for in vitro measurements performed
on a DMSO solution at pH=7.2, and 300:1 for
in-vivo measurements performed on a CAM
membrane topically treated with ALA, a pre-
cursor of PpIX (see § 3.2 for details). The
values obtained are in reasonable agreement
with the estimates given in the litterature [27]
6.2.5 Setup temporal resolution
The two devices that limit the temporal
resolution of the setup are the PMT and
the current-to-voltage converter circuit con-
nected in series between the PMT and the
DSO. The loss of temporal resolution due to
the PMT can be approximated by the sum
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of the anode pulse rise time and the electron
Transit Time Spread (TTS)≈ 2.2ns+ 1.2ns,
for a total of ≈ 3.5ns, which is negligible
with respect to the contribution made by the
current-to-voltage circuit. The latter is char-
acterized by an RC response time. A load
resistance value of Rload = 500 Ω was chosen
in order to have a comfortable signal inten-
sity during in vivo measurements. With the
help of a very short light pulse (the nearly
delta excitation laser pulse: ≈ 300 − 400 ps)
and with two different load resistances, the
parasite capacitance of the circuit was mea-
sured to be 145 pF . The characteristic tem-
poral response of the setup is therefore set to
be Rload × C = 72ns, which is the setup’s
temporal resolution. This response time of
≈ 72ns is negligible if the measured signals
have typical lifetimes larger then 10µs, as is
the case for the delayed-fluorescence lifetime
of PpIX.
6.2.6 Background Optical Noise
To generate a well defined maximum op-
tical background noise, we placed a non-
fluorescing white reflecting coated plate
(SphereOptics®, White Reflecting Coating,
reflection > 98% of incident light) perpen-
dicular to and in contact with the end of the
optical fiber, and recorded the signal gener-
ated by this diffusely reflected light. The aim
was to evaluate if this maximum optical back-
ground noise could still be considered as neg-
ligible when compared to the weak DF sig-
nal expected from an in vivo measurement
of the PpIX’s DF. The back-scattered signal
was recorded after a delay of 3µs from the
excitation and averaged over 30 sweeps.
An appreciable optical background signal,
probably due to both the parasitic lumines-
cence of the optical fiber itself and the Sphere-
Optics plate, plus the luminescence of the
band-pass filter located in front of the PMT,
was observed. The intensity of this back-
ground noise was in the worst case one order
of magnitude smaller than the expected ex-
perimental signal. The background noise cre-
ated by the reflection of the laser excitation
on the sample can therefore be neglected.
6.3 Results and Discussion
6.3.1 Examples of In Vitro Lifetime
Measurements
The luminescence lifetime of two porphyrins,
PdTCPP and PpIX, in aqueous (PBS) and
DMSO solutions respectively, were carefully
characterized in vitro to confirm that the sen-
sitivity of the setup would allow to observe lu-
minescence lifetime changes due to variations
in O2 quencher concentration. By bubbling
during 30min different, well defined, oxygen-
nitrogen gas mixtures1, the O2 dissolved in
1Oxygen solubility at 1 atm, 25°, is 2.2± 0.09mM in DMSO [2] and 2.5mM in water.
72
6.3 Results and Discussion
pO2 [O2] Measured lifetime Literature
[mmHg] [%] [µs] [µs]
0 0 358± 15 340− 360
7.4 1 61.2± 1.5
37 5 12.2± 0.5
74 10 6.2± 0.3
155 21 3.11± 0.2
Table 6.2: PdTCPP phosphorescence quenching by oxygen: Lifetime measurements of an 83µM
solution of PdTCCP in PBS at room temperature, pH 7.4, at different pO2 values.
the porphyrin solutions was changed. All
measurements were carried out at room tem-
perature (22°) and the solutions were freshly
prepared (within 1 h from the measurement)
and stored in quartz cuvettes.
As a validation measurement, the life-
times of a PdTCPP solution in PBS (83µM ,
pH = 7.4) were measured, by the analysis
of the averaged luminescence decay signal
over 30 sweeps at 5 different pO2. An ex-
cellent linear Stern-Vollmer relationship was
verified and good agreement was found be-
tween our measurement at pO2 = 0 and the
values reported in the literature for oxygen-
free PdTCPP solutions (see Figure 6.6). No
attempt was made to compare lifetimes at
other O2 concentrations as the strong depen-
dency of Henry’s coefficients on temperature
and exact solvent nature cannot be easily cor-
rected for, see Table 6.2) [67, 71, 72].
Figure 6.6: Verification of the Stern-
Volmer equation (τ0 = 0.358ms, kq =
2.04 (mmHg ms)−1) for a solution of
PdtCPP in PBS (83µM , pH = 7.4)
As mentionned in §6.1, there are few
in vitro PpIX’s delayed fluorescence lifetime
measurements in the literature and they are
not directly comparable, due to the sensitiv-
ity of PpIX’s DF lifetime to pH, temperature,
concentration of the solution and quencher
concentration [8, 14, 35, 42, 59]. Therefore a
directly comparative study could not be per-
formed for this molecule. A PpIX solution in
DMSO (1.6µM , pH=7.2) was prepared and
stored in a quartz cuvette as described before.
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The measurements reported in Table 6.3 al-
low us to confirm the possibility (in vitro) of
measuring changes in PpIX’s lifetime ascrib-
able to changes in the O2 concentration. Our
measurement at pO2 = 0 is here compared
with the one published by Mik et al. [40] and
found to be in reasonable agreement with it.
The same PpIX solution was measured
(after 3h of pure N2 bubbling) with a com-
mercial (Perkin Elmer LS 50B) time resolved
spectrofluorometer to compare the spectrum
of the measured luminescence with that of the
prompt fluorescence. This allowed to confirm
that the luminescence measured was really
the delayed fluorescence as it exhibited the
same spectroscopy as that of the prompt flu-
orescence, but displayed lifetimes character-
istic of the triplet state (see Figure 6.7).
Figure 6.7: PpIX’s luminescence spectrum.
Measurements performed with a Perkin-
Elmer LS 50B spectrofluorometer. (A):
Prompt fluorescence; (B): Delayed fluores-
cence measured 1.3 ms after the excitation.
The gain difference is ca. a factor of 100.
6.3.2 Examples of In Vivo Mea-
surements
When using PpIX as a PS, the usual ap-
proach consists in administering to the pa-
tient a precursor of the drug. The most com-
monly used precursor molecules are 5-amino-
levulinic acid (ALA) or certain of its esterified
derivatives [9, 17, 50]. The biosynthetic path-
way involves the combination of two ALA
molecules to form a pyrrole unit, and four of
these finally are combined to form one PpIX
moiety, which itself is a part of haemoglobin
[20, 29]. Because of the enzymatic activity in
diseased or cancerous tissues, the production
of PpIX is locally and selectively strongly en-
hanced, as compared to the surrounding nor-
mal tissue [3, 16, 21].
Our setup must allow, in this case, to
measure through the PpIX’s delayed fluores-
cence, the pO2 at any location where the
PS is being formed. In this section, we re-
port three examples of in vivo delayed fluores-
cence measurements, performed on the chick
chorio-allantoic membrane (CAM) model.
Fifteen fertilized eggs underwent routine
handling in order to obtain healthy develop-
ing CAMs until day 10 [24, 36, 64]. Four
hours before the measurements and after re-
moval of the upper part of the shell, as de-
scribed by Lange et al. [36], the chick em-
bryos where topically administered a droplet
of ALA solution1. As described in §6.1, the
1droplet volume 20µl, 152mM ALA-H2O solution, adjusted to pH 6.0, corresponding to ≈ 40mg/kg.
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pO2 [O2] Measured lifetime Literature
[mmHg] [%] [µs] [µs]
0 0 1630± 120 1200± 100
7.4 1 56± 4 270± 20
22.2 3 14± 0.4 90± 7
Table 6.3: Influence of variations in pO2 on PpIX’s DF lifetime: Luminescence lifetime measure-
ments of an 1.6µM solution of PpIX in DMSO at room temperature, pH=7.2, at different pO2
values.
DF lifetime is related to the concentration of
molecular O2 which acts as quencher in this
case.
It should be noted that the oxygen con-
centration in the CAM is also influenced by
molecular O2 diffusing from the atmosphere.
In order to reduce this O2 inflow significantly
and make the CAM’s tissular [O2] decrease
measurable, just before start of irradiation,
we placed an impermeable barrier on the
CAM: the region to be measured was covered
by a round microscope cover glass (∅ 20mm,
0.15−0.19mm thick, Schott D263M). The op-
tical fiber probe was made to point towards
the middle of the cover glass (≈ 100µm from
the surface, probed surface diameter ≈ ∅
500µm).
The probing laser (405nm) excites the
PpIX molecules produced during the 4h of in-
cubation and the resulting luminescence was
collected by the fiber tip and analyzed as
described earlier. It was demonstrated that
the probing laser pulses did not photody-
namically or otherwise damage the CAM and
did not significantly affect the tissular oxygen
concentration if the total number of consecu-
tive pulses was limited to 30. Therefore, for
the following in-vivo measurements, only 20
shots were averaged.
The first in vivo experiment presented
demonstrates the phenomenon of tissular
oxygen consumption during laser irradiation,
as monitored by measuring the PpIX’s DF
lifetime. Measurement of oxygen consump-
tion was performed using the following ex-
perimental protocol: four series of 400 prob-
ing laser shots (at a pulse frequency of 10Hz)
were fired at the CAM sample, with a break
of 1min of darkness between each series. The
DF measurements of the firsts 20 and the
lasts 20 probing shots of each series were av-
eraged, recorded and compared. Using this
experimental protocol, we observed an appre-
ciable shift (towards longer values) in the PS’s
DF lifetime, between the first and the last
group of 20 laser shots of any given series (400
shots in 40 s). The 60 s break between two
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Figure 6.8: PpIX’s delayed fluorescence reciprocal lifetime change, as measured in CAM, showing
PDT-induced tissular oxygen consumption and its regeneration during the treatment breaks. Re-
sults from 4 sequential series of 400 laser shots each (3.4mJ/cm2 per pulse, spot diameter ∅500µm),
separated by 1 min breaks. To demonstrate oxygen consumption, the initial and final oxygen levels
are deduced from the DF recovered from the firsts 20 and the lasts 20 laser shots of each series.
Their respective, averaged, reciprocal DF lifetimes are shown. The 4 different symbols in the graph
corresponds to the 4 consecutive laser shots series.
consecutive series allows for (predominantly
vascular) oxygen to re-diffuse to the region of
the probed spot, thereby restoring - at least
partially - the tissular oxygen concentration,
as confirmed by a shortening of the observed
DF lifetime (see figure 6.8).
The second in vivo example illustrates the
relation between the PS’s DF lifetime and the
concentration of oxygen in the atmosphere
surrounding the CAM sample: A small gas
chamber (see figure 6.9(a)) was built for eas-
ily regulating the oxygen content in the atmo-
sphere surrounding the sample. A small hole
(A) in the top part of the chamber allowed
for positioning the fiber tip at the CAM’s sur-
face, while two lateral inlets-outlets (B and C)
allowed to flush it continuously with known
N2/O2 gas mixtures. We used it to mea-
sure the DF lifetime of PpIX (endogenously
produced by the CAM, following the ALA
administration protocol described above) un-
der different O2 atmosphere conditions. The
CAM was introduced in the chamber and left
for 3 minutes, in view of an approximate equi-
libration of O2 in the CAM itself, immersed
in a homogeneous atmosphere of known, sta-
ble composition. The linear relation obtained
with 12 different samples (see figure 6.9(b))
satisfies the Stern-Volmer equation (see equa-
tion 6.1), confirming and validating these in
vivo measurements. These results show no-
ticeable dispersion, increasing with the ap-
plied oxygen concentration, leading to the in-
creasing error bars at 5, 10, 15 and 21 % O2
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(a) Gas chamber to control the
O2 concentration on the atmo-
sphere surrounding the egg
(b) The DF lifetime in function of the ammont of
oxygen in the chamber’s atmosphere
Figure 6.9: (b): Relation between PpIX’s DF reciprocal lifetime, measured on the CAM’s surface,
as a function of oxygen concentration in the controlled atmosphere gas chamber (a).
content, linked to intra-sample and/or inter-
sample variations, such as the actual vascu-
lar and micro-vascular density in the probed
area.
The third in vivo experiment was de-
signed to evaluate the scale/importance of
any intra sample dispersion, when locally
measuring the pO2. This experiment was con-
ducted in the same way as the previous one,
but the oxygen concentration was measured
in 8 different points of the same egg’s CAM
(see Figure 6.10(b)). The results showed
sizable differences, increasing with the ap-
plied oxygen concentration, to be ascribed
directly to local, intra sample, fluctuations
(i.e. location-specific attributes which influ-
ence the measured pO2 value, such as the ac-
tual vascular density in the probed area), as
shown by the large error bars at 15% and 21%
O2 content, Figure 6.10(b). As in the previ-
ous experiment, this dispersion increases in
parallel to that of the pO2. It may originates
in (i) the increasing measurement errors when
the lifetimes become shorter (at high pO2)
and (ii) in the fact that the amplitude of any
pO2 variation, linked to the density of the vas-
culature, is directly proportional to the pO2
itself.
6.4 Conclusion
We have designed, developed and character-
ized a time-resolved optical fiber-based spec-
trofluorometer for the in vivo detection of the
delayed fluorescence of photosensitizers with
simultaneous spectral and temporal resolu-
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(a) Measurement spots on the CAM (b) The DF lifetime in function of the ammont of
oxygen in the chamber’s atmosphere in 8 different
location of the same egg
Figure 6.10: Intra sample fluctuations, measured by exciting the CAM of the same egg in 8
different locations with different environmental oxygen concentration.
tion. Our setup is designed in such a way
that: (i) In vivo and in vitro lifetime mea-
surements can be easily performed through
the use of a ∅500µm optical fiber, allow-
ing for the measurement of poorly lumines-
cent, endogenously produced, small photo-
sensitizer concentrations (C = 1 × 10−5M)
with a lifetime ranging from a few hundreds
of nanoseconds to a few milliseconds. (ii) In
vitro solutions can be easily measured at dif-
ferent temperatures (15°- 60°) and with differ-
ent gas concentrations by bubbling the appro-
priate gas mixture in the measuring cuvette.
(ii) In vivo CAM samples can be easily mea-
sured under controled conditions of tempera-
ture and moisture and with controled gas con-
centrations in the surrounding atmosphere,
by using a simple gas chamber. (iii) In vivo
and future clinical measurements on hollow
organs can easily be performed, thanks to the
simple fiber-based excitation/sensing design.
(iv) Liquid and solid state (powders, crystals
and deposited thin films) samples can be an-
alyzed. (v) The excitation wavelength can be
adjusted (400 to 850 nm) by simply changing
the dye of the laser or through the use of a
grating. Moreover, if an increased sensitivity
is needed (one order of magnitude) it is pos-
sible to place the sample directly inside the
light-tight enclosure (see figure 6.2) and/or
modifying the delay or the acquisition time.
The described setup offers the following
advantages as compared to other commercial
setups (e.g., Perkin-Elmer LS 50B):
(a) its high sensitivity over a large spec-
tral range (185-900 nm) coupled to the ability
of measuring much shorter events (on the or-
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der of 100 ns) and a better dynamic range
both in the time and intensity dimensions.
Indeed, the temporal dynamic range can be
easily adapted to measure nano seconds up
to steady state events and the intensity dy-
namic range start at several Watts down to
≈ 2.5 × 10−10W (i.e. approx. 1000 photo-
electrons whithin 30µs)
(b) the possibility to excite the sample
with a short (≈ 300 ps) and spectrally defined
laser excitation pulse, which allows to excite
selectively the molecules of interest and, con-
sequently, to obtain measurable signals from
low concentrations samples. The use of a
very tightly focused laser beam (rather than
the much larger image of a traditional lamp)
results in the coupling of essentially all the
available excitation energy into an optical
fiber, enabling to probe small (∅ ≈ 100 µm)
samples.
(c) the compactness of the instrumenta-
tion (≈ 25 litres) and the use of a fiber-based
probe for both sample excitation and lumi-
nescence collection meet all the requirements
needed for laboratory and clinical settings.
Measuring the oxygen partial pressure
(pO2) can provide valuable information for
the early diagnosis and characterization of
numerous diseases related to changes of the
tissues metabolism in hollow organs, as dis-
cussed in §1. Because delivery of O2 takes
place primarily in the micro-circulation, it is
of high relevance to develop pO2 measuring
techniques that have a sufficient spatial reso-
lution to be applicable in the capillaries, ar-
terioles and venules in vivo. Therefore, an
evolution of the system presented here to-
ward an imaging delayed-fluorescence time-
resolved spectrometer, that can be adapted
to an eye fundus camera for example, would
be particularly valuable in this context. Since
Visudyne® also presents a pO2-dependent de-
layed fluorescence lifetime (data not shown),
such an approach would enable us to indi-
vidualize the light dose for the treatment of
AMD by PDT.
More generally, the technique presented in
this report will help to understand the impact
of oxygen on tissue sensitization. This is why,
following this study, several well accepted
photosensitizers used in the clinic, exhibit-
ing delayed fluorescence, are currently being
investigated with our CAM model. Oxygen
concentration measurements performed be-
fore, during and after PDT are conducted on
this model to demonstrate the feasibility of
this approach and to optimize the treatment
conditions.
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Abstract
Tissular molecular oxygen is monitored during photodynamic therapy. The oxy-
gen concentration in living tissue, expressed hereafter as the tissular pO2 in %, is
evaluated by measuring the photosensitizer’s delayed fluorescence lifetime. This
enables the collection of real time data reflecting the local availability of oxygen
in a small region around the excited photosensitizer (PS) molecules. In this study
5-amino-levulinic acid (ALA), a precursor of the photosensitizer protoporphyrin IX
(PpIX), was administered topically (20µl ; 20mg/ml) in vivo, over a selected area
at the surface of the chick egg chorioallantoic membrane (CAM). After a drug-light
interval of 4h, the eggs were irradiated with a CW laser with different light doses
(λPDT = 405nm, 0.4 − 2.25 J/cm2) and the diminishing pO2 was then monitored
during photodynamic therapy (PDT), using our optical fiber-based spectrofluo-
rometer which measures the delayed fluorescence lifetime of PpIX as a proxi for
the local pO2. The pO2 reduction (due to various photochemically initiated reac-
tions between the PS and oxygen, leading to the formation of cytotoxic reactive
species) was recorded and correlated with the observed vascular damage (basically,
the efficacy of blood vessel closure, on an arbitrary scale), measured with an epiflu-
orescence microscope in the irradiated region of the CAM, 18− 20 hours after the
treatment.
The PpIX delayed fluorescence lifetime was found to be in the range from ≈ 15µs
to 60µs in normal physiological, respectively hypoxic, conditions. These delayed
fluorescence signals were only ≈ 1/300 of the prompt (i.e. normal) fluorescence
of PpIX, but could still be easily detected with the present simple and clinically
compatible device.
The results show a strong correlation between PDT-induced vascular damage and
tissular oxygen consumption. Furthermore, PDT efficacy was found to be strongly
reduced at low pO2. This real-time knowledge about tissular pO2, gained through
the measurement of the PS’s delayed fluorescence, may be used to adjust the light
dose applied, thus reducing intra- an inter- patient fluctuations and stabilizing the
clinical outcome of PDT.
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7.1 Introduction
Photodynamic therapy (PDT) is an attrac-
tive treatment modality, especially for local,
superficial early stages cancers in the hollow
organs and other regions of the body eas-
ily accessible to light application. Thanks
to its partial selectivity and to the mini-
mally invasive procedures involved, PDT has
established itself as the treatment of choice
in, among others, dermatology and also cer-
tain ophthalmologic conditions, such as poly-
poidal choroidal vasculopathy (PCV) and wet
age-related macular degeneration (AMD). To
obtain the desired cytotoxic and healing ef-
fects, PDT relies on the presence in the target
tissue of a photosensitizer (PS) and molecular
oxygen (O2(3Σg) noted 3O2 for short or sim-
ply O2 if unambiguous), and the administra-
tion of light at wavelengths matching, at least
partially, the absorption spectrum of the PS.
The present work focuses on the use of pro-
toporphyrin IX (PpIX) as the PS1. In gen-
eral, this entails the topical or systemic ad-
ministration of 5-amino-levulinic acid (ALA,
a biochemical precursor of PpIX), followed
by a drug- to light-application time interval,
necessary for the biosynthesis and accumu-
lation of PpIX in the cells of the target tis-
sue. PpIX is the last intermediate in the heme
biosynthetic pathway [14, 57] before the en-
zyme ferrochelatase inserts an Fe(II) ion in
the macrocycle to make heme. PpIX, in con-
trast to heme, is a photoactive substance with
a relatively high singlet oxygen yield (≈ 56%
in specific in vitro conditions [46]), and with
a high fluorescence quantum yield. ALA-
based PDT as well as PDT based on the use
of chemical derivatives of ALA, are now ap-
proved for certain medical purposes and in
common clinical use for the treatment of pre-
malignant and malignant conditions in der-
matology.
In most cases, ALA-based PDT relies on
cell apoptosis rather than on tissue necro-
sis, leading to good cosmetic results as most
of the connective tissue is not destroyed.
For that reason and thanks to its limited
side-effects and the minimal invasiveness of
the clinical procedure, it is in many cases
prefered to alternative treatments [20], like
surgery, cryotherapy or the application of 5-
fluorouracil. However, despite the encour-
aging results, clinicians are sometimes dis-
suaded from using this therapy due to the
fluctuations in intra- and inter patient ther-
apeutic outcome. These fluctuations, fre-
quentely linked to the uneven tissular dis-
tribution of the PS and/or oxygen, might in
1Although there is still some controversy about exactly which molecule is responsible for the observed, post-
ALA administration, fluorescence and therapeutic effects, PpIX is the commonly accepted candidate. PpIX also
does play a role in the erythropoietic protoporphyria (EPP) condition, where lack of ferrochelatase induces its
accumulation in the cells, causing skin photosensitivity and liver disfunction [50].
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some cases, be counterbalanced by perform-
ing local, fluorescence-based measurements
of the PS concentration, and then adjusting
the local light dosimetry [3–5]. Nevertheless,
since PDT involves three main interdepen-
dent variable elements (light dose, photosen-
sitizer concentration and oxygen partial pres-
sure), optimal treatment dosimetry remain a
challenge. Thus the interest in finding effi-
cient ways for monitoring the local PS con-
centration and pO2, to optimize and drive the
delivery of laser light to the tissue.
Light dose optimization for PDT is the fo-
cus of ongoing research in several groups [8,
10, 23, 28, 40, 54]. Different approaches have
been proposed to efficiently monitor PDT in
view of improving its clinical outcome [64].
One of them is explicit dosimetry in which the
quantities of light, drug and oxygen are con-
tinuously and separately monitored during
treatment. Alternatively, implicit dosime-
try makes use of a surrogate of the biolog-
ical damages, such as the photodegradation
(bleaching) of the photosensitizer, to predict
the clinical outcome [24, 54, 61].
Recent studies tried to correlate the clini-
cal outcome of PDT with the so called direct
dosimetry, which entails the direct measure-
ment of singlet oxygen (O2(1∆g) noted 1O2
for short) during the therapy [26, 40, 62].
Previous studies [12, 34, 42, 43, 52] have
provided strong evidence that 1O2 is in fact
the major active cytotoxic species interacting
with target tissues and inducing cell apopto-
sis. Therefore, accurate monitoring of 1O2,
though quite difficult to do, might lead to a
better prediction of the clinical outcome than
other monitoring techniques.
A simplistic summary of the photochem-
ically induced reactions (type-II photochemi-
cal reaction pathway) can be represented by
the following chemical scheme:
S0 + hν → S1 Photon absorption
by the PS
S1
ISC−−−→ T1 Intersystem crossing
T1 + 3O2 → S0 + 1O2 Collisional energy
transfer between the PS
and molecular O2
S0 is the singlet ground state of the PS
which is excited (upon absorption of a photon
of energy hν) to the first excited singlet state
S1. The latter undergoes intersystem crossing
with a certain quantum yield (up to 90% for
certain porphyrins [11] and ≈ 60% for PpIX
[46], measured in in vitro conditions) to the
long lived lowest triplet state T1, which has
a lifetime ranging from µs up to ms. This is
why the tissular oxygen in the triplet ground
state (3O2 ) has enough time to undergo a col-
lision with the PS in the T1 state, to form the
highly reactive and cytotoxic singlet molec-
ular oxygen 1O2. Once generated, 1O2 un-
dergoes de-excitation through several path-
ways among which a low probability radia-
tive decay with emission of an infrared pho-
ton at 1270nm. This 1O2 luminescence is
88
7.1 Introduction
in fact characterized by a very weak signal,
making its measurement not easily applica-
ble in the clinical context (the luminescence
emission of 1O2 has a probability of 10−8
and a charateristic lifetime of ≈ 100ns un-
der in-vivo conditions [38–40]). These fast
and weak signals from 1O2 at 1.27 µm are
difficult to work with under clinical condi-
tions, where simple, robust setups and real
time measurements are preferred. Moreover,
detecting a weak infrared luminescence signal
in vivo is not a simple matter: several biolog-
ical molecules, when excited, may also emit
in this spectral range. The above may sub-
stantially increase the complexity and cost of
the instrumentation, as well as the duration
of the data acquisition process [26]. Finally,
such signal intensity-based measurements are
subject to errors due to source fluctuation,
detector drift, geometry changes, and pho-
todecomposition of luminescent species. To
overcome these problems, a compromise be-
tween direct and explicit dosimetry would be
appropriate.
Hence the idea to measure the production
of excited singlet oxygen via the consump-
tion of the PpIX’s triplet state (T1 in the
above chemical scheme), which is efficiently
quenched by the molecular oxygen found in
the tissue: according to Redmond and Gam-
lin [46], a fraction ranging from 55% to 80%
of the PpIX T1 population is quenched by
3O2, depending on the actual in vitro condi-
tions. Therefore, measuring the photosensi-
tizer’s luminescence lifetime offers an alter-
native to measuring the radiative decay of
1O2. Furthermore, in contrast to intensity
measurement methods, lifetime measurement
methods have the advantage of being inher-
ently self-referential and to be less prone to
the above mentioned problems [36].
PpIX’s phosphorescence signal, from the
radiative path connecting T1 to S0, may
not be easily detected in vivo because the
phosphorescence quantum yield is too low
and/or because this luminescence takes place
at wavelengths too long to be easily de-
tected [2, 31, 35, 51, 55, 58]. This difficulty
can be overcome by measuring PpIX’s delayed
fluorescence (DF) lifetime as a substitute for
its phosphorescence lifetime [21, 29, 32].
Along these lines, Mik et al. [31, 32] re-
ported in vitro and in vivo experiments us-
ing PpIX’s DF lifetime signals, to assess the
amount of oxygen in tissues. As compared
to other oxygen sensing techniques, DF mea-
surements have the advantage to record the
oxygen concentration in a close proximity of
1 Given the diffusivity of molecular oxygen (3O2) in tissue (D ≈ 1.7×10−5 cm2/s, [16, 33]) and using PpIX’s
triplet state maximum in vivo lifetime (τ ≈ 60µs), the distance reachable by an O2 molecule to interact with
excited PpIX molecules is calculated to be on the order of ≈ 1µm (δ = √6Dτ , [45]). If the same computation
is done for singlet oxygen (1O2), whose lifetime of ≈ 250ns is much shorter, the reachable radius is less than 40
nm.
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the photosensitizer1, on the order of 1µm.
The critical oxygen diffusion distance, usually
defined as the distance between a hypoxic tis-
sue (i.e. a tissue in a situation of critically low
oxygen level) and the nearest vessel has been
measured by [16] to be on the order of 100µm
in a tumoral tissue. It is therefore clear
that this DF-based oxygen sensing method
is able to spatially discriminate between hy-
poxic zones and normally oxygenated tissue,
provided that a small enough probing laser
beam is used.
The chicken egg chorioallantoic mem-
brane (CAM) has proven to be a good in
vivo model to assess vascular modifications;
in particular it is well suited to characterize
PDT’s vascular effects [6, 9, 19, 25, 47, 48].
In this work, we use this in vivo model to
examine if any robust correlation exists be-
tween oxygen consumption during PDT and
the resulting vascular damage.
7.2 Materials and Methods
7.2.1 Delayed Fluorescence Life-
time Measurement
The tissular pO2 can be determined by mea-
suring the lifetime τ of the PS’s triplet state
thanks to the well known Stern-Volmer rela-
tionship (7.1):
I0/I = τ0/τ = 1 +Kqτ0[pO2] (7.1)
where I and τ refer to the intensity and
lifetime of the PS’s phosphorescence for a
given tissue pO2 while I0 and τ0 refer to the
values measured in the abscence of oxygen,
and Kq is the Stern-Volmer constant. In
this study, tissular oxygen concentrations are
given as values of pO2 in units of percent (%),
meaning that the tissue is assumed to be sat-
urated and in equilibrium with an oxygen-
containing gaseous mixture (usually air or
calibrated nitrogen/oxygen mixtures) at a
pressure of 1 atm. The lifetime τ is deter-
mined indirectly, by detecting the DF of the
PS’s excited triplet state, as previously de-
scribed in the literature [21, 29, 32, 44]. For
this purpose, we have constructed and used
a fiber-based, time-resolved spectrofluorome-
ter, (7) in Figure 7.1(b), which has been de-
scribed in detail in Piffaretti et al. [44].
In short, the essential features of the mea-
surement method are as follows (see Figure
7.1): the PpIX molecules synthetized in the
CAM, (1), are excited with a nitrogen-laser-
pumped dye laser (part of item 7) (LTB®
model MSG 803-TD, 405nm) pulsed at a rep-
etition rate of 10 Hz. The dye laser wave-
length is set at 405nm to match the PpIX’s
peak of absorption. As we are only interested
in probing the superficial tissues of the CAM,
the 405nm wavelength is more than adequate
from a tissue penetration point of view. The
laser light is conveyed to the sample by an
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(a) Close-up of the treated CAM zone (b) General view of the setup
Figure 7.1: Tissular oxygen measurement in the CAM. (a) (1) CAM surface; (2) Protective drop
of acqueous serum; (3) 0.19 mm cover-glass; (4) PDT treatment fiber; (5) Excitation/probing fiber;
(6) Fiber holder. (b) (1) CAM in the open egg; (8) PDT treatment laser; (4) Fiber used for PDT
irradiation; (7) Spectrofluorometer with dye laser excitation source; (5) Excitation and probing
fiber; (6) Fiber holder.
optical fiber (5) (Laser Components® HCG-
M0550T) which is a multimode optical fiber,
with core diameter ∅550 µm, and numerical
aperture (NA) of 0.22. The radiant exposure
of the laser pulse, at the distal fiber tip was
3.5mJ/cm2. After each laser pulse, the DF
photons emitted by the relaxing PS molecules
are collected by the same optical fiber (5)
and focalized on a gated photomultiplier tube
(PMT, part of item 7). The PMT is blinded
(gated to the ’off’ state) during the first 3µs
after the laser excitation pulse, to avoid satu-
ration by the much stronger normal (prompt)
fluorescence signal. This DF decay signal is
averaged over 30 consecutive sweeps, bringing
the total acquisition time to 3 s, and the av-
eraged decay is then digitized and mathemat-
ically fitted to a single or multiple exponen-
tial function, using the Levenberg-Marquardt
non-linear least-squares fit algorithm. In our
case, the resulting computation errors on the
in vivo lifetimes were limited to ±5% [44].
7.2.2 Handling of the Chick Em-
bryo’s CAM and ALA Ad-
ministration
The chick embryo’s CAM model has been de-
scribed previously [9, 15, 25, 56] and was
used with minor modifications. Briefly, fertil-
ized chicken eggs were disinfected and trans-
ferred (blunt end up) into an automatic turn-
incubator, set at 37℃, 60% relative humidity
(RH), and in normal atmospheric pO2 condi-
tions1, i.e. 21% [30, 49]. On embryo devel-
opment day 3 (EDD 3), a portion of the egg-
shell was removed at the pointed end of the
1 Given the geographical location (400 m above see level) of the experimental setup, this corresponds to a
partial pressure of approximately ≈ 150mmHg of O2.
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egg, creating a hole of approximately ∅3mm
in diameter, which was covered with cling film
(Parafilm®) and, at later times, always kept
pointing up. This procedure causes the em-
bryo and its enveloping CAM to locally re-
tract from this artificial opening, exposing at
its surface a flattened portion of the mem-
brane, and providing an access to observe and
treat the CAM’s capillary plexus and vascu-
lature. The eggs were then returned to the
incubator (blunt end down) and kept in a
static position. At EDD 11, the eggs were
removed from the incubator for topical ALA
administration: a zone of the CAM character-
ized by homogeneous vascularization was vi-
sually selected and a 20µl droplet of a 0.15M
(20 mg/ml) ALA acqueous solution in 0.9%
NaCl, adjusted to pH 6 with NaOH, was de-
posited in the centre of this zone. The eggs
were then returned to the incubator and kept
static until further use. As a rule, any ma-
nipulation of the CAM after ALA application
was done in total darkness or under subdued
light.
7.2.3 PDT Irradiation and CAM
Tissular Oxygen Depletion
Measurements
The study design was guided by the following
rationale (see Figure 7.2):
Protocol I was used to determine the ex-
istence of a robust relationship between PDT
duration and pO2, while using a minimum
number of eggs: thus, each egg was submitted
to a number of successive, cumulative, irradi-
ations - and measurements.
Protocol II seeked to check the same re-
lationship as protocol I using: (i) a different
batch of eggs, (ii) intermediate durations for
the incremental PDTs and (iii) a longer to-
tal treatment time (900 s), in order to con-
firm and improve the precision of the relation
observed using protocol I, while still keep-
ing the cumulated total measurement time
under a certain maximum (6 times 3 s). In
fact, in protocols I and II, pO2 measurements
were performed once during each 3 s OFF pe-
riod of the treatment laser, i.e. immediately
after each incremental PDT irradiation pe-
riod and the difference with the initially de-
termined baseline pO2 value was computed
to be the tissular oxygen depletion assignable
to the corresponding, cumulated, PDT treat-
ment time.
Protocol III was used to prove that the
parasitic effects of the multiple, intermediary,
measurements used in protocols I and II were
small.
The normal, baseline value of the pO2 was
first determined for each egg before starting
any PDT irradiation protocol. The treatment
laser was then switched on and off and pO2
measurements performed according to one of
the three experimental protocols described
above. In protocol III (described in more
detail under §7.3.4), pO2 measurements were
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Figure 7.2: Time sequences of the experimental protocols used in experiments 3 and 4. The
figure shows the cumulative PDT irradiations, interspersed with O2 measurements during which
the PDT source was suppressed. PDT irradiation durations were: a = 150 s, b = 75 s, c = 375 s,
d = 150− 900 s , while the O2 measurement duration was: m = 3 s
performed just once before and once after a
continuous, predetermined irradiation period.
The difference between those two pO2 values
was computed to be the tissular oxygen de-
pletion assignable to the corresponding, un-
interrupted, PDT treatment time.
Details of the PDT irradiation and tissu-
lar oxygen measurement procedures were as
follows: At EDD 11, 4h after ALA admin-
istration, the egg was taken out of the incu-
bator and placed under the combined PDT-
irradiation/DF-measurement setup (Figure
7.1(a)). The drug-light interval of 4h allowed
time for the cells to produce sufficient tis-
sular of PpIX (see §7.3.1). This PpIX bio-
synthesized in-situ serves both as the PS for
the PDT and for measuring the pO2, through
its delayed fluorescence lifetime (see §7.2.1).
In order to minimize re-oxygenation of the
tissue1 during PDT by atmospheric oxygen,
a round microscope cover-glass (3) (Menzel-
Gläser ® ∅20mm, thickness 0.15mm) was
gently floated on the CAM’s surface (1) af-
ter depositing two drops (2) of human physi-
ologic serum (≈ 80µl of 0.9% NaCl). This liq-
uid layer, acting as a cushion, was essential to
avoid any adherence between the cover-glass
and the CAM and possible subsequent injury
to the CAM surface.
A PDT treatment zone, featuring blood
vessels and capillaries with diameters rang-
ing from 5 to 300µm, was visually chosen
approximately in the middle of the zone un-
der the cover-glass. The tip of the optical
fiber (5) was aimed towards the center of this
zone, and held at a distance of ≈ 100µm
1 During PDT or tissular oxygen measurement, oxygen may only diffuse from the CAM vasculature and
from the tissues adjacent to the treated zone - not from the shielded surface of the treated zone.
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(a) CAM model, objective 4x (b) CAM model, objective 10x
Figure 7.3: CAM vascular network after the i.v. injection of FITC, no PDT was administered to
the egg
above the cover-glass. It was kept in place
by a metal fiber holder (6). The PDT light
was provided by a CW solid state diode laser
(8) (Oxxius®, 405nm, 1.3mW total power at
the distal end of the fiber) and administered
through another optical fiber (4) (MedLight®
Frontal light distributor, NA = 0.37, core di-
ameter ∅600µm). This treatment fiber was
chosen and its distance to the CAM adjusted
so as to deliver a homogeneous PDT treat-
ment spot (∅ 8mm) on the selected zone
of the CAM vasculature. Small irradiances
(≈ 2.5mW/cm2) were preferred so as to avoid
significant photothermal effects. The period
during which the eggs were kept out of the
incubator was limited to about 15 min.
To keep the DF measurement durations
small with respect to PDT exposure times,
thus minimizing phototoxic effects and oxy-
gen consumption due to the DF measure-
ments themselves, only 30 consecutive laser
sweeps were used and averaged for the oxygen
measurements. Thus, as mentioned above,
the total acquisition time for one such mea-
surement was 3 s, as compared to a mini-
mum PDT exposure time of 75 s, and the cor-
responding total light dose delivered by the
probing laser was limited to ≈ 100mJ/cm2 ,
as compared to a minimum PDT light dose of
≈ 190mJ/cm2, both at 405nm. A light dose
of 100mJ/cm2 was found to have barely de-
tectable PDT vascular effect. Therefore, we
chose to set the minimal PDT light dose to
approximately the double of this value.
At the end of the PDT treatment, the
cover-glass was carefully removed from the
treated zone. Only very small iatrogenic
damages were identified after these mechan-
ical operations. In other words, when the
cover-glass insertion and removal was per-
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(a) CAM model 4x (b) CAM model 10x
Figure 7.4: CAM vascular damage after a PDT total optical dose of 2.25 J/cm2, laser spot ∅5mm
formed with all needed care, induced injury
was imperceptible. The eggs were then re-
turned to the incubator, while waiting for the
vascular damage assessment.
7.2.4 Vascular Damage Assessment
The treated eggs were taken out of the in-
cubator 16 − 18h after termination of the
PDT irradiation protocol1. An intra-venous
( i.v.) injection of 20µl of a 150µM solution
of fluorescein isothiocyanate-dextran (FITC,
150KDa, 25mg/ml in NaCl 0.9%) was ad-
ministered into one of the large CAM veins,
while 1ml of india ink (Parker®-Quink) was
injected under the CAM to increase contrast
and screen out the continuously changing
background fluorescence. Vascular damage
due to PDT was then examined and recorded
photographically with an epifluorescence mi-
croscope (Nikon ® E600FN, excitation wave-
length between 450 nm and 490nm, emission
wavelength: > 520nm), see Figure 7.3 and
7.4.
The damage extent was classified on the
basis of blood vessel closure: Effectively, the
diameter of the largest blood vessels closed by
the PDT treatment was used as an arbitrarily
chosen index of vascular damage (see §7.3.4).
7.3 Results
7.3.1 PpIX Build-up Kinetics after
ALA Topical Administration
Limited experimental data have been pub-
lished about the localization and build-up ki-
1 This standard time period has been in use in our laboratory for several years, partly for practical reasons,
as the measurements are performed overnight. Although it was not methodically optimized, it corresponds to
a state of the CAM where PDT damage has had the time to fully develop while the counteracting processes of
vessel repair and neo-angiogenesis have not yet interfered significantly with the PDT results.
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netics of PpIX in the CAM following topi-
cal administration of ALA [17, 27] [18, 19].
In view of optimizing DF signal quality, we
performed a first experiment using 10 eggs,
whereby each egg was examined after a vari-
able waiting time (ranging from 0 to 6 h) fol-
lowing the topical administration of ALA (see
Figure 7.5).
During the several hours of incubation,
ALA is absorbed by the vasculature where
it circulates, and diffuses out of the vascula-
ture into almost all egg tissues: thus, PpIX is
formed and accumulated in most of the tissue
volume of the chick embryo. In Figure 7.5(a),
the resulting spatial distribution of PpIX in
the CAM is shown, 4 hours after ALA admin-
istration: The picture reveals a slightly more
intense fluorescence (lighter areas) around the
center of the administration zone and near
the walls of the large vessels, where ALA in-
teracted longer and in higher concentrations.
As an illustrative example, the luminescence
intensity in the administration zone was, in
fact, measured to be≈ 30% higher than 5mm
away from this zone.
As shown in Figure 7.5(b) and in agree-
ment with the litterature [17–19, 27], the
maximum of PpIX accumulation is reached
approx. 4h after ALA administration. Ac-
cordingly, a drug-light interval of 4h was cho-
sen for the PDT and used throughout this
study. The zone where ALA was topically ad-
ministered was then selected to perform DF
measurements as this resulted in an adequate
signal-to-noise ratio.
7.3.2 In vivo Monitoring of Tis-
sular Oxygen Concentration
through PpIX’s Delayed Flu-
orescence
In a second experiment, we collected data
from 12 eggs exposed to precisely determined
oxygen/nitrogen gaseous mixtures, whose
oxygen concentration was gradually and suc-
cessively decreased. The relative concentra-
tions of O2 were respectively 21%, 15%, 10%,
5%, 3%, 1% and 0%.
Before each measurement, the egg was al-
lowed to stand in the controlled atmosphere
of the gas chamber for 10min to establish
an approximate equilibrium between envi-
ronmental and tissular pO2. The DF life-
time of PpIX was then determined with our
optical fiber-based spectrofluorometer. Fig-
ure 7.6(a) confirms the validity of the Stern-
Volmer equation in our experimental condi-
tions (see Equation 7.1): PpIX’s DF recip-
rocal lifetime appears to be a linear function
of the eggs’ environmental oxygen concentra-
tion. Note the relatively large error bars,
corresponding to ± one standard deviation.
These error bars increase with the relative
concentrations of O2, at least partially due
to the decreasing accuracy, when determin-
ing gradually shorter lifetimes, whose inverse
are plotted here.
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(a) Spatial distribution (b) Fluorescence pharmacokinetics
Figure 7.5: PpIX fluorescence in the CAM model after topical administration of a droplet (20µl)
of 0.15M ALA solution. (a) Spatial distribution. Fluorescence image recorded 4 h after adminis-
tration (λEx = 405nm, λEm > 460nm), the white circle shows the location where the ALA droplet
was deposed. (b) Fluorescence pharmacokinetics
7.3.3 In vivo Measurement of Tis-
sular Oxygen Concentration
as a Function of PDT Irradi-
ation Time
In a third type of experiment, we performed
DF-based O2 measurements on a total of 35
eggs, submitted to increasing cumulated PDT
illumination times, where each data point is
the average of measurements performed on 12
to 20 different eggs.
Figure 7.6(b) shows DF reciprocal life-
time measurements acquired after illumina-
tion protocols I or II (illustrated in §7.2.3).
The vertical scale on the right hand side of
Figure 7.6(b) gives an indication of the cor-
responding residual tissular O2 concentration
based on the results obtained during of the
experiments under controlled atmosphere (re-
ported in Figure 7.6(a)). The results show a
decreasing oxygen tissular concentration (i.e.
an increasing oxygen consumption) during
the first 500 s of cumulated PDT time, while a
limiting asymptotic value is reached at longer
treatment times, very near the zero concen-
tration level for tissular O2. The relatively
large error bars (± one standard deviation)
are probably due, at least in part, to local dif-
ferences in the aptitude of CAM tissues to re-
new the consumed O2, depending on their dif-
ferent metabolic activities, and possibly also
to inhomogeneities in the spatial distribution
of the photosensitizer.
7.3.4 Tissular Oxygen Depletion as
an Index of PDT Efficiency
To establish the expected correlation between
tissular oxygen consumption during PDT and
the corresponding, observed vascular damage,
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(a) PpIX’s reciprocal lifetime under con-
trolled atmosphere
(b) PpIX’s reciprocal lifetime as a function of PDT du-
ration
Figure 7.6: Delayed fluorescence reciprocal lifetime of PpIX in the in vivo CAM model. (a)
PpIX’s reciprocal lifetime under controlled atmosphere. (b) PpIX’s reciprocal lifetime as a function
of PDT duration. Protocol I (), Protocol II (), Protocol III ().
we performed a fourth experiment on five lots
of 20 eggs. These eggs were subjected to
PDT treatment, using different optical doses
as detailed hereunder and following the gen-
eral scheme of Protocol III (see Figure 7.2 ).
The CAMs were prepared, handled and mea-
sured as indicated previously.
Eggs Irradiation Optical dose
lot period [sec] [J/cm2]
1 150 0.38
2 300 0.75
3 450 1.13
4 600 1.5
5 900 2.25
Table 7.1: PDT light dose administration
protocol for eggs lot, see §7.2.3 for details.
The normal, baseline value of tissular
pO2 was first determined for each egg before
starting the chosen PDT irradiation proto-
col. The eggs were then submitted to PDT
illumination under a constant irradiance of
2.5mW/cm2 for durations ranging from 150
to 900 s as indicated in Table 7.1
Immediately after treatment, each egg’s
tissular O2 concentration was again mea-
sured, through the described PpIX DF recip-
rocal lifetime determination. Following this,
the difference between the initial and final
values of this DF reciprocal lifetime, i.e. the
difference between initial and final values of
the pO2 estimator, was taken as the measure
of tissular O2 consumption ascribable to the
PDT treatment. Thereafter, the eggs were re-
turned to the incubator and allowed to stand
for the usual 16 − 18h. The eggs were then
subjected to the procedure described under
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§7.2.4 to determine the extent of vascular
damage caused by the PDT, as measured by
the selected arbitrary damage index.
In Figure 7.6(b), PpIX’s reciprocal DF
lifetime and the corresponding residual tissu-
lar pO2 are shown as a function of PDT illu-
mination time (). The results show the ex-
pected diminishing pO2 with increasing light
dose. It is wort noting that this pO2 appears
to reach a very low limiting (plateau) value
for illumination periods longer than about
500 sec (≈ 1.3 J/cm2). Figure 7.7 illustrates
the correspondingly increasing oxygen con-
sumption as computed by the differences in
reciprocal lifetimes.
Figure 7.7: Lifetime difference as a function
of PDT illumination.
In Figure 7.8(a), the vascular damage in-
dex is plotted as a function of the PDT treat-
ment duration. The data shows, despite the
substantial error bars, a reasonable correla-
tion between these two parameters. Figure
7.8(b) shows the vascular damage index as
a function of reciprocal lifetime differences,
which are taken as a measure of tissular oxy-
gen consumption during the treatment. Here
again a clear correlation between those two
parameters is found. It is also of inter-
est to note that despite the fact that (as
shown in Figure 7.6(b)) for illumination peri-
ods greater than 500 s, the residual pO2 does
not decrease significantly anymore, the ob-
served tissular damage continues to increase
with increasing light dose, at least until an
irradiation time of 900 s. This suggests that
the PDT mechanism is still operating at these
very low oxygen concentrations.
7.4 Discussion
This paper reports the first study aiming
at measuring, in vivo and in real time, the
level of molecular oxygen contained in tis-
sue, using the DF of a PS, in order to op-
timize PDT. The results demonstrate a cor-
relation between the PDT-induced vascular
damage and the oxygen consumption assessed
by the change of DF lifetime. These ob-
servations are in agreement with numerous
articles reporting the role played by oxy-
gen in the tissue damage induced by PDT
[12, 26, 34, 40, 43, 52, 62, 63]. Consequently,
adjusting the PDT light dose, based on the
monitoring of the tissular pO2 through the
PS’s DF, appears feasible.
Thus, our approach appears as a promis-
ing way to control the efficacy of PDT, and
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(a) As a function of PDT duration (b) As a function of tissular oxygen con-
sumption
Figure 7.8: PDT-induced vessel damages in the CAM model. (a) As a function of PDT duration.
(b) As a function of tissular oxygen consumption, as measured by the reciprocal PpIX DF lifetimes
differences
reduce intra- and inter-patient fluctuations in
its clinical outcome. It is an essentially im-
plicit light dosimetry method, because the
pO2 change, a parameter which is propor-
tional to the production of singlet oxygen,
is measured close to the PS (about 1µm).
Therefore, this method is likely to be much
more directly related to the tissular effects
induced by PDT than the approaches based
on an explicit light dosimetry (light dose; PS
global concentration; etc.) [22, 24, 54, 61].
In addition, most of these other approaches,
for quantifying PDT outcome, suffer from the
weakness that the pO2 is not measured at
a subcellular or tissular scale. Furthermore,
the method presented here does not require
the use of exogenous oxygen sensors since it
is based on the DF measurement of the PS
itself, which is present in the PDT anyway.
This feature is of importance since, besides
ALA, several precursors of PpIX are now ap-
proved by the medical authorities of a large
number of countries.
Since, in our study, both the light used to
excite the DF and the light used for PDT have
the same wavelength, it cannot be excluded
that the DF excitation could induce a reduc-
tion in pO2, as well as PpIX photobleaching
and/or vascular damage, thus leading to ar-
tifacts. However, as already noted, the DF
excitation light dose, for a 30 laser pulse se-
ries used to perform a “measurement” (see
§7.2.1), is much smaller than the light dose
used to induce the smallest detectable PDT
effect, as indicated in §7.3.4. In addition, we
have demonstrated in a separate study that,
in the absence of PDT, the DF excitation
light does not induce any detectable vascu-
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lar effect, in our applied conditions. Finally,
comparing the evolution of the DF lifetime
for the three different measurement protocols
described in §7.2.3 (see Figure 7.6 (b)), indi-
cates that this DF excitation light does not
induce measurable vessel closure.
A drug-light interval of 4 hours was used
for the present study. It should be noted
that other incubation periods may lead to
other values of the DF lifetimes, even if
all other conditions are identical, since it is
well known that the PpIX buildup, which
takes place in specific tissue/cellular compart-
ments, is followed by a diffusion of the PS
to other compartments presenting other mi-
croenvironments [1]. The changed microen-
vironments may then lead to changed local
pO2 and hence change in DF lifetime, as well
as changed vascular occlusion efficiency. As
a consequence, it could be that the results
we report in Figures 7.6 and 7.8 may differ if
longer or shorter drug-light intervals are used.
The relatively large error bars observed in
Figure 7.6(a), which increase with the relative
concentrations of O2, are due, at least par-
tially, to the decreasing accuracy when deter-
mining gradually shorter lifetimes, whose in-
verse are plotted here. Another possible cause
may reside in variations of oxygen availability
to PpIX molecules, depending on their tissu-
lar and/or cellular localization, where differ-
ent metabolic activities occur. Indeed, the
much smaller error bars at very low pO2 val-
ues, i.e. below 5 %, support this hypoth-
esis, since death of the eggs when the pO2
tends to 0 % also implies the end of all these
different metabolisms, therefore erasing their
previous differences. Similarly, the relatively
large error bars affecting the DF lifetimes pre-
sented in Figures 7.6(b), 7.7, and 7.8 may
well be due to local differences in tissue oxy-
gen renewal during PDT. These local differ-
ences could, e.g., be due to spatial and/or
temporal differences in the metabolic activ-
ity, blood perfusion, inhomogenous distribu-
tion of the PS, etc. Therefore, one approach
to reduce these fluctuations would consist of
probing a larger area (say, 1 − 2 cm in di-
ameter) so that the measurement is averaged
over a larger surface. Our observations fur-
thermore suggest that it might be of interest
to image the PS’s DF lifetime at “high” spa-
tial resolution in the hope of getting informa-
tion regarding the changes of tissue oxygena-
tion at a tissular and even a cellular level.
Recording such images at different times af-
ter the beginning of PDT and at different
drug-light intervals would certainly help to
identify treatment strategies to target spe-
cific tissue structures (vessels versus stroma,
for instance). Finally, it should be noted
that the fluctuations, affecting the DF life-
time measurements, due to the instrumenta-
tion and the shot noise are negligible as com-
pared to the other factors mentioned above.
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Indeed, repeated measurements performed in
identical conditions, at the same location and
on the same sample confirm this. Never-
theless, if necessary, the shot noise can be
further improved by reducing the time dur-
ing which the detector is blinded to reject
the prompt fluorescence. The resulting in-
crease of DF radiant energy detected will de-
crease the shot noise, but will also increase
the risk to detect: (i) the emission of other
endogenous luminophores presenting “long”
(between 100ns and 1µs) luminescence life-
times; (ii) luminescence emitted by the in-
strumentation (laser spontaneous emission,
luminescence from the optics in the setup).
This is why we have, in this study, selected
a time delay of 3µs for “blinding” the detec-
tor, which corresponds to an optimal tradeoff
between this delay and the observed signal-
to-noise ratio.
The error bars affecting the measurements
of the diameter of the largest occluded blood
vessels, which are shown in Figure 7.8 are
likely to be due to various factors, includ-
ing: (i) The selection of the area treated by
PDT: indeed, somewhat different results may
be obtained if the relative density of large and
small vessels, or of veins versus arteries, dif-
fers from place to place. Although the rela-
tive importance of this source of fluctuations
is difficult to assess quantitatively, it proba-
bly plays a minor role, as described by Lange
et al. who used a similar metric to quantify
the vascular effects induced by PDT in the
CAM model [25]; (ii) the inhomogenous dis-
tribution of PpIX, as reported by many au-
thors [59, 60]; (iii) intrinsic errors while mea-
suring the vessels diameter: the fluctuations
due to this last reason could be reduced using
quantitative image analysis programs to char-
acterize the vascular network, as proposed by
Nowak-Sliwinska et al. [41]. One may con-
clude, considering the above-mentionned fac-
tors, which are possibly responsible for the
rather large fluctuations affecting measure-
ments of the DF lifetime and blood vessel
closure efficacy, that probing of larger well-
selected areas, as indicated above, will most
likely help to reduce these fluctuations.
The results presented in Figure 7.8(b) in-
dicate that the vascular occlusion effects of
PDT and the differences in reciprocal DF life-
time (which can be seen as a metric for the
tissular oxygen consumption) are correlated.
We have also observed that, for illumination
periods longer than 500 s (1.25 J/cm2), the
vascular damage continues to increase for in-
creasing light doses. This is interesting con-
sidering that the measured residual pO2 does
not decrease significantly anymore after 500 s,
as it is already very close to 0% (see Fig-
ure 7.6(b)). This observation indicates that
some PDT-related mechanism still continues
to be effective at very low pO2. One explana-
tion for this phenomenon is that all the oxy-
gen provided by the blood stream is immedi-
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ately consumed during the PDT illumination.
This hypothesis is realistic since the blood
vessels affected by PDT, depending among
others on their size, will close, to a large ex-
tent, after the end of the illumination [9], at
the applied conditions. Consequently, in such
conditions, the PDT effect would be “oxy-
gen supply dependent”, as reported by several
groups [13, 37, 53]. Although this explana-
tion is the most probable, other phototoxic
mechanisms, that do not involve molecular
oxygen, as suggested by Plaetzer et al. [45],
could cause a PDT effect in the abscence of
a significant pO2. We suggest that experi-
ments, similar to those presented in this pa-
per, but performed at different fluence rates,
may help to understand the nature of these
effects.
Finally one may note that the approach
presented here is of interest, not only for
PpIX-based PDT, but also when other PSs
with a detectable DF, or a difficult to de-
tect phosphorescence, are used. One may
even suggest that the technique presented in
this paper be used to monitor the pO2 during
the treatment of age-related macular degen-
eration with Visudyne®. Indeed, application
of the DF measurements to the retina may be
helped by the unique optical properties of the
eye, and making use of such measurements
may help compensate, to some extent, for
the inter-patient fluctuations observed during
AMD-PDT [7]
In conclusion, the present work has
demonstrated in vivo that the DF of a photo-
sensitizer can be used to determine the pO2
in tissues, thus helping to predict the tissu-
lar effects induced by PDT. The applications
of this approach to other systems are numer-
ous. Thus, the technology developed here
may help to get information on the mecha-
nisms involved in the oxygenation and pho-
tosensitization of various materials, including
biological tissues.
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8Introduction
8.1 A Brief Overview on Actinic Keratosis
Actinic keratosis (AK) is the name of a pathological condition of the skin, where hyperpro-
liferation of the keratinocytes, the cells present in the epidermis (the outermost skin layer),
occurs, usually caused or stimulated by daylight. AK is the most common skin condition
treated by dermatologists. The skin lesions are clinically identified as rough, scaly, crusted,
pink to reddishbrown papules. They are found on sun-exposed skin, especially on the head,
neck, forearms, and hands. The patients at greatest risk are middle-aged and elderly men, with
fair skin and blue eyes, especially those with occupations involving prolonged exposure to UV,
such as farmers, sailors, and construction workers [65].
The account that follows is based on the cited literature, and aims to give a brief overview on
the epidemiology, prevalence, and available therapies for treating this condition. The incidence
of AK is especially large in populations characterized by skin types I or II, on the Fitzpatrick
skin type scale. In a study performed in Australia, Quaedvlieg et al. [45] reported that between
40% and 50% of the population over 40 years, was affected by AK. Similar studies conducted in
the UK and in the USA, reported prevalence rates ranging from 20% to 25% of the population
over 60 years [11, 47]. Considerable efforts and means are provided for its treatment. Thus it
has been estimated that the annual costs (data from 2004) generated by this condition were of
the order of $1 billion in the USA [1].
AK is clinically described as a non-severe cutaneous malignancy and, indeed, AK lesions
are characterized by substantial spontaneous remission (55% after 1 year and 70% after 5-
year follow-up [10]), and a low evolution rate to the more severe and potentially metastatic
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squamous cell carcinoma (SCC: 0.60% at 1 year and 2.57% at 4 years [10]). AK is also notable
for its slow evolution. Three main reasons justify the treatment of AK. The first - and most
important - one resides in the difficulty to distinguish those AK lesions which will eventually
evolve into the dangerous SCC, from the ones that will spontaneously disappear. Secondly,
AK lesions are treated to provide relief for frequent symptoms, such as tenderness or itching.
Finally, treatment may also be desirable for aesthetic, or cosmetic reasons.
Several effective treatments are available to heal AK sufferers, even though, it is worth
reminding that, for this conditions, the best treatment is prevention (sun screen, sun hat).
Curettage, cryosurgery and topical treatments such as application of 5-fluorouracil and photo-
dynamic therapy (PDT) are the most common treatments [12, 43]. Curettage is effective for
almost all clinical types of AK, but this approach has potential complications such as scarring
and infection, and local anesthesia is frequently required before the procedure. Cryosurgery is
generally well tolerated, presenting, in certain cases, only transitory hypopigmentation. This
treatment is, however, limited to patients with only a small number of tiny, localized lesions.
The topical application of 5-fluorouracil has a high success rate, but generally not well toler-
ated . It is also characterized by prolonged erythema in the treated zones. Finally, the topical
treatment by PDT is well tolerated and presents excellent cosmetic outcome.
8.2 Treatment of Actinic Keratosis by Photodynamic Therapy
Photodynamic therapy (PDT) is a minimally invasive treatment modality, used in a number of
diverse conditions, which allows, in many cases, the selective and highly localized destruction
of abnormal cells. The use of PDT for treating AK is relatively recent [43, 44]. Compared to
the classical treatment modalities for AK, mentioned previously, PDT offers interesting specific
advantages, but also suffers from certain drawbacks, such as a relatively high cost, and the pain
experienced during skin irradiation, which needs to be properly managed by the clinician.
A PDT treatment requires the administration of a auxiliary, photoactive product to the
patient: the photosensitizer (PS). In dermatology, the PS of choice is Protoporphyrin IX (PpIX)
and the PDT procedure relies on the administration of a precursor of this PpIX, namely 5-
aminolevulinic acid (ALA). The ALA molecule is relatively small and penetrates easily into
the skin tissue, where it stimulates the endogenous production of the PpIX (see §2.4.1).
In the case of AK lesions, this topical administration modality is very convenient, as the
ALA molecule has just to diffuse and penetrate ≈ 100µm from the skin surface [20] to reach
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the hyperplastic and dysplastic cells, where it induces the production of PpIX. Recently, new
PpIX precursors, derived from ALA, have been synthesized, such as 5-ALA methyl ester (MAL,
Metvix®) and 5-ALA hexyl ester (HAL, Hexvix®), which were developed to improve lesion
targetting and reduce the drug-light interval [2, 13, 34, 37, 50].
To further improve the homogeneity of the distribution of the biosynthesized PpIX, it is
also of common practice to apply a gentle curettage to carefully scrape out the lesion’s scales
and crust typical of this condition. The complete treatment is minimally invasive, without
the need of any surgical preparation (debunking) prior to PDT illumination. The locally
biosynthesized PpIX is activated by illuminating the topically ALA-treated skin with simple,
inexpensive and non-coherent lamps like light emitting diodes (LED) arrays. While combining
ALA administration with red light illumination, allows to treat non-melanoma skin cancers
down to a depth of 2mm [13, 34, 41], in the US, AK lesions are commonly treated with blue
light (405nm), which actually penetrates efficiently only up to 200 − 300µm in the skin. [30,
42, 43, 55, 56].
PDT has proved to be an efficient treatment modality for AK and is also characterized by
excellent cosmetic outcome. Several studies reported a clearance rates varying from 68% to
89% after a single treatment, with follow-ups of up to 12 months [17, 27, 36, 41, 42, 55]. Despite
these encouraging results, the technique still suffers from lesion recurrences and heterogeneous
clinical outcome. This may be due to the fact that the efficacy of PDT depends on a several
parameters, including the PS’s microscopic and macroscopic distribution at treatment time, the
light dose, the tissular oxygen distribution, the irradiance and the tissue’s optical properties at
the treatment wavelength. Therefore, it turns out to be difficult to ensure that optimal values
(of all these measurable parameters) are applied during each individual treatment [46].
Different strategies were developed to study and monitor the dosimetry of PDT [6, 24, 32,
40, 64, 66], but none of them is currently in routine or systematic use. In fact, the param-
eters involved in the cascade of reactions leading to PDT effect may vary dynamically and
interdependently during the treatment. Moreover, sophisticated technologies and challenging
measurement modalities are not well accepted in the clinical field, which explains the limited
use of these strategies (e.g. PDT dose monitoring by measuring the 1O2 luminescence inten-
sity [40]). In the case of AK, the lesions being confined to the epidermis, simple treatment
monitoring techniques could be sufficient to enhance the treatment protocol and improve the
clinical outcome. Moreover, given the superficial location of these AK lesions, heterogeneous
distribution of oxygen in the tissue might not be a crucial problem, as several studies have
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shown that oxygen efficiently diffuses in the skin to a depth of 0.4mm [54]. We can thus
assume that, in the epidermis, oxygen is abundantly supplied by the atmosphere and, that,
during PDT illumination, its concentration (or equivalently, the pO2) in these superficial layers
of the skin will not be significantly reduced. As a consequence, measuring the oxygen consump-
tion, as we did in Part II of this thesis, would not help to individialize the PDT light dose. In
contrast, measuring the photosensitizer’s photobleaching (i.e. the reduction in the fluorescence
intensity of PpIX, caused by the PDT irradiation) may be a useful way to evaluate - and adjust
- the administration of the PDT light dose [4, 14, 16, 21, 49].
8.3 Objectives of the Actinic Keratosis Clinical Study
The objective of this study, performed in cooperation with the HUG (Hôpitaux universitaires
de Genève), was to determine if the PDT clinical outcome, and the pain induced during the
treatment of AK, were correlated with the PpIX’s fluorescence intensity, as measured before
and after irradiation. As a consequence, our study could also provide useful information, to
determine if the PDT light dose, used in the treatment of AK, might be individually adjusted,
on the basis of a simple, optical monitoring strategy, which could possibly also help to predict
the treatment’s outcome.
To reach these goals, a new imaging device was designed and adapted, with convenience
and ergonomy in mind, to the measurement of the lesion’s fluorescence, in a clinical environ-
ment. We aimed, during the design phase, to build a system, which could eventually become
a standard tool for quantitative measurements of the skin fluorescence and reflectance. Our
imaging system was designed for a standard observation of the skin under white light illumina-
tion, to enable the comparison of macroscopic aspects, such as skin roughness, pigmentation,
and extent of the lesions, with the recorded fluorescence pattern.
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9.1 Study Design
This clinical study was designed in collaboration with the Hôpitaux Universitaires de Genève
(HUG) in order to study the PDT treatment of AK lesions. In more detail this study aimed
at quantitatively recording and correlating the PS’s fluorescence and the PDT induced PS’s
photobleaching with: patient’s age, roughness of the lesion’s surface, incubation period, pain
experienced during the treatment, and eventually the clinical outcome. In our case the PS was
PpIX induced by topical ALA-methylester (MAL) administration.
From September 2009 to January 2010, a total of 25 patients (µage = 72± 11 years, 77 AK
lesions) were included in the study and treated by PDT. The treatment outcome was evaluated
at three different times, scheduled at 1-2, 6-7, and 12 months after the PDT session. All the
patients included in this study were specifically informed about the clinical procedure (including
the additional measurements) and gave oral informed consent. During the entire clinical study
a single and experienced MD (Dr Behrooz Kasraee, here shortened with BK), was in charge
of the patient enrollment and PDT treatment. Therefore, all the gathered measurements were
less affected by subjective differences in lesion preparation, in lesions roughness judgment, and
differences in the handling of the specific PDT and monitoring devices.
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9.2 Patient Management
9.2.1 Lesion Identification
Each AK lesion was identified by BK by feeling the roughness of the lesion surface with the
index finger. The lesions were than graded in a scale from 1 to 3, where 1 imply a barely
detectable difference with respect to normal skin. Subsequently BK, demarcated the lesion
borders by following the roughness threshold grade 1, with a green permanent marker (Steadler®
Lumocolor-M). Therefore, the determination of the roughness and the border of each lesion,
allowed to study the influence of the latter over the intensity of the PpIX fluorescence measured
before PDT illumination.
9.2.2 Lesion Preparation
Prior to MAL administration all the lesions were gently scrapped clean with a curette (Bruns®
17-003-0) in order to efficiently remove the stratum corneum and the hyperkeratotic tissue.
This lesion preparation is a standard procedure [11, 22, 37, 43, 62] to facilitate the diffusion
of the MAL cream into the lesion, and ensure an efficient PDT illumination. This procedure
was not intended to be a therapeutic curettage, and generally no bleeding was observed (see
Figure 9.1).
(a) A gentle curettage was performed be-
fore MAL administration
(b) No bleeding or very limited bleeding
was observed after this procedure
Figure 9.1: To enhance the MAL cream penetration and to remove the scales and crusts that may
interfere with the PDT illumination, the stratum corneum of the AK lesions was gently removed
before MAL administration.
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Successively, all AK lesions were precisely indexed in order to localize them even several
months after the treatment. Additionally, the fluorescence imaging device’s orientation and
angle, with respect to the lesion, were precisely defined and kept constant for each fluorescence
measurement. These rules of conduct had to be strictly defined since we aimed at comparing
fluorescence intensities of the lesions at two different times during the procedure, namely just
before and just after the PDT treatment. Due to the limited field of view (∅40mm, see §9.3.1)
a precise positioning of the monitoring apparatus by the operator was required in order to
allow repeatable observation of the lesion.
(a) Lesion bandage to shield the lesion
from daylight during PpIX accumulation
(b) Anatomical sketch
Figure 9.2: MAL administration and documentation of all the information gathered during the
lesion preparation procedure.
After this preliminary, and important, preparation procedure, a layer of 1mm of MAL
cream , inducing the PpIX precursor, was administered over the entire surface of the lesion.
The lesion was then covered with a non-occlusive (gauze plus aluminum foil) bandage to avoid
the interaction between the parasitic daylight and the PpIX accumulated within the lesion (see
Fiugre 9.2(a)). The tissular PpIX concentration will, in fact, increase during the 3h drug light
interval (DLI), e.g. PpIX pharmacokinetic in Figure 7.5(b)). The patients were asked to wait
for a DLI of 180min before being illuminated. Nevertheless, in order to study the influence of
the drug-light interval on: (i) the clinical outcome, and (ii) the lesion fluorescence measured
before the treatment, a subgroup of lesions were treated after only 60min.
All the information gathered during this preparation phase (number of lesions, surface
roughness, delimitation and the drug-light interval) were reported and documented on the
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patient’s anatomical sketch (see Figure 9.2(b)).
9.2.3 PDT Treatment and Pain Assessment
The PDT light dose was delivered with a standard red LED panel delivery device (Aktilite®
CL128, 632±10nm, [39]) providing an irradiance of 67mW/cm2. The irradiation time (540 s ,
36 J/cm2) and the distance between the lesion and the LED panel (≈ 5 cm) were kept constant.
Moreover to further homogenize the illumination, each lesion was irradiated perpendicularly.
Consequently, for patients presenting multiple lesions, each of them was illuminated separately.
PDT illumination session are frequently associated with amoderate to severe pain sensation.
Actually, pain is the main adverse effect for this treatment modality. Therefore a painkiller
(Méfénacide®, 500mg) was given to each patient 1 hour before treatment [48, 58, 62, 63].
Additionally the lesions were sprayed with cold water (T≈5℃), during illumination, to further
reduce the burning sensation. Even though the pain sensation was thus well managed, the
protocol provided the possibility to interrupt the PDT illumination for breaks of 1-2 min, to
give the patient time to recover.
The pain experienced by the patient was quantified with the help of a visual analog pain
scale as reported by Johnson [29], Langley and Sheppeard [31]. On this scale, the pain feeling
is classified from 1 to 10, see Table 9.1. For each lesion, the patients were asked to rank their
pain feeling during the illumination between 1 and 10.
9.2.4 Evaluation of the Clinical Outcome
No pain 0
Mild pain 1-2
Moderate pain 3-4
Severe pain 5-6
Very severe pain 7-8
Worst imaginable pain 9-10
Table 9.1: Visual analogi-
cal pain scale
The clinical outcome was assessed by two physicians: Dr
Behrooz Kasraee and Dr Denis Salomon. The latter was
blinded to the initial diagnostic and to the treatment proce-
dure. The two MDs were asked to rank the lesions’ evolution
in a scale from 1 to 5 (5 implied the complete clearance of
the treated zone). For that purpose they compared the clin-
ical wide field pictures taken before PDT and during the
follow-up consultations. Successively the PDT efficacy for
each lesion was computed by averaging the two MDs’ evalu-
ations.
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9.3 Clinical Setup and Evaluation
9.3.1 Monitoring Apparatus
The monitoring system was designed to be simple and ergonomic, in order to be accepted in the
clinical field. Figure 9.3 depicts the main parts of this monitoring system. A standard clinical
photo camera ((1), Nikon®-D90 coupled with the objective Nikon® AF D 50mm f/1.4) was
used as fluorescence imaging sensor. A custom illumination apparatus was developed to excite
the inspected lesions with a constant and homogeneous illumination. A stable and spatially
homogeneous excitation is in fact important to record quantitative fluorescence images. The
custom illumination apparatus was mainly composed of 4 functional components: the emission
filter (2), the excitation diodes (3), the excitation homogenizing tube (4), and the fluorescence
reference ring (5).
(a) Clinical monitoring apparatus (b) Fluorescence reference ring
Figure 9.3: (a) Fluorescence monitoring apparatus: (1) Standard photo camera Nikon®-D90, (2)
Emission filter, (3) Excitation diodes, (4) Excitation homogenizing tube. b) Zoom picture over the
reference ring (5): The fluorescence image of the reference spot is showed in the up-right corner of
the right image; Ex. 405nm, filtered by a Kodak® Wratten filter n°9, LP460
The emission filter stage (2) involves simply a long pass filter (Kodak® Wratten filter n° 9,
see curve (A) in Figure 9.5) mounted on a sliding support to easily switch from conventional
white light reflectance imaging to fluorescence imaging.
The diode excitation stage (3) was designed with two sets of 5 diodes placed radially along
the circumference of the excitation tube. The first set emits a broad white light emission
(superbrightled® RL5-W6030, 400-660 nm) to record conventional white light reflectance im-
ages. The second emits a narrow blue band light (superbrightled® RL5-UV2030, see curve (Ex)
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in Figure 9.5) to efficiently excite the PpIX accumulated within the lesion and thus record flu-
orescence images. This stage was alimented by a commercially available power supply (24V
DC, 20µA). With the help of a switch, it was possible to select between the two illumination
modes. An excitation filter (Edmund® NT52-530, see curve (B) in Figure 9.5) had to be placed
in front of the blue diodes to reject the parasitic fluorescence of the printed circuit board (PCB)
where the diodes where mounted.
(a) Reflectance image from the white re-
flecting coating
(b) Reflectance profile
Figure 9.4: Spatial excitation profile measured by recording the reflectance of a white reflecting
coating following the excitation with the blue diodes.
The homogenizing tube (4) is an aluminum tube having an highly diffusing coating (Delrin®)
on its internal surface. The length was optimized to obtain a compact (450mm) and light
weight (total weight ≈ 1.7 kg) system. This system delivers a flat excitation profile over
the entire focal plane. Indeed, Figure 9.4 depicts the illumination profile. This non-filtered
reflectance image was acquired on a non-fluorescing white reflecting coating (SphereOptics
Hoffman® SRM-99H) with blue diode excitation. This measurement illustrate the homogeneity
of the excitation profile over the entire field of view.
The fluorescence reference ring (5) was designed to be fastened to the distal end of the
homogenizing tube (see Figure 9.3(b)). These stable fluorescent spots localized in the image
focal plane allow the normalization of the fluorescence of the inspected lesions. These spots
contain stable fluorescing pigments (Lentalux®) embedded in epoxy resin. Their emission
spectrum is depicted in Figure 9.5. Pits located around the ring were filled with increasing
concentrations of this mixture.
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Figure 9.5: Spectral characterization of the optical elements of the fluorescence excitation appara-
tus. Black lines define the emission spectra normalized to unity, (Ex) is blue diode excitation, (Ref)
emission of the fluorescence reference dots, (PpIX) is the emission of the PS. Gray lines indicate the
optical densities of the two filters used: (A) emission filter to reject the excitation, (B) Excitation
filter to reject the parasitic luminescence of the printed circuit board
9.3.2 Image Processing
The fluorescence images were analyzed with a standard image processing software (ImageJ®
version 1.41). Figure 9.6 depict the analysis areas. With the help of simple and basic oper-
ations a region of interest (ROI) was selected by following the lesion borders (L). The mean
fluorescence intensity of the lesion was computed in the ROI and simultaneously the total lesion
surface was evaluated. Similarly, two circular control areas were defined to account for inten-
sity variations. The first area contained the reference fluorescing spot (Ref), and the second
contained a lesion free portion of the field (Ctrl). In order, to compare the results coming from
different images, the fluorescence intensities of the lesion and the of control zone were first
normalized by the mean fluorescence intensity of the reference spot. Eventually the lesion’s
fluorescence bleaching (BPS) was calculated by subtracting the normalized fluorescence mea-
sured after PDT (FA) from to one measured before PDT (FB), see Equations 9.1. Note that
the tissue autofluorescence (TAuto) was shown to remain constant even after PDT irradiation
(data not shown). The PpIX contribution to the recorded fluorescence signal before and after
irradiation is symbolized respectively by FPS and F ′PS and the stable fluorescence intensity of
the reference spot by FRef (Note that in Equation 9.1 the excitation is considered constant,
thus FRef also remains constant).
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FB = (FPS + TAuto)/FRef
FA = (F ′PS + TAuto)/FRef
BPS = FB − FA = (FPS − F ′PS)/FRef
(9.1)
(a) Fluorescence intensity shortly before PDT (b) Fluorescence intensity just after PDT
Figure 9.6: Fluorescence images of the PpIX accumulated within actinic keratosis lesions recorded
just before and just after the PDT session (Ex. 400nm, Em. LP460, see Figure 9.5 for details).
MAL was administered 180 min before illumination, (Ctrl) Control zone, (Ref) fluorescence refer-
ence spot, (L) Lesion.
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Results
In the present study, the normalized fluorescence intensity measured before PDT illumination
(FB), the fluorescence photobleaching (BPS), and other clinical parameters were monitored
during the PDT of 77 lesions, 26 patients. The lesions were subdivided in three different
groups as a function of the drug-light interval: 46 lesions were treated 180 min after MAL
application, 20 lesions after a period ranging from 90 to 140 min, and 11 lesions after 60
min. In the original protocol, only two incubation periods (60, 180 min) were foreseen. The
third incubation period (90-140 min) was imposed upon us by the management of the timing
sequences in the clinical environment. Note that the time precision in the incubation periods
is effectively ≈ ±15min.
During the first two follow-up consultations, in total, only 13 patients (37 lesions) were
controlled. For the last scheduled follow-up consultation (12 months after the treatment),
which will fall between September 2010 and January 2011, all the patients have been formally
convened. Consequently in that case a much higher participation is expected (see details in
§10.2 and §11).
In the following paragraphs we will present the study results by first considering the pa-
rameters that may influence or may be influenced by FB. Successively the PDT treatment
outcome is evaluated as a function of FB and BPS .
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10.1 Fluorescence Intensity Related Parameters
10.1.1 Incubation Period
We consider here the fluorescence intensity (FB) of the lesions treated with an incubation period
of 60 min (n=11) and 180 min (n=46). The fluorescence intensity of the lesions characterized
by an incubation period ranging from 90 to 140 min are not considered here.
The results show a statistically significant difference of the fluorescence intensity measured
60 min and 180 min after MAL administration (see Figure 10.1). These differences confirm
that the drug-light interval is a crucial parameter regarding the fluorescence build-up in the
lesion. In order to asses whether a shorter incubation time (60min vs 180min) would reach the
same clinical performance, in section 10.2 we will study the relationship between fluorescence
intensity and clinical outcome.
Figure 10.1: Normalized fluorescence intensity measured before PDT illumination (FB) and after
an incubation time of 60 and 180 min. (T-test = 6.58, degree of freedom = 40, p < 0.05).
10.1.2 Lesion Roughness and Patient Age
To study of the influence of the lesion roughness and of the patient age, on the PpIX fluorescence
signal (FB), we have considered only the lesions administered 180 min before PDT (n=46).
To emphasize the influence of lesion roughness we subdivided them in the three subgroup
depending on their roughness grade, see §9.2.1 for details. In the considered cohort, 16 lesions
were characterized by a roughness grade of 1, 16 by a grade of 2, and 14 by a grade of 3. The
influence of the patient age was studied by analyzing the fluorescence signal (FB) as a function
of the age of each patient in the running year (2010).
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No correlation with the fluorescence intensity was observed (see Figure 10.2) neither for the
lesion surface roughness nor for the patient age, suggesting that those two parameters are not
relevant for the tissular production of PpIX.
(a) Normalized fluorescence and roughness (b) Normalized fluorescence and patients’
age
Figure 10.2: Normalized fluorescence intensity measured before treatment (FB) as a function of
lesion’s surface roughness and patient’s age (incubation period 180 min).
10.1.3 Pain
To study the relationship between the pain, experienced and evaluated by the patient, and
the fluorescence signal FB all the treated lesions were considered independently from all other
clinical parameters (n=77). Figure 10.3(a) shows the pain experienced during the PDT illumi-
nation as a function of the fluorescence signal measured just before illumination (FB). Figure
10.3(b) plots the pain, but this time in function of the fluorescence signal normalized by the
lesion surface, see §9.3.2 for more details. Note that the number of lesions characterized by the
same pain grade is mentioned, in round brackets, on the right hand part of the plots.
Even though the number of lesions is not sufficient to conclude on this topic the results shows
the absence of correlation (see Figure 10.3). This is probably tied to some extent to strong
patient subjectivity in pain evaluation and also probably to other uncontrolled parameters, e.g.
differences in the physiology or lesions innervation. Neveretheless by analysing the distribution
of the experienced pain, we confirm that PDT is associated with a moderate to severe pain
feeling. In fact, 60% of the treated lesions were graded with a pain feeling on the scale smaller
than 5 (mild to moderate pain), and almost all the lesions (85%) were graded below 7 (see
Table 9.1).
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(a) Pain as a function of the normalized fluores-
cence
(b) Pain as a function of the normalized flu-
orescence × lesion surface
Figure 10.3: Pain experienced by the patient during PDT irradiation as a function of the fluo-
rescence intensity measured before treatment (FB)
10.1.4 Fluorescence Photobleaching
The measured normalized fluorescence (FB) was correlated with the calculated photobleaching
(BPS) following PDT (see Equation 9.1). All the treated lesions (n=77), independently of
the precursor incubation period and of all other possible parameters, were considered for this
analysis. The results shows a strong linear correlation (see Figure 9.5), suggesting that the
PpIX’s fluorescence measured with our system is independently of the drug light interval and
equally photobleached during all the PDT sessions. The PpIX molecules accumulated in the
epidermis may indeed interact efficiently with the illumination light and the tissue oxygen which
in part diffuses from the atmosphere, so that an efficient fluorescence photobleaching occurs.
Nevertheless, by analyzing in more detail as shown in Figure 10.4 we can easily appreciate that
the linear regression has roughly a slope of 1, but in the same time we see that the regression
line is affected by an offset of ≈ 0.1. This possibly suggests the existence of an unbleachable
part of the accumulated PpIX or, alternatively, the presence of unbleachable photoproducts
(see §11 for details).
10.2 Clinical Outcome
During the first two follow-up consultations 13 patients (37 lesions) were controlled. Eleven
patients (27 lesions) attended the first consultation (1-2 months), and only 8 patients (28
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Figure 10.4: PpIX fluorescence photobleaching (BPS) in function of the normalized fluorescence
measured before treatment (FB)
lesions) attend the second consultation 6-7 months after the PDT treatment. Eventually only
6 patients (18 lesions) have complete file record (i.e. they attend both follow-up consultations).
(a) Clinical outcome as a function of the nor-
malized fluorescence measured before illumi-
nation (FB)
(b) Clinical outcome as a function of PpIX’s
photobleaching (BPS)
Figure 10.5: Clinical outcome of AK lesions treated by MAL-PDT and controlled at 1-2 months
(•) and at 6-7 months () after the PDT session
In Figure 10.5 the clinical outcome of all the 37 lesions controlled during the first two
follow-up consultations are plotted as a function of the PpIX fluorescence measured before
treatment (FB, see Figure 10.5(a)), and respectively in function of the PpIX photobleaching
(BPS , see Figure 10.5(b)). The symbols (•) refer to the clinical outcomes assessed during the
first consultation (1-2 months), () to the ones evaluated 6-7 months after PDT treatment.
Note that if two symbols gave the same clinical outcome a small vertical shift was applied in
order to distinguish all the different data points.
For the 18 lesions with a complete file record, we can follow the evolution of the clinical
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outcome by looking at the graphs of Figure 10.5 along vertical lines. In fact, if a lesion
was controlled during both follow-up consultations the two symbols (•,) are aligned along
the vertical axis or even superimposed. Nevertheless to simplify the analysis of the clinical
outcome evolution from the first (1-2 months) to the second (6-7 months) control consultation
the respective clinical outcome is plotted in Figure 10.6.
(a) First follow-up consultation after 1-2
months from PDT
(b) Second follow-up consultation after 6-7
months from PDT
Figure 10.6: Clinical outcome evolution, of AK lesions treated by MAL-PDT, from 1-2 months
(•) to 6-7 months () after the PDT session
Despite the fact that the final clinical outcome is missing at this point in time (evaluation at
1 year after the PDT treatment), the present results show that the use of either the normalized
fluorescence, or the amount of photobleaching are valuable parameters to predict the clinical
outcome. In addition by looking at Figure 10.6, the clinical outcome seems to stabilize itself
at the higher and hence better clinical outcomes.
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Discussion
Studying the correlation between the PpIX fluorescence intensity and/or its photobleaching
during PDT of AKs with the clinical outcome is an interesting and important topic. Surpris-
ingly, to our knowledge [16, 19], only a very limited number of publications have addressed this
issue in detail. Our study demonstrats that this correlation, although not perfect, does exist as
long as relatively short follow up times (7 months) are considered. It should be noted that to
conclude over the evolution of the clinical outcome the last follow-up consultation needs to be
accomplished, thus the final degree of correlation will be determined after the end of this thesis.
The PpIX fluorescence intensity was measured before and after PDT with an imaging device
developed in our laboratory. Although this device provides, in our conditions, reproducible,
background free and linear (data non shown) values of PpIX fluorescence, some of its features
can still be improved for a more convenient and routine use in clinic. The irradiance of the
excitation light should and will be increased, typically by one order of magnitude, to reduce
the time that necessary to record the fluorescence images with an acceptable signal to noise
ratio. Such a modification will not significantly increase the PpIX photobleaching since the
fluorescence acquisition time will be reduced accordingly.
By analyzing the recorded images and the plots reporting the fluorescence intensity, we show
that important intra- and inter- patient variations affect these measurements. These variations
are probably due to parameters influencing the PpIX accumulation as reported by Dögnitz
et al. [13], such as the precursor diffusion rate, the lesion’s temperature, temporal and spatial
variations of the metabolic activity, and differences in the density of active cells. Moreover, as
was speculated by Wiegell et al. [62], the tissular PpIX content may be influenced by anatomical
and regional differences in the skin’s aptitudes to accumulate PpIX. Unfortunately, the limited
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number of patients involved in the present study does not enable us to subdivide the treated
lesions according to their anatomical subgroups.
The precursor’s (Metvix®) incubation period, or the drug-light interval necessary to allow
the biosynthesis of the photosensitizer (PpIX), is a parameter of major interest especially
in the clinical field where optimal time management is becoming more and more important.
Statistical relevant differences were observed between the fluorescence intensities measured
after 60 min or 180 min of the precursor incubation time. This results is supported by several
publications reporting the fluorescence pharmacokinetics of PpIX in various tissues including
the skin [8, 26, 35, 57, 59]. In addition, similar results were observed by several groups active
in the development of PDT based therapy to treat AK [17, 18]. This is consistent with the fact
that the PpIX concentration within the lesions is directly related to the treatment efficacy [2, 13,
18, 52]. Therefore, to reach a sufficient accumulation of PpIX in the lesions, the AK treatment
guidelines recommend a precursor’s incubation period of at least 180 min or, alternatively,
an incubation period of 180 min or shorter, but under occlusive bandage [38, 41, 42]. These
guidelines are actually supported by our preliminary clinical results suggesting that a non
occlusive incubation of only 60 min is not sufficient to reach satisfactory accumulation of PpIX
and, consequently, to have good clinical results.
However, it should be noted that, although the results presented in Figure 10.1 are statisti-
cally relevant to support this statement regarding the PpIX fluorescence, more patients should
be treated with an incubation time of 60min to corroborate this statement.
We also studied the influence of the patient’s age and of the AK lesion’s roughness on
the PpIX fluorescence intensity. As reported in the literature, we observed that the patient
age is not a parameter that significantly influences the biosynthesis of PpIX [2, 33]. This
conclusion is somewhat surprising since we were expecting an impact of the skin aging on the
precursor penetration and on the metabolic activities that play a role in the PpIX build-up.
Similarly, no correlation was observed between the roughness of the lesion surface and the PpIX
fluorescence intensity. To our knowledge no one tried to look for a correlation with these two
parameters. However the work of Wiegell et al. [61] demonstrated a positive correlation between
the measured AK-PpIX fluorescence and the lesion’s redness and inflammation. Even though
the rational that brought Wiegell et al. [61] to study this correlation is somewhat similar to
ours, the results can not compared. Indeed the concepts of redness and inflammation are not or
very poorly correlated with the concept of “roughness”, as far as AK’s are concerned. Similarly,
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Smits et al. [51] reported that there was a positive correlation between the PpIX fluorescence
intensity and the “severity” of AK’s. According to the classification proposed by Anwar et al.
[3], Cockerell and Wharton [7], Yantsos et al. [65], the grade of AKs is closely related to the
proliferation of atypical keratinocytes involving different percentages of the epidermis (i.e. the
grading is tightly related to the amount of dysplastic and hyperplastic cells within the lesion).
As a consequence, the absence of correlation we have observed between the PpIX fluorescence
and the lesion roughness indicates that this features is also not correlated with the “severity”
grading.
In the present study we also failed to demonstrate a correlation between the pain expe-
rienced by the patient during the PDT and the normalized fluorescence intensity. Although
several groups have extensively studied the pain sensation during the PDT illumination, no
clear agreement has been found up to now regarding this correlation. Some studies demon-
strated a statistically significant correlation [9, 62, 63], whereas others, as it is our case, did not
observed a clear correlation [25, 61]. This discrepancy is probably due, at least in part, to the
difficulty of measuring and documenting the sensation of pain. Pain is a difficult parameter to
study because it is subject to large intra- and inter- patient variations. In fact, pain assessment
is strongly affected by subjective and emotional aspects that depend on the patient’s earlier ex-
periences of pain, and on the degree of anxiety of the patient during treatment [25, 28, 29, 60].
It should be noted that the heterogeneity of the AK lesions is very likely to be the most impor-
tant factor playing a role in this discrepancy. In fact, in general, the PpIX fluorescence and the
pain seems to be correlated in normal tissue and early AKs, whereas this correlation no longer
exist for more advanced lesions [5, 63]. Therefore, even this correlation would exist in all tissue
types, the fluctuation associated with the AK lesions heterogeneity may be to important to
reveal to reveal with the limited number of cases studied at present. As already mentioned, the
lesions could not be adequately subdivided in different anatomical zones in the present study
due to the small cohort considered. This may also degrade the correlation between the PpIX
fluorescence and the pain since it has been reported that anatomical innervation differences
may play an important role [23, 48].
Nevertheless, Wiegell et al. [62] claimed that no pain difference was observed between
different anatomical zones after correction by the fluorescence intensity measured in these
zones. This study concluded that differences in pain score found between different parts of the
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body are probably due to varying ability of the skin to accumulate PpIX, more than differences
in innervation of the skin.
The strong linear correlation presented in Figure 10.4 between the PpIX’s photobleaching
and the normalized fluorescence before PDT is an expected, but interesting result. The corre-
lation, with a slope of 1, is in agreement with several studies reporting that, in well oxygenated
conditions, the PpIX and the PpIX’s photoproducts can be efficiently and completely bleached
during the illumination [14, 15, 46, 49, 53]. In fact, in our situation the oxygen depletion
induced by the PDT illumination is probably not so large as to limit the PDT effect and the
PpIX photobleaching. It is also worth while to note that this correlation is observed for all the
treated lesions, independently of the anatomical place and independently of all other possible
tissue parameters. In addition, the limited deviation from the regression line (R2 = 0.91)
further supports the possibility to use the fluorescence intensity, measured before treatment,
as a surrogate of the PpIX photobleaching following PDT. Finally it should be noted that
the intercept of this regression line with the Y axis appears to be not exactely at (0, 0), but
near (0.1, 0). Since all backgrounds and offsets have been corrected for, as described in §9.3.2,
this suggest that a “non-photobleachable” fraction of the fluorochrome might be present in the
skin. This interesting conclusion deserved further studies to clearly determine if this effect is
due to the localization of PpIX in different tissue compartments and/or to the luminescence of
different fluorochromes.
Finally, when the clinical outcome is evaluated 1-2 months and 6-7 months following PDT,
an high levels of fluorescence intensity, or PpIX photobleaching, corresponded to a more potent
therapeutic effect. These encouraging results are supported by other publications that report
on correlations between the photobleaching and clinical outcome [4, 16, 19, 49]. However it
should be noted that most of these studies reported that the fluorescence photobleaching and
not the fluorescence intensity, is well correlated with the clinical outcome. This discrepancy
could be explained by the fact that these groups used either “point” measurements, instead of
imaging measurements and/or because they measured the fluorescence qualitatively instead of
using a scientific camera presenting a linear response, as was the case in our study. With this
imaging system, it appears that a PpIX fluorescence intensity of 0.4, and a PpIX fluorescence
photobleaching above 0.3, will lead to a positive clinical outcome for both the 1-2 months and
6-7 months follow-ups. Moreover by looking the results presented in Figure 10.1 they suggests
that a Metvix® incubation time of 60 min is not sufficient to successfully treat AK by PDT.
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Actually, it is worth while noting that only 13 patients, out of 25 treated, attended the
follow-up consultations. The scanty participation was tied to an organizational problem and
also to the fact that the studied cohort was composed by an elderly population (µage = 72±11
years). Therefore several patients refused to attend the scheduled follow-up visit, probably
considering that it was not necessary. Moreover, 3 among the treated patients died in the
period between the PDT treatment and follow-up visits.
In conclusion, we can claim that, in the case of AK treated with Metvix®, the fluorescence
measured before PDT and the PpIX fluorescence photobleaching are both well and linearly
correlated with clinical outcome. In addition a statistically relevant difference of the fluores-
cence intensity is observed when the incubation time varies from 60 to 180 min. Finally these
preliminary clinical results support that a satisfactory clinical outcome can only be reached if
the PpIX fluorescence intensity or the PpIX fluorescence photobleaching are above a certain
threshold. However, surprisingly no correlation was observed in the present study between
the pain and the PpIX fluorescence measured before treatment, as well as between this last
parameter and the lesion roughness and the patient’s age.
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12
Conclusions
In this thesis, we focused on three projects in the field of photomedicine. The common, long
term goal was to find methods and tools allowing for a better control of the parameters for the
corresponding light-based treatment, in order to reduce, as much as possible, the inter- and
intra-patient variations in the treatment’s outcome.
Substantial differences existed in the technical and human environment of these three
projects. Finally, it was interesting to find that occasionally economical interests or issues
of intellectual property could also influence the approache token. In the CAM study (Part II),
the measured values of tissular oxygen consumed during PDT, as determined by measuring
the DF of the PS, were found to be, as expected, nicely correlated with the induced PDT
vascular effects, suggesting a method for monitoring, controlling, and possibly adapting the
light dose during PDT treatments. Similarly, in the actinic keratosis study (Part III), the mea-
sured amount of photobleaching of the photosensitizer was also found to be, correlated with
the clinical outcome of the treatment, again suggesting a method for optmizing this treatment.
However, in the infrared thermal laser therapy study (Part I), we could not find, with our
setup, the hypothesized correlation between the eye fundus reflectance, and the occurence of
retinal burns, and could not, therefore, propose this method as a monitoring solution.
But in all three experiments, exploring the complexity of the corresponding, detailed bio-
technical situation, was a mind-stimulating experience, which in addition to the positive results,
found in two out of three studies, has led us to formulate some suggestions for future research
and applications, as detailed hereunder.
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Future Prospects
For the HRL “subthreshold” thermal treatment study, we propose a strategy where the laser
delivery device would be combined with an optical coherence tomograph, allowing for real-time
monitoring of the reflectance of a selected structure in the chorioretinal volume. Thus, during
the infrared laser therapy, the denaturation of proteins, which causes changes in the tissue
reflectance, could be detected, and, by monitoring the reflectance of a specific deep seated
structure, it may be possible to optimize the light dose administered to the eye fundus.
From a clinical point of view, HRL therapy still needs to be more extensively assessed by
a scientific study, comparing its clinical outcome with the results of another standard therapy.
The study should be focused on those pathologies where HRL seams to be more efficient than
other standard therapies (e.g. Retinitis Pigmentosa). To support the current clinical use
of HRL, to support the fact that the applied laser shots must be at the upper limit of the
subthreshould regime, deeper insight on the processes initiated by the thermal laser need to be
gained.
In the in vivo CAM oxygen measurement study, our measurements were affected by large
error bars. One possible cause may reside in the gradient in tissular oxygen concentration,
existing within the studied CAM region. The oxygen concentration, at a specific CAM location,
probably depends on the distance to the nearest artery. We therefore propose to work with
larger CAM surface zones (≈ ∅2 − 4 mm zones, rather than ≈ ∅500µm zones probed in the
present experiments), to effectively average out these inhomogeneities. Another interesting
possibility, would be to quantify the existing oxygen gradient, in the space between artery
and vein. Such measurements could confirm that the observed errors are indeed linked to
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pO2 inhomogeneities in the CAM, and, possibly, be used to verify the differences in oxygen
consumption between normal, hyperplastic, dysplastic, and malignant tissues.
Referring to the delayed fluorescence measurement method applied in the above study, an
identical strategy could be applied when using photosensitizers other than PpIX. Verteporfin
(BPD-MA, Visudyne®), used in ophthalmology for the treatment of choriodal neovascolariza-
tion in the case of wet AMD, is an interesting candidate. Here too, measuring the tissular
pO2 and adapting the light dose accordingly, could yield valuable information and lead to an
improved PDT efficacy and possibly early detection of the disease.
Regarding the delayed fluorescence measurement setup used, by substituting the single
optical fiber, used as a probe, by an optical fiber bundle, we could increase the fraction of
collected photons. For example, by using one of the fibers in the bundle to excite the sample,
and by then collecting the luminescence with the entire bundle, we could increase the collection
fraction by about a factor of 3. This would also allow us to reduce the probing laser excitation
intensity, thus further reducing the perturbation induced by the measurement in the probed
tissue. As a possible, additional benefit, replacing the single probing fiber by an optical fiber
bundle, and adapting the time-resolved spectrofluorometer so as to sequentially inject the
excitation light in the different fibers of the bundle, it would be possible to draw a 2D map of
the oxygen distribution in the inspected sample.
Regarding theActinic Keratosis outcome evaluation study, let us first note that confirmation
of the preliminary clinical outcome evaluation, at 1 year from the treatment, is scheduled to
take place between September 2010 and January 2011. To verify the conclusions drawn from
the present study and broaden its field of application, further clinical studies could be designed.
For example, to explore if the clinical outcome would be indeed more stable if the the drug light
interval is individualized in function of the lesion fluorescence measured just before illumination.
The photobleaching of the photosensitizer could be measured in function of the clinical
result, when treating deeper seated lesions such as nodular BCCs, or during the treatment of
deeper skin structures (sebaceous glands, hair bulbs). This would allow to verify if the results
found in this study could be applied to the treatment of non superficial targets. Finally the
same developed imaging apparatus, could be adapted and used as a simple and quantitative
Wood’s lamp to quantify a skin pigmentation defect(e.g. in vitiligo) or evaluate the efficacy of
various existing treatments for the menagement of pigmentation disorders.
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Appendix, Part II
II.A PpIX’s Luminescence and Signal Processing
The luminescence emitted by a fluorochrome (PpIX in our case) is actually consequence of
energy relaxation leading the electrons being in the excited electronic state to be transfered
in a lower energetic state. The desexcitation probability of this excited population is found
to be proportional to itself. Therefore, by integration of the excited population over time, the
emitted luminescence results to follow an exponential decay.
In a more general situation, a real system maybe composed by different fluorochromes
conformations (aggregates), different environments surrounding the studied fluorochromes and
different possible deexcitation pathway. Thus, the emitted luminescence would be characterized
by a sum of exponential decays (see Equation 1).
L(t) =
∑
i
Lie
−t/τi (1)
where L(t) is the total luminescence, Li are the specific intensities of each emissive contribution
at t = 0, and τi are the characteristic lifetimes.
In our case, the PpIX’s luminescence is recorded by mean of a transducer, a photo multiplier
tube (PMT) which transforms the emitted photon into an analog electrical signal which is
successively digitalized and exported in an ASCII format by a digital storage oscilloscope
(DSO). Thus, the recorded signal is analyzed and fitted by a multi-exponential mathematical
scheme to model the emissive phenomenon.
Non-linear regression by least squares estimation (NLS) is a well known and approved
method to efficiently fit the recorded data [yi] to a mathematical model. The strategy used
to estimate the regression function f(~t; ~β) is based on the minimization of the sum of the
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squared residuals, i.e. the sum of the squared deviation between the observed data [yi] and
the estimated model [f(~ti; ~ˆβ)] (see Equation 2).
Q =
n∑
i=1
[yi − f(~ti; ~ˆβ)]2 (2)
To iteratively minimize the residuals, different algorithms can be employed, the most reliable
and most commonly used is the Levenberg-Marquardt computational method. During the
fitting process, the estimated model’s parameters (βˆ0, βˆ1, . . .) are treated as the variables,
and the independent variable values ( t1, t2, . . .) are treated as coefficients of the regression
function. To successfully fit the recorded data initial estimates of each model’s parameter
(βˆ0, βˆ1, . . .) must be provided. Successively, the algorithm adjusts and update those parameter’s
to minimize the residuals (see Equation 3) and therefore produces a better mathematical fit to
the measured data.
dQ(βi) = 0 (3)
During this process, it is very important to provide a precise initial estimate to assure the
conversion of the algorithm to the real minimum of the residual function (Q(βi)) and not to
local minimum that would produce unacceptable solutions. Additionally, to further enhance
the regression quality, the recorded data are unevenly weighted to increase the contribution
of these data points that are less affected by the noise, thus giving to the points with a lower
variance a greater statistical weight (See Equation 4).
Q =
n∑
i=1
wi [yi − f(~xi; ~ˆβ)]2 (4)
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II.B Algorithm Performances
The results of a fitting calculation are regretfully influenced by the initial parameters fed to the
algorithm. The ability to provide a stable mathematical solution with only weak sensibility to
the initial parameters is a very important characteristic of a fitting algorithm. The algorithm
performances need to be tested with simulated experimental data, where the exact solution is
known, and therefore the fitting process and the performance of the algorithm can be deeply and
precisely analyzed. Preliminary PpIX in vitro and in vivo measurements show that molecule
relaxation is characterized by a bi-exponential phenomena with lifetime in the µs range. To
have a more realistic situation the simulated data S(t) were artificially created with a bi-
exponential mathematical decay model to which was added a certain amount of random noise
(see Equation 5). Different scenarios were taken into account to simulate different possible
experimental data and evaluate the influence of several different parameters over the fitting
quality. The goal of these simulations was to test the limits and the working range where the
fitting solution can be considered accurate.
S(t) = A1 exp(t/τ1) +A2 exp(t/τ2) + rnd(k) (5)
With exception of the initial estimated model’s parameters (Ai and τi, see Equation 5), the
quality of the fitting was studied by changing three important algorithm’s parameters:
1. The standard error added to the simulated data rnd(k) (µrnd = 0, σrnd = [1 × 10−4 -
5× 10−3]).
2. The delay between the laser excitation pulse and the beginning of the signal’s analysis
(See ∆D in Figure II.B).
3. The period T over which the signal was analyzed.
The simulations were carried out by considering always the same exponential decay (A1 =
0.5 Volt, τ1 = 40 µs, A2 = 2 Volt, τ2 = 10 µs) and by an indipendent evaluation of the effects of
each studied parameter. Therefore, the simulated experimental data were fitted 100 different
times, the fitting solution’s variation was recorded and analysed. The goal was, in fact, to
precisely define the parameters range that will permit to obtain an accurate fit minimizing, at
the same time, the errors over the evaluated lifetimes.
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Figure 1: Illustrative figure for the definition of two parameters considered for the analysis of
the algorithm’s solution. ∆D is the signal analysis delay from the excitation pulse, T the signal
analysis period.
The influence of the added random error is of main interest, in particular to evaluate the
accuracy of the solution when real data are analyzed. In fact, by knowing the relation between
dispersions of the algorithm’s solution in function of the simulated data error, we are able, by
measuring the dispersion between the recorded data and the algorithm’s solution, to precisely
define the error over the solution found. As a consequence, the dispertion over the simulated
signal intensity needs to be smaller than 2mV to obtain a fitting solution with a lifetime error
smaller that 5% (see table II.B).
Table 1: Errors of the fitting process in function of the standard deviation (σrnd) of the random
error added to the simulated data
Standard deviation of the random error (σrnd) EA1 [%] Eτ1 [%] EA2 [%] Eτ2 [%]
1× 10−4 18.12 0.01 4.92 0.06
1× 10−3 17.98 0.013 5.50 1.75
2× 10−3 18.24 0.01 4.43 3.94
3× 10−3 15.92 1.65 13.90 26.80
4× 10−3 17.13 0.48 7.96 15.43
5× 10−3 16.89 1.06 10.04 22.07
The delay between the laser excitation pulse and the beginning of the signal’s analysis,
affects only marginally the fitting process. We could, anyway conclude that this delay ∆D has
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to be smaller than the shortest lifetime. (see table 2). Finally, we observed that the fitting
quality is not dramatically dependent on the analysis period T . Nevertheless, the analysis
period T should not be smaller than the half of the longest lifetime 3. Moreover, by considering
very long analysis periods, we observed the efficacy of the algorithm (variance based weighted
data) to ponderate the experimental data and therefore consider only the data not dramatically
affected by a strong error. II.B
Table 2: Errors of the fitting process in function of the delay (∆D) form the excitation source
Delay form the excitation, ∆D [µs] EA1 [%] Eτ1 [%] EA2 [%] Eτ2 [%]
1 9.59 0.04 2.16 0.20
2 18.10 0.08 5.37 0.74
3 25.47 0.34 9.06 2.48
4 33.06 0.09 9.14 0.22
5 39.60 0.23 10.71 0.87
10 62.73 0.69 24.06 3.25
14 78.54 79.50 16.82 9.29
Table 3: Errors of the fitting process in function of the analysis period (T )
Analysis period, T [µs] EA1 [%] Eτ1 [%] EA2 [%] Eτ2 [%]
20 17.77 0.25 6.34 1.93
50 18.13 0.01 4.85 0.02
100 18.13 0.01 4.87 0.02
300 18.12 0.0 4.89 0.01
500 18.13 0.01 4.85 0.02
The performances of the algorithm where also studied in function of the guessed parame-
ters entered. The stability of the solution is tightly bind to the local minima present in the
residual function. The algorithm typically converge to the correct solution even if the guessed
parameters are one order of magnitude away from the real solution. As general rule, to reach
in a fast way an accurate approximated solution the guessed parameters should be close as
much as possible to those of the real solution.
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(a) Logaritmic decay 300µs (b) Logaritmic decay 500µs
Figure 2: Data error at the of the signal do not affect at all the fitting results
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III.A Nikon-D90 Sensor Linearity
In the following paragraph we will describe the experience used to verify the linearity of the
optical sensor, please refer the bracketed numbers and letters to Figure 1.
(a) Edmound® - EIA gray scale
pattern slide, (A) Region of inter-
est where the trasmitted light was
measured
(b) Setup used to measure the linearity of the
CMOS sensor
Figure 1: Verification of the linearity of the sensor of a Nikon®- 90D photo camera
The linearity of the CMOS-sensor of the photo camera ((1), Nikon®- 90D) was verified
by recording the transmitted light through a standard gray scale pattern slide (GSP, (2),
Edmound® - EIA linear transmission). The GSP is, in fact, characterized by nine different
zones (see Figure 1(a)) with calibrated transmission. Therefore, by illuminating the GSP with
a diffused excitation source and by measuring the average pixel value, of a defined surface (A),
the linearity of the sensor was verified. With more details, a white light, fiber based, light
source ((3), Richard Wolf®-IP20) was directed on a white reflecting coating ((4), SphereOptics
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Hoffman® SRM-99H) to generate an homogeneous illumination of the GSP. Successively, to
further reject the inhomogeneities of the intensity distribution of this illumination the GSP
was translated horizontally. As a consequence the light transmitted through the 9 different
zones was measured completely independently of the intensity distribution of the illumination.
A very good linearity was observed, see Figure 2.
Figure 2: Linearity of the CMOS photo camera sensor
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III.B Quantitative Light Measurements with Consumer Grade
Photo Cameras
Consumer grade cameras, compared to scientific cameras, are much cheaper and additionally
not designed for quantitative measurements. The main problem, with consumer grade camera,
is that the manufacturing companies do not supply precise specifications of the specific optical
components used. For instance, the exact transmission of the red-green-blue (RGB) filter
and the spectral sensitivity of the sensor are unknown. Moreover, as a general rule, all these
camera have an integrated image precessing unit that modify automatically the recorded pixels
to improve the appearance and reduce the dark noise of the recorded scene, thus loosing the
quantitative information of the amount of light reaching the camera sensor.
(a) Standard gray scale pattern slide,
(A) Region of interest
(b) Red-Green and Blue pixels of the
zoom area (A)
Figure 3: Non-interpolated - RAW values, recorded by the CMOS sensor
Modern semi-professional and professional camera allow the user to record unprocessed im-
ages (i.e. RAW image) which claim to be the rigorous digital transformation of the accumulated
charges on the camera sensor (see Figure 3). Therefore, by appropriately analyzing “RAW im-
ages” and by calibrating the photo camera, quantitative measurement are also accessible with
these less expensive devices. As a consequence the “RAW images” were transformed, without
any data distrotion, into a more user friendly image format (Portable Pixel Map (ppm)) to be
able to analize the 12-bit (dynamic range: 0 - 4096) values recorded in the three separately
channels. The image transformations (i.e. “the developing a raw image”, by analogy with the
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process of film development) was realized with the help of a standard tool dcraw program. For
all quantitative analysis we developed the RAW images with the following command:
dcraw -4Dh foo.NEF foo.ppm
Where the options of the command:
• 4: Linearly transformation of the 12 bit recorded images into the 16 bit computer compat-
ible format. This option will also fix the picture gamma to 1. To verify these operations
we analyzed a saturated images and we observed that the maximal value was still 4096;
• D: Transform the RAW data without pixel interpolation (see Figure 3) and do not scale
the channels to compensate the inhomogeneous CMOS sensitivity.
• h: Create an half-size color image by grouping the red and blue pixels (see Figure 3)
avoiding any value interpolation. Hereupon, for the green pixels, the average of two
successive pixel has been evaluated to create an half-size image. This operation enable to
rigorously analyze the pixel values of the red and blue channels (the PpIX fluorescence
emission is in fact almost exclusively recorded within the red channel)
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